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Abstract 
In vivo glia-to-neuron conversion mediated by transcription factors is emerging as a possible cell 
replacement strategy to respecify brain resident cells into lost neuronal cell types and to reinstate the 
function of disrupted circuitries in the presence of injury, neuropsychiatric disorders or other insults. 
Different factors, such as the absence or presence of injury, the cell type of origin and the choice of 
transcription factors influence the ability to convert cortical glia into neurons in vivo. However, the role 
that post-translational modification of transcription factors or the intrinsic heterogeneity of the starting 
cell population have in this process is largely unknown. 
In this thesis, I show that the ability of the proneural transcription factor ASCL1 to direct cell fate-switch 
in proliferative postnatal cortical glia is increased by the lack of protein phosphorylation. I found that, in 
postnatal cortical astrocytes cultures transduced with retroviruses encoding for three forms of ASCL1 
differing in their phosphorylation states, the induction of a phospho-deficient mutant leads to increased 
reprogramming efficiency compared to the wild type protein or a phospho-mimetic mutant. However, 
independently on its phosphorylation state, ASCL1 is not able to efficiently convert postnatal cortical 
glia into neurons in vivo but rather decreases the proportion of astroglia favouring generation of 
oligodendroglia. The exogenous expression of both phospho-mutants leads to an increase in mature 
oligodendrocytes, consistent with a role of Ascl1 in the differentiation of oligodendrocyte progenitors. 
Moreover, I demonstrated that co-transduction of Bcl2 with Ascl1 successfully induces glia-to-neuron 
conversion. Remarkably, when associated with Bcl2, both phospho-mutants showed a greater 
neurogenic ability compared to the wild type protein and the phospho-deficient mutant drove the 
formation of a higher proportion of NeuN-expressing neurons. In summary, while the phosphorylation 
state of ASCL1 does not seem to promote cell fate-switch per se, it influences the maturation level of 
reprogrammed postnatal cortical glia and the conversion efficiency in association with BCL2. 
Furthermore, I describe an adaptation of a clonal labelling system, called StarTrack, for in vivo cortical 
astrocyte-to-neuron conversion and, eventually, clonal analysis of induced neurons. Here, I illustrate the 
results obtained from preliminary experiments in which the tamoxifen-activated proneural factors 
ASCL1ERT2 and NEUROG2ERT2 are induced in GFAP-expressing postnatal cortical astrocytes. These 
experiments revealed the limitations of the system, such as insufficient expression levels of the plasmids 
expressing Ascl1ERT2 and Neurog2ERT2 and the failure to induce formation of DCX-positive neurons to 
date. After identification of the pitfalls of the system, I describe a possible strategy to circumvent them. 
In the future, coupling tamoxifen-inducible activation of forced neurogenesis in astrocytes with clonal 
labelling of converted cells will permit the identification of the glial clones from which induced neurons 
are generated and, conversely, identification of the astrocytic populations that expressed the proneural 
factors but failed to reprogram.  
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Together, understanding the mechanisms favouring the execution of neurogenic programs instructed 
by transcription factors and the reasons, why some glial subpopulations fail to erase their original fate 
and switch lineage, will help developing strategies to improve cell fate conversion for regenerative 
medicine. 
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Zusammenfassung 
Die Transkriptionsfaktor-vermittelte in vivo Glia-zu-Neuron Umwandlung, ist eine neu aufkommende, 
mögliche Zellersatz-Strategie um residente Zellen im Gehirn Zellen in verloren gegangene neuronale 
Zelltypen umzuwandeln und die Funktion angesichts von Verletzungen, neuropsychatrischer 
Krankheiten und weiterer Insulte unterbrochener Verschaltungen wiederherzustellen. Verschiedene 
Faktoren, wie z.B. das Vorhandensein oder Fehlen von Verletzungen, der Ursprungszelltyp und die Wahl 
der Transkriptionsfaktoren beeinflussen die Fähigkeit, kortikale Glia in vivo in Neuronen umzuwandeln. 
Die Rolle, die die post-translationale Modifikation von Transkriptionsfaktoren oder die intrinsische 
Heterogenität der Ausgangszellpopulation bei diesem Prozess spielen, ist allerdings weitestgehend 
unbekannt. In dieser Arbeit zeige ich, dass die Fähigkeit des proneuralen transkriptionsfaktors ASCL1 
den Wechsel des Zellschicksals proliferativer postnataler kortikaler Glia zu dirigieren, durch das Fehlen 
der Proteinphosphorylierung erhöht wird. In postnatalen kortikalen Astrozytenkulturen, die durch 
Retrovieren mit verschiedenen Formen von ASCL transduziert werden, welche sich in ihrem 
Phosphorylierungsstatus unterscheiden, konnte ich feststellen, dass die Induktion einer phospho-
defizienten Mutante, im Vergleich zum Wilttyp Protein oder einer phospho-mimetischen Mutante, zu 
einer erhöhten Reprogrammierungseffizienz führt. Unabhängig von seinem Phosphorylierungsstatus, 
ist ASCL1 jedoch nicht in der Lage, postnatale kortikale Glia in vivo effizient in Neuronen zu konvertieren. 
Vielmehr verringert es den Anteil an Astroglia, die die Bildung von Oligodendroglia begünstigen. Im 
Einklang mit der Rolle von Ascl1 bei der Differnzierung von Oligodendrozyten-Vorläufern, führt die 
exogene Expression beider Phosphomutanten zu einem Anstieg reifer Oligodendrozyten. 
Darüberhinaus konnte ich zeigen, dass die Co-Transduktion von Bcl2 mit Ascl1 erfolgreich eine Glia-zu-
Neuron Umwandlung induziert. Bemerkenswerterweise zeigten beide Phosphomutanten in Verbindung 
mit Bcl2 eine erhöhte Neurogenität im Vergleich zum Wildtypprotein, die phosphodefiziente Mutante 
führte zu einer anteilig vermehrten Bildung NeuN-exprimieremder Neuronen. Zusammenfassend kann 
man sagen, dass, obwohl der Phosphorylierungsstatus von ASL1 per se keinen Zellschicksal-Wechsel zu 
fördern scheint, es in Verbindung mit BCL2 dennoch den Reifegrad reprogrammierter postnataler 
kortikaler Glia und die Umwandlungseffizienz beinflusst. 
Des weiteren beschreibe ich die Anpassung eines klonalen Kennzeichnungssystems namens StarTrack 
zur in vivo Astrozyt-zu-Neuron Umwandlung und letzendlich klonalen Analyse induzierter Neuronen. 
Hier verdeutliche ich Ergebnisse aus Vorversuchen, in welchen die Tamoxifen-aktivierten proneuralen 
Faktoren ASCL1ERT2 und NEUROG2ERT2 in GFAP-exprimierenden postnatalen kortikalen Astrozyten 
induziert werden. Diese Experimente zeigten die sogenannten „Stolperfallen“ des Systems auf, wie z.B. 
unzureichende Expressionslevel der Ascl1ERT2 und Neurog2ERT2 exprimierenden Plasmide und die bis 
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heute erfolglosen Versuche die Formation DCX-positiver Neuronen zu Induzieren. Nach Identifikation 
dieser Hindernisse im System, gehe ich weiterhin auf mögliche Strategien ein um diese zu verhindern. 
Die Kopplung von Tamoxifen-induzierbarer Aktivierung forcierter Neurogenese von Astozyten mit der 
klonalen Markierung umgewandelter Zellen wird es erlauben, gliale Klone zu identifizieren, aus denen 
Neuronen gebildet werden können. Umgekehrt wird auch die Identifikation astrozytischer Population 
welche zwar proneurale Faktoren exprimieren jedoch nicht umprogrammiert wurden möglich.  
Das Verständnis der Mechanismen, die die Ausführung Transkriptionsfaktor-angewiesener neurogener 
Programme begünstigen, wie auch der Gründe, warum manche gliale Subpopulationen nicht in der 
Lage sind ihr Ursprungsschicksal zu überschreiben und ihre Abstammungs-/Entwicklungslinie zu 
wechseln, wird in Zukunft dabei helfen, neue Strategien zu entwickeln um die Umwandlung des 
Zellschicksals für die regenerative Medizin zu verbessern.
Introduction 
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1    Introduction 
1.1 Proneural transcription factors 
During brain development, neurons forming the neocortex are derived from the division and 
differentiation of neural stem cells and neural progenitors residing in the germinal zones lining the 
ventricles, namely ventricular and subventricular zone (VZ/SVZ) (reviewed in Kriegstein and Alvarez-
Buylla 2009). Specific genetic programs instructing the differentiation of neural progenitors into 
different subtype of neurons are activated by proneural factors, transcription factors that are necessary 
and sufficient to initiate differentiation of progenitor cells into neurons (reviewed in Bertrand et al. 
2002). Knowing the mechanisms that instruct differentiation of diverse neuronal types has been of help 
to develop strategies to convert non-neuronal cell types into neurons, thus posing the basis for 
transcription factor-based reprogramming (reviewed in Masserdotti et al. 2016), which has the potential 
to become a cell-based therapy for brain repair (reviewed in Heinrich et al. 2015).  
The work presented in this thesis explores the potential of two proneural factors to convert glial cells 
into neurons in the postnatal murine cortex, namely ASCL1 and NEUROG2. Throughout the manuscript, 
consistent with the Guidelines for Nomenclature of Genes, Genetic Markers, Alleles, and Mutations in 
Mouse and Rat (http://www.informatics.jax.org/mgihome/nomen/gene.shtml), genes’ and proteins’ 
symbols are going to be indicated as follows: italicised letters for genes (e.g. Neurog2, Ascl1SA6); 
regular, uppercase letters for proteins (e.g. NEUROG2, ASCL1SA6). The paradigm of forced conversion 
of one cell type into another will be named as: reprogramming; conversion; cell fate-switch; lineage 
conversion; lineage reprogramming. Those instances in which a specific concept or finding is 
summarised by the collection of numerous multiple works in a review are going to be indicated as 
“reviewed in”. 
1.1.1    Proneural transcription factors: origin, structure and function 
Proneural transcription factors are a subset of basic Helix-Loop-Helix (bHLH) transcription factors. They 
were first identified in Drosophila as a group of genes necessary and sufficient to initiate development 
of nervous tissue and to promote specification and differentiation of neuronal cells (reviewed in 
Bertrand et al. 2002). They contain a basic Helix-Loop-Helix (bHLH) motif (Fig.1.1), first described by 
Villares & Cabrera in 1987 (Villares and Cabrera 1987). This motif comprises the basic domain and the 
HLH domain: the basic domain is involved in direct binding to the main groove of the DNA, while the 
HLH domain, composed by two alpha-helices connected by a loop, is involved in dimerization with the 
HLH domain of another proneural factor or of an E protein to form a four-helix bundle (reviewed in 
Bertrand et al. 2002; Villares and Cabrera 1987). The necessity of bHLH factors to dimerise was first 
Introduction 
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observed by Chien and colleagues in 1996. They demonstrated that while the bHLH motif of ATONAL 
was necessary to induce neurogenesis and specify the sensory organ of Drosophila,  the aminoacidic 
residues required for this specification were actually not involved in DNA-binding, suggesting the 
requirement for dimerization with a co-factor (Chien et al. 1996). 
 
 
The bHLH motif binds to a DNA sequence called E-box, a consensus sequence of six nucleotides 
(CANNTG) (Fig.1.1), and its presence is sufficient to have proneural function (reviewed in Bertrand et al. 
2002; Hinz et al. 1994). After the discovery of bHLH transcription factors in Drosophila, several related 
genes have been discovered in vertebrates, including humans (reviewed in Dennis et al. 2018; Ho et al. 
2008; Huang et al. 2014). The bHLH motif of vertebrate proteins is highly conserved among all neural 
bHLH factors, even though some portions are specific to each family of bHLH genes (reviewed in 
Bertrand et al. 2002; Ferré-D’Amaré et al. 1993). In vertebrates there are in total eight families of bHLH 
genes, but only a sub-set is actually classified as proneural: Neurogenin1 (Neurog1) (Ma et al. 1996), 
Neurogenin2 (Neurog2) (Fode et al. 1998; Ma et al. 1996), Achaete Scute-Like1 (Ascl1) (Guillemot et al. 
1993), NeuroD4 (Tomita et al. 2000), Atonal bHLH Transcription Factor1 (Atoh1) (Ben-Arie et al. 1997) 
and Atonal bHLH Transcription Factor7 (Atoh7) (Brown et al. 2002) (reviewed in Bertrand et al. 2002, 
Dennis et al. 2018). The classification as proneural genes depends on whether they can promote 
neuronal differentiation and specification and whether they can activate NOTCH/DELTA-mediated 
lateral inhibition (as defined in Dennis et al. 2018). Proneural genes are regulating neurogenesis and the 
determination of neuronal identity in different areas of the brain, including dorsal telencephalon (Fode 
et al. 2000), ventral telencephalon (Casarosa et al. 1999; Fode et al. 2000), tectum (Tomita et al. 2000), 
cerebellum (Ben-Arie et al. 1997) and retina (Brown et al. 2002). 
Their proneural activity is exerted through different mechanisms: activation of lateral inhibition via 
transactivation of Delta ligands (Castro et al. 2006; Hinz et al. 1994); activation of cascades of genes 
implementing a neuronal differentiation program (Hinz et al. 1994; Ma et al. 1996); positive-feedback 
loops in which proneural bHLH proteins promote the expression of other bHLH proteins which, in turn, 
Fig.1.1 Structure of a basic Helix-
Loop-Helix transcription factor. The 
basic Helix-Loop-Helix (bHLH) motif 
is constituted by a basic domain 
(blue) with affinity for the main 
groove of DNA and two alpha-helices 
joined by a loop (green). The 
consensus sequence for binding of 
bHLH transcription factors is 
CANNTG (E-box). Picture from 
Dennis et al. 2018. 
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induce neuronal differentiation  (Koyano-Nakagawa et al. 2000); repression of alternative glial fates (Cai 
et al. 2000; Inoue et al. 2002; Nieto et al. 2001; Tomita et al. 2000). 
The proper orchestration of their activity is necessary for brain development and is mediated by several 
mechanisms. E proteins bind the HLH domain of proneural factors thus forming homodimers or 
heterodimers with other HLH proteins and acting as transcriptional cofactors (Le Dréau et al. 2018; 
Massari and Murre 2000). The presence of E proteins available for dimerization increases the half-life 
of proneural factors, as demonstrated by the double half-life of NEUROG2 upon co-expression of E12 
as compared to NEUROG2 alone (Hindley et al. 2012).  Another class of HLH proteins present in the 
cortex during development, namely ID proteins, act as transcriptional repressors by binding to E proteins 
and sequestering them (reviewed in Massari and Murre 2000; Wang and Baker 2015; reviewed in Yokota 
2001). A further essential negative regulator of proneural factors is Notch signalling, acting via lateral 
inhibition; in fact, proneural genes themselves activate the expression of DELTA ligands (reviewed in 
Bertrand et al. 2002; Castro et al. 2006; Hinz et al. 1994). These ligands bind NOTCH receptors on 
neighbouring cells, which intracellularly release the NOTCH intracellular domain thus leading to the cell 
non-autonomous activation of their transcriptional targets, namely Hes genes. HES proteins are HLH 
transcription factors that repress transcription either via direct binding on enhancer sequences or via 
binding and sequestering of E proteins (reviewed in Bertrand e al. 2002; Chen et al. 1997; reviewed in 
Dennis etal. 2018). Another important developmental pathway, Wnt signalling, is involved in the timely 
regulation of proneural factors during early corticogenesis via induction of Neurog1 and Neurog2 
expression by beta-catenin (Bluske et al. 2012). Wnt signalling is also involved in the induction of bHLH 
genes in the adult hippocampus, where beta-catenin directly binds the promoter region of NeuroD1 to 
activate its transcription (Kuwabara et al. 2009). Similarly, Bone Morphogenetic Protein (BMP) signalling 
timely regulates the gene expression of Neurog2 during development by activating its transcription 
(Segklia et al. 2012). BMP also induces increased expression of ID proteins, which can heterodimerise 
with E proteins, thus leading to increased instability of proneural factors and their subsequent 
degradation (Viñals et al. 2004), or with the bHLH factor OLIG2, thus inhibiting oligodendrogenesis 
(Samanta and Kessler 2004). Finally, Fibroblast Growth Factor (FGF) signalling is involved in the decision 
of neuronal cell fate by activating RAS/ERK signalling, which controls which proneural gene is to be 
expressed in the developing telencephalon via phosphorylation of ASCL1 (Li et al. 2014), as will be 
explained in more detail in section 1.2.2. FGF signalling also acts as downstream effector of Sonic 
Hedgehog (Shh) signalling to regulate expression and segregation of proneural factors in the 
diencephalon (Martinez-Ferre et al. 2016) . 
In the following section, I will focus on the developmental role of the two proneural factors I used for 
my direct lineage-reprogramming studies, namely ASCL1 and NEUROG2. 
 
Introduction 
 
 8 
1.1.2    Achaete Scute-Like1 and Neurogenin2: role in development 
The mouse proneural factors Achaete Scute-like1 (Ascl1) and Neurogenin2 (Neurog2) were first 
identified by Guillemot and Joyner in 1993 and by Fode and colleagues in 1998, respectively. These 
factors are expressed in a subset of neural progenitors constituting the ventricular zone during 
development (Fode et al. 2000). Neurog2 is expressed in the dorsal telencephalon and thalamus (Fode 
et al. 2000), in the epibranchial placodes (Fode et al. 1998), in motor neuron precursor cells (Lee et al. 
2005) and in the ventral midbrain (Kele et al. 2004). Ascl1 is strongly expressed in the ventral 
telencephalon and thalamus and only at low level in the dorsal telencephalon (Fode et al. 2000), but is 
also found in the spinal cord and in the ventral midbrain (Borromeo et al. 2017; Guillemot and Joyner 
1993; Kele et al. 2004). Both proneural factors are first detected in the telencephalon of the murine 
embryonic brain by embryonic day 10.5 (E10.5) and their expression is much more pronounced in 
ventricular progenitors by E12.5 (Guillemot and Joyner 1993; Lo et al. 1991; Sommer et al. 1996). The 
complete loss of Ascl1 leads to perinatal death due to respiratory failure and feeding defects (Guillemot 
et al. 1993). Similarly, homozygous Neurog2-/- mutants mostly die within the first day of life, due to 
feeding defects; the few Neurog2-/-  pups who can survive display severe growth retardation and die at 
postnatal stages (Fode et al. 1998). Heterozygotes for either Ascl1-/+ or Neurog2-/+ instead live and 
don’t display obvious developmental defects (Fode et al. 1998; Guillemot et al. 1993). 
The study of mutants for Ascl1 and Neurog2 revealed that they have a role in the specification of 
neurons along the dorsoventral axis of the telencephalon during cortical development (Fode et al. 
2000). In fact, expression of Neurog2 in neuronal progenitors is involved in cortical identity specification 
in the pallium, while expression of Ascl1 in neuronal progenitors is involved in interneuronal 
specification in the subpallium (Casarosa et al. 1999; Fode et al. 2000) (Fig.1.2A). The maintenance of 
these two distinct domains is ensured by NEUROG2 expression, as demonstrated by the fact that 
Neurog2 mutant embryos display ectopic expression of Ascl1 in the dorsal telencephalon at E12.5-13.5 
(Fode et al. 2000) and subsequent misexpression of a set of genes usually expressed in ASCL1-positive 
progenitors during the transition from proliferation to differentiation, namely Dlx genes (Fode et al. 
2000; Porteus et al. 1994). Thus, NEUROG2 is restricting the expression of ASCL1 to the ventral 
telencephalon, but not vice versa, as highlighted by the fact that in Ascl1 mutant embryos there is no 
ectopic expression of NEUROG2 (Fode et al. 2000). Similarly, Neurog2 mutants show Wnt-mediated 
ectopic expression of ASCL1 in prethalamic progenitors at E12.5 but not at later stages (Bluske et al. 
2012). Moreover, experiments in which the coding sequences of Ascl1 and Neurog2 were swapped in 
the mouse genome revealed that ASCL1 is an instructive developmental proneural factor (Parras et al. 
2002). In fact, ectopic Ascl1 expression in the ventral spinal cord is able to respecify the identity of a 
subset of spinal motor neurons, overriding the developmental instructive program (Parras et al. 2002). 
Conversely, misexpression of NEUROG2 during development does not change the fate of cells, but can 
Introduction 
 
 9 
compensate for the loss of Ascl1 in terms of neurogenesis (Parras et al. 2002). Interestingly, forced 
expression of Neurog2 in the adult ventral subependymal zone (SEZ) re-specifies the identity of newborn 
neurons towards the glutamatergic lineage in vivo (Péron et al. 2017) but induces glutamatergic fate in 
neural stem cells of the adult ventral SEZ in vitro (Berninger et al. 2007). 
 
 
 
Neurog2 is not the only Neurogenin expressed during cortical development and classified as proneural 
gene. Neurog1 has in fact a similar pattern of expression and partial functional redundancy with 
Neurog2 (Fode et al. 2000; Ma et al. 1999; Nieto et al. 2001). Neurog1/2 contribute to the promotion 
of two different waves of neurogenesis during development (Dixit et al. 2014; Ma et al. 1999; 
Schuurmans et al. 2004). In the ventral pallium, until E12.5 Neurog1/2 direct the formation of the early-
born Cajal-Retzius neurons, which are generated before cortical glutamatergic neurons, and at later 
stages they both contribute to the specification of layer II/III neurons (Dixit et al. 2014). In the piriform 
cortex, Neurogenins exhibit different functions depending on the stage: Neurog1 delays the genesis of 
deep-layer neurons at early stages (E12.5) while at later stages Neurog2 specifies Cajal-Retius cells 
formation (Dixit et al. 2014), indicating that Neurog1 can only induce cortical identity, while Neurog2 
can also specify Cajal-Retius neuronal fate (Dixit et al. 2014). In the neocortex instead, Neurog1/2  are 
involved only in the first wave of neurogenesis, as until E14.5 they are both required to activate the 
specification of glutamatergic cortical early-born (deep-layer) neurons, while repressing the alternative 
GABAergic fate (Schuurmans et al. 2004). After this stage, in a second wave, upper-layer cortical neurons 
Fig.1.2 Developmental expression domain of NEUROG2 and ASCL1. A, During brain development, the proneural 
factors NEUROG1 and NEUROG2 are expressed in neural progenitors lining the ventricle (red), where they 
direct differentiation of cortical projection neurons. ASCL1 and its downstream targets DLX1/2 are expressed 
in progenitors lining the lateral ganglionic eminence (LGE) and medial ganglionic eminence (MGE) (green), 
directing differentiation of progenitors into GABAergic interneurons. B, Cortical neurons migrate from the 
VZ/SVZ to the cortex via radial migration, whereas interneurons generated in the ganglionic eminences reach 
the cortex via tangential migration. 
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are specified in a Neurogenin-independent manner, requiring instead Pax6 and Tlx genes, also for the 
suppression of the GABAergic alternative fate (Schuurmans et al. 2004). The loss of Neurog2 in mutant 
mice can be partially compensated by Neurog1 (Fode et al. 2000; Ma et al. 1999).  Neurogenins are also 
involved in the specification of neurons in the piriform cortex by inducing a dorsal phenotype; in fact, 
Neurog1/Neurog2 double mutants show ventralisation of these cells and their subsequent death (Dixit 
et al. 2014). Neurog2 also specifies the polarity of the leading process of pyramidal neurons at the 
initiation of radial migration (Fig.1.2B), as the mutation of a single amino acid on the protein leads to 
inhibition of radial migration and loss of unipolar morphology due to lack of phosphorylation and 
subsequent inability to bind NEUROG2’s cofactors (Hand et al. 2005). This means that Neurog2 is 
necessary for the specification of morphology of pyramidal neurons. NEUROG2 controls radial migration 
during corticogenesis through direct induction of the small GTP-binding protein RND2 (Heng et al. 2008). 
In the ventral midbrain, loss of Neurog2 leads to a substantial loss of dopaminergic neurons which is 
due to the failure to differentiate into dopaminergic neurons of Neurog2-/- SOX2-expressing 
progenitors (Kele et al. 2004). Similarly, neural precursors of the epibranchial placodes in Neurog2-/- 
embryos fail to differentiate into cranial sensory neurons (Fode et al. 1998). Neurog2 is also involved in 
specification of motor neurons (Lee et al. 2005; Ma et al. 2008). In fact, loss of phosphorylation of 
NEUROG2 leads to normal levels of neurogenesis but impaired motor neuron specification (Ma et al. 
2008). 
While Neurogenins are involved in the specification of glutamatergic neurons in the telencephalon, 
Ascl1 is required for the specification and migration of GABAergic interneurons (Casarosa et al. 1999). 
ASCL1 directs in fact tangential migration of neuronal cells generated in the ventral telencephalon 
towards the neocortex (Fig.1.2B) through induction of Ephb2 expression to define the migratory route 
(Liu et al. 2017). The guidance mechanism requires the presence of DLX2 for migration through the 
ventricular zone/subventricular zone, while ASCL1 is involved in the passage through the intermediate 
zone (Liu et al. 2017).  
In addition to their role in neuronal specification, Neurog2 and Ascl1 play an important role in regulating 
neural progenitors’ maintenance and differentiation. Interestingly, Neurog2/Ascl1 double mutants 
show a disruption of the radial glial scaffold at the ventricle, accumulation of proliferating neural 
progenitors and a premature differentiation of progenitors into immature astrocytes during mid-to-late 
embryogenesis (Nieto et al. 2001). This indicates a role for both transcription factors in the lineage 
restriction of cortical progenitors, and their requirement to exit stemness and commit to a 
differentiated fate (Nieto et al. 2001). Moreover, it indicates that Ascl1 and Neurog2 are repressing the 
astroglial lineage (Nieto et al. 2001; Tomita et al. 2000). Double mutants also lose the expression of 
HES5, while single mutants don’t, thus indicating a functional redundancy of ASCL1 and NEUROG2 in 
the activation of Notch signalling (Fode et al. 2000). The analysis of transcriptional targets of ASCL1 in 
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the developing ventral telencephalon shows that ASCL1 maintains the proliferative state of neural 
progenitors via activation of genes promoting cell cycle progression (Castro et al. 2011, 2006). ASCL1 
binds both closed and open chromatin in proliferating neural progenitors. Binding to regions of closed 
chromatin is usually followed by increased chromatin accessibility, indicating that ASCL1 promotes the 
opening of genomic regions, and by transcriptional activation of ASCL1 target genes during cell 
differentiation (Raposo et al. 2015). One of Ascl1 effectors, MYT1, promotes neuronal differentiation 
via direct binding on RBPJ-binding sites and repression of Notch1 and several of its downstream targets 
(Vasconcelos et al. 2016). Ascl1 has a role in regulating the proliferation and differentiation of neural 
progenitors also in the developing cortex (Garcez et al. 2015), where it is expressed at lower levels (Fode 
et al. 2000; Vasconcelos et al. 2016). In fact, in cortical progenitors of E14.5 embryos, ASCL1 activates 
its effector CENPJ, a centrosome associated protein regulating the plane of division of apical progenitors 
and the migration and morphology of neurons (Garcez et al. 2015). In the adult neurogenic niches, Ascl1 
is expressed in proliferating adult neural stem cells (aNSCs) and intermediate progenitors (Andersen et 
al. 2014; reviewed in Encinas and Fitzsimons 2017). The loss or reduction of Ascl1 expression leads either 
to incapacity of adult neural stem cells to exit quiescence or to lower proliferation rates of active aNSCs, 
indicating a role of Ascl1 in the promotion of the activation of aNSCs (Andersen et al. 2014). The exit 
from a quiescent state is mediated by ASCL1’s transcriptional control of cell cycle-regulating genes 
(Andersen et al. 2014). Moreover, Ascl1 has a role in the specification of proliferating adult neural 
progenitors. In fact, overexpression of Ascl1 respecifies subependymal zone-derived aNSCs expanded in 
vitro into GABAergic interneurons (Berninger et al. 2007). 
Finally, Ascl1 is also involved in the generation of oligodendrocyte progenitors (OPCs) in the murine 
ventricular zone (Nakatani et al. 2013; Parras et al. 2007; Parras et al. 2004). Here, a subset of PDGFR-
positive OPCs expresses ASCL1, which is necessary for the embryonic formation of an early population 
of OPCs between E11.5 and E13.5; the proneural factor cooperates with OLIG2 for the specification of 
oligodendrocytes at this stage (Parras et al. 2007). Ascl1 has also an interesting role in postnatal stages, 
where it is expressed by progenitors of neuronal and oligodendroglial lineages and is necessary for the 
postnatal formation of OPCs derived from the subventricular zone (Nakatani et al. 2013; Parras et al. 
2007). Ascl1 mutants exhibited loss of neuronal precursors and OPCs at the subventricular zone and in 
the olfactory bulb at birth (Parras et al. 2004). Similarly, the deletion of Ascl1 in OPCs of the embryonic 
and adult spinal cord results in decreased proliferation of these progenitors, while their differentiation 
potential remained unaltered, thus illustrating a role of this proneural factor in the regulation of the 
proliferative state of OPCs (Castro et al. 2011, 2006; Kelenis et al. 2018). 
As for proneural genes in general, the regulation of Ascl1 and Neurog2 is exerted through similar 
pathways (reviewed in Bertrand et al. 2002, Dennis et al. 2018). For instance, in neural progenitors the 
BMP pathway transiently activates Neurog2 at E14-15, thus regulating its transcripts’ levels (Segklia et 
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al. 2012). Conversely, BMP-mediated activation of Id1 leads to sequestering of the E protein E47, thus 
hampering E47 dimerization with ASCL1 and subsequently leading to degradation of ASCL1 (Viñals et al. 
2004). This indicates a role of the balance of E proteins and Id proteins in the determination of the 
function and stability of ASCL1. Moreover, at low level of BMP induction in neural tube-derived neural 
stem cell (NSC) colonies in vitro, Neurog2 and Ascl1 promote sensory and autonomic neuronal fate, 
respectively (Lo et al. 2002). Another important regulator of proneural function is Notch signalling, 
through NOTCH-mediated lateral inhibition (reviewed in Bertrand et al. 2002). Ascl1 is more sensitive 
than Neurog2 to lateral inhibition, as demonstrated by the fact that, after treatment of NSCs colonies 
in vitro with a DELTA ligand, ASCL1-mediated neurogenesis is reduced more strikingly than the 
NEUROG2-mediated one (Lo et al. 2002). Interestingly, both proneural factors’ expression levels 
oscillate every 2-3 hours in neural progenitors as an effect of lateral inhibition (reviewed in Guillemot 
and Hassan 2017; Imayoshi et al. 2013). Notably, the NOTCH-dependent mechanism acts on Ascl1 gene 
expression generating an oscillatory pattern in which to high levels of ASCL1 correspond low levels of 
HES1 and OLIG2, and vice versa (Imayoshi et al. 2013). However, differentiating neurons display 
sustained expression of ASCL1, while differentiating astrocytes and oligodendrocytes have high (but not 
sustained) levels of HES1 and OLIG2, respectively (Imayoshi et al. 2013). Protein degradation is also 
involved in the regulation of proneural factors’ activity. In fact, BMP-mediated induction of Id proteins 
and subsequent sequestering of E proteins leaves ASCL1 without a dimerization partner, thus leading to 
its proteasomal degradation (Viñals et al. 2004). Moreover, ASCL1 is degraded through the action of E3 
ubiquitin ligase HUWE1, which adds ubiquitin moieties to the protein for its destabilisation and further 
proteasomal degradation (Gillotin et al. 2018; reviewed in Guillemot and Hassan 2017). Little is known 
about NEUROG2 destabilisation and degradation instead, besides that the presence of E proteins 
increases its stability (Hindley et al. 2012). Another mechanism of regulation of proneural factors is 
phosphorylation, as I will review in section 1.2. 
1.2 Post-translational modifications of proneural transcription factors 
1.2.1 Phosphorylation of proneural transcription factors 
The importance of post-translational regulation of proneural transcription factors is gaining recognition, 
as several studies are demonstrating its role in modulating proneural activity and fate choice (reviewed 
in Dennis et al. 2018, Guillemot and Hassan 2017). Single-site or multi-site phosphorylation has in fact 
been shown to regulate and modulate a variety of aspects of the activity of bHLH factors (Hand et al. 
2005; Hindley et al. 2012; Li et al. 2011; Li et al. 2012; Ma et al. 2008; Quan et al. 2016) (Fig.1.3). 
The most prominently described proneural factor to be phosphorylated is NEUROG2. Hand and 
colleagues showed that Tyrosine 241 (Y241) is the acceptor site of a phosphoryl group. Phosphorylation 
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of this specific residue is necessary to induce radial migration of cortical neurons and to specify unipolar 
pyramidal morphology (Hand et al. 2005). Additional works on NEUROG2 demonstrated that it is target 
of phosphorylation by CDK2 and GSK3 (Ali et al. 2011; Hindley et al. 2012; Li et al. 2012). Two Serine 
residues, S231 and S234, located at the C-terminus of the protein, are phosphorylated by GSK3 to timely 
regulate NEUROG2 activity during cortical development and influence the choice of dimerization 
partner (Li et al. 2012; Ma et al. 2008). During early corticogenesis, beta-catenin negatively regulates 
Gsk3, thereby leading to homodimerization of NEUROG2 (Li et al. 2012). At later stages of 
corticogenesis, after E14.5, Wnt signalling is reduced thus no longer repressing Gsk3 (Li et al. 2012). 
Subsequently, GSK3 directly phosphorylates NEUROG2, thus favouring heterodimerisation with E47 at 
the expense of more transcriptionally active interactions and consequently reducing its proneural 
activity (Li et al. 2012). The identification of nine Serine/Proline (SP) residues in Xenopus NEUROG2 
(XNEUROG2) as targets of the cell cycle-dependent kinase CDK2, revealed that phosphorylation can also 
be involved in cell cycle coordination and cell differentiation (Ali et al. 2011). In fact, Ali and colleagues 
demonstrated that in presence of CyclinA/CDK2 XNEUROG2 is phosphorylated; this hampers its DNA 
binding activity thus maintaining the cells in a proliferative state. Conversely, a Serine/Alanine (SA) 
mutant which cannot be phosphorylated at CDK2-target sites (called phospho-deficient mutant) retains 
its neurogenic ability in a dosage-dependent manner (the higher the number of SP sites mutated, the 
higher the neurogenic potential) (Ali et al. 2011). Interestingly, not only this SA9 mutant (carrying 
mutation on all nine sites) is activating the downstream effector of Neurog2, NeuroD1, but it also seems 
to be less sensitive to lateral inhibition and to ubiquitination (Hindley et al. 2012), thus ensuring 
prolongation of the neurogenic effect.  A similar mechanism has been described for another proneural 
factor of Xenopus, NeuroD4, which is phosphorylated at six SP and Threonine/Proline (TP) sites with a 
dosage-dependent effect (Hardwick and Philpott 2015). The phospho-deficient mutant showed 
increased neurogenic ability and control of lateral inhibition via upregulation of Delta ligand gene 
(Hardwick and Philpott 2015). 
A more recent study, comprising Drosophila as well as mouse proneural factors, demonstrated the 
existence of one Serine or Threonine residue within the bHLH motif of different proneural proteins, the 
position of which is highly conserved, that is target of phosphorylation. Interestingly, the authors 
generated both phospho-deficient mutants (S>A or T>A) and phospho-mimetic mutants. In the latter, 
the substitution of the Serine or Threonine with an aspartic acid residue (D) mimics the constitutive 
presence of the large negatively charged phosphoryl group (Quan et al. 2016). This conserved residue 
acts as a binary switch for neurogenesis: phospho-deficient mutants have neurogenic capacity and bind 
the DNA; phospho-mimetic mutants behave as a strong loss of function allele for neurogenesis and 
cannot bind the DNA, probably due to the repulsion between the negative charges of DNA and aspartic 
acid (Quan et al. 2016). 
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Besides proneural factors, another bHLH factor has been described to be target of phosphorylation, 
namely OLIG2. When S147 is phosphorylated, OLIG2 forms homodimers and the fate of a group of 
neural stem cells in the spinal cord is directed toward motor neuron generation (Li et al. 2011). However, 
S>A mutation prevents motor neuron formation while promoting oligodendrocytes formation (Li et al. 
2011). This switch between lineages is due to the choice of a different dimerization partner, as 
unphosphorylated OLIG2 prefers NEUROG2 or other bHLH proteins as cofactors (Li et al. 2011). 
 
 
 
 
 
 
Fig.1.3 Phosphorylation of murine bHLH factors. Phosphorylation sites of murine bHLH transcription actors so 
far described lead to different consequences upon post-translational modification. Some change the DNA-
binding affinity, like the six serine residues targeted on mouse ASCL1, while others change the choice of 
dimerization partner (e.g. S147 on mOLIG2). Phosphorylation of a tyrosine residue on mNEUROG2 is required 
for migration and maturation of cortical neurons, while T149, which is located within the bHLH of mNEUROG2, 
acts as an on-off switch of proneural activity by affecting the binding of the proneural factor to DNA. 
m=mouse. 
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1.2.2 Phosphorylation of ASCL1 
Similarly to what described for NEUROG2 (Ali et al., 2011; Hand et al., 2005), ASCL1 contains six SP 
residues which are target of phosphorylation by CDK2 during Xenopus development (Ali et al. 2014; 
Wylie et al. 2015). The phosphorylation of these residues maintains progenitor cells in proliferative state 
and blocks neurogenesis (Ali et al., 2014; Wylie et al., 2015). Loss of phosphorylation via S>A mutation 
of these residues confers neurogenic activity both in vivo and in vitro, resistance to lateral inhibition and 
to CyclinA/CDK2-mediated cell cycle regulation; the effect seems to be dosage-dependent (Ali et al. 
2014). Interestingly, in a neuroblastoma model in Xenopus, in which the wild type form of Xenopus 
ASCL1 is highly phosphorylated, cells fail differentiating into neurons but neurogenic differentiation is 
restored upon exogenous expression of the phospho-deficient mutant (Wylie et al. 2015). 
Another important pathway regulating mouse ASCL1 proneural function is the RAS/ERK signalling 
pathway. The pathway is directly phosphorylating six SP residues in the mouse protein, thus activating 
the neurogenic and gliogenic differentiation programs while inhibiting cell proliferation (Li et al. 2014). 
The direct phosphorylation on the proneural factor has been demonstrated via serum starvation of cells 
in vitro, which by reducing RAS/ERK activity leads to reduced phosphorylation of ASCL1, and via 
exogenous expression of activated ERK in vivo during corticogenesis, which increased phosphorylation 
of ASCL1 (Li et al. 2014). A phospho-deficient mutant ASCL1 has increased neurogenic potential 
compared to the wild type protein (Li et al. 2014). Interestingly, the effect on ASCL1 is depending on the 
level of activity of RAS/ERK: when the pathway is activated, wild type ASCL1 activates the gliogenic 
differentiation pathway via transactivation of Sox9 and the neurogenic pathway via transactivation of 
Dlx1/2, whereas in the presence of boosted activity of RAS GTPase the protein responds by increasing 
transactivation of Sox9 (Li et al. 2014). The phospho-deficient is instead resistant to RAS/ERK activity, as 
its transactivation potential does not change when RAS is boosted (Li et al. 2014). Interestingly, the 
phospho-deficient mutant cannot transactivate Dlx1/2 (Li et al. 2014), thus hinting at the necessity of 
intact SP sites to bind the promoter and at a different mechanism to promote its neurogenic potential. 
Thus, it seems that SA6 phosphorylation of ASCL1 in vivo is balancing the neurogenic and 
oligodendrogenic activity of ASCL1. 
1.3 Direct reprogramming 
1.3.1 Direct cell fate-conversion: an historical perspective 
Differentiation was thought to be an irreversible process from which the cell would assume its final, 
unchangeable identity. Notably, developmental biologist Waddington theorised that the epigenetic 
landscape of the cell is like a series of valleys and hills, where the differentiated state corresponds to 
one of the valleys (reviewed in Ladewig et al. 2013; Waddington 1957). In order to go from one 
Introduction 
 
 16 
differentiated state to the other, the cell would have to overcome various hurdles represented by the 
hills (reviewed in Amamoto and Arlotta 2014, Ladewig et al. 2013; Waddington 1957). In 1962 Gurdon 
demonstrated that nuclei from the blastula or from hatched tadpole gut cells of Xenopus laevis 
contained all the information necessary to generate one adult frog individual and the potential to do it 
(Gurdon 1962). This work on somatic cell nuclei transplantation was the first one to ever demonstrate 
that is was possible to revert the state of a differentiated cell, like that of tadpole gut cells, to a 
pluripotent state that can generate all tissues of the organism (reviewed in Amamoto and Arlotta 2014; 
Gurdon 1962). Another important milestone in the field of reprogramming was reached in 2006, when 
Takahashi and Yamanaka successfully identified four transcription factors, namely OCT4, SOX2, KLF4 and 
c-MYC, that were capable of reverting differentiated fibroblasts to a pluripotent state. This work, which 
led to the generation of human induced pluripotent stem cells (hiPSCs) (Takahashi and Yamanaka 2006), 
was the premise to many other studies on cell fate-switch. 
Almost thirty years after Gurdon’s reprogramming of tadpole gut cells into pluripotent stem cells, the 
first demonstration of direct conversion of one differentiated cell type into another has been published. 
MYOD was in fact identified as the first bHLH transcription factor able to induce direct lineage-
reprogramming, converting cultured mouse embryonic fibroblasts into myocytes (Fig.1.4) (Tapscott et 
al. 1988). The first direct reprogramming of a non-neuronal cell type into neurons was achieved in 2002, 
when cortical postnatal astrocytes were converted into neurons via exogenous expression of Pax6 
(Heins et al. 2002) (Fig.1.4). The quest for understanding how to overcome the hurdles a cell faces to 
change its lineage (Waddington’s hills), brought researchers to  learn from developmental factors, as 
direct lineage-conversion partially recapitulates development (Camp et al. 2015; reviewed in 
Masserdotti et al. 2016). Thus, many transcription factors involved in the development of organs have 
to-date been used to force lineage-conversion of cells (reviewed in Amamoto and Arlotta 2014, 
Masserdotti et al. 2016). Besides heart and neuronal cells, researchers obtained also other cell types 
through direct cell fate-switch, such as astrocytes, OPCs, beta-cells in the pancreas (Caiazzo et al. 2015; 
reviewed in Heinrich et al. 2015; Yang et al. 2013; Yang et al. 2011). 
The successful conversion of astrocytes into neurons (Heins et al. 2002) opened the lead to a vast area 
of research (reviewed in Amamoto and Arlotta 2014, Masserdotti et al. 2016). Soon, other murine or 
human cell types were converted in neuronal cells, like fibroblasts, hepatocytes and pericytes (reviewed 
in Amamoto and Arlotta 2014; Karow et al. 2012; Vierbuchen et al. 2010), and the first attempts to 
directly specify subtypes of induced neurons brought to the conversion of fibroblasts into dopaminergic 
neurons and motor neurons (Caiazzo et al. 2011; Son et al. 2011). Moreover, in 2015 for the first time 
some groups have identified cocktails of small molecules able to induce conversion of fibroblasts or 
astrocytes into neurons in vitro (Li et al. 2015; reviewed in Masserdotti et al. 2016; Zhang et al. 2015). 
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Further advances came recently, with pioneering work on in vivo direct reprogramming (Heinrich et al. 
2014; Niu et al. 2013; Qian et al. 2012; Torper et al. 2013). The first instance of such work was published 
in 2012, when murine cardiac fibroblasts were converted into cardiomyocytes via the exogenous 
expression of Gata4, Tbx and Mef2c (Qian et al. 2012). The in vivo conversion of non-neuronal cells into 
neurons was achieved for the first time one year later, when endogenous astrocytes or transplanted 
fibroblasts expressing exogenous transcription factors were converted into neurons in the mouse brain 
(Niu et al. 2013; Torper et al. 2013). Noteworthy, the availability of hiPSCs as a tool opened the way to 
conversion of hiPSCs into different cell types, including neurons, and to the generation of 3D-human 
brain organoids (reviewed in Amamoto and Arlotta 2014, Heinrich et al. 2015; Lancaster et al. 2013). 
The possibility to have a 3D structure recapitulating the developing human brain in a dish is giving access 
to a model that mimics a functional brain circuitry (Quadrato et al. 2017), thus allowing to screen for 
further factors instructing human brain development that could be employed for direct neuronal 
reprogramming (reviewed in Amamoto and Arlotta 2014, Heinrich et al. 2015). 
1.3.2 Direct neuronal reprogramming: lessons from in vitro paradigms 
The first instance of forced conversion of a cell type into neurons came in 2002, when Heins and 
colleagues directly reprogrammed cultured cortical astrocytes via exogenous expression of Pax6. Such 
neuronal induction seemed to be mediated by interactions with bHLH factors, as PAX6 reduced the 
expression of Ascl1 and Olig2 (Heins et al. 2002). More recently, it has been demonstrated that co-
expression of Ascl1 with Dlx2 increases the reprogramming success from circa 30% to circa 90% of 
transduced cells converted into neurons (Heinrich et al. 2010). Ascl1- and Neurog2-induced neurons 
usually acquire identities matching to the specification role of these proneural factors during 
development (Heinrich et al. 2010; Karow et al. 2012, 2018). Neurog2 induction yields in fact 
glutamatergic neurons (Heinrich et al. 2010), while Ascl1 alone or in combination with Dlx2 or Sox2 
induces formation of GABAergic interneurons from astroglia or pericytes (Heinrich et al. 2010; Karow et 
al. 2018, 2012), as indicated by marker expression and electrophysiological recordings. Nevertheless, 
recent work from Karow and colleagues showed with single cell RNA sequencing that in human 
Fig.1.4 Timeline of major milestones in the field of cellular reprogramming.  
Introduction 
 
 18 
pericytes-to-neurons reprogramming cells can be converted into neurons of two different lineages 
(Karow et al. 2018), as I will discuss later. 
Mouse embryonic fibroblasts induced by three factors together, namely Ascl1, Brn2 and Myt1l (BAM), 
generate both glutamatergic and GABAergic neurons (Vierbuchen et al. 2010). The exogenous 
expression of Ascl1 alone is sufficient to induce the cell fate-switch, but co-expression of Ascl1 with Brn2 
and Myt1l greatly increases conversion efficiency (Vierbuchen et al. 2010). More recently, some of the 
mechanisms underpinning the BAM-mediated conversion were elucidated. In fibroblasts and neural 
progenitors, ASCL1 alone binds chromatin at genomic loci that are very similar to those it binds in the 
BAM combination (Wapinski et al. 2013). The direct binding of ASCL1 is possible thanks to a trivalent 
chromatin state present in fibroblasts; conversely, BRN2 is recruited by ASCL1 to bind ASCL1 target sites 
(Wapinski et al. 2013). Thus, ASCL1 has been described to be an “on-site pioneer” factor capable of 
binding chromatin immediately (Wapinski et al. 2013) and is able to initiate an early response through 
expression of neuronal genes (Treutlein et al. 2016). Within 12 hours from its binding to target sites, 
ASCL1 opens the chromatin, thus leading to the gain of accessibility of many neuronal-related genes 
(Wapinski et al. 2017). Eventually, also MYT1L has a role in the neuronal fate-switch. In fact, it represses 
fibroblast-identity programs and other somatic programs, such as a later-emerging competing myogenic 
program, in order to maintain neuronal identity of induced neurons (Mall et al. 2017; Treutlein et al. 
2016). A similar repressive role has been described for the transcriptional repressor REST in the context 
of astrocyte-to-neuron conversion. The activation of the tamoxifen-dependent protein NEUROG2ERT2 
after 6 days of culture fails to induce neuronal conversion, as compared to the activation of the protein 
after 2 days of culture (Masserdotti et al. 2015). This delayed activation results in lower binding of 
NEUROG2 to its target genomic loci, which is mediated by REST at early stages and by increased 
presence of the repressive marker H4K20me3 at later stages, thus hampering NEUROG2-mediated 
activation of transcription (Masserdotti et al. 2015). 
These studies show that in fibroblasts and postnatal cortical astrocytes ASCL1 can activate the neuronal 
program to convert cells into neurons either alone or with other factors, in this case DLX2 or BRN2 and 
MYT1L (Heinrich et al. 2010; Vierbuchen et al. 2010). Nevertheless, the activity of ASCL1 appears to be 
context-dependent, as demonstrated also by the fact that alone it fails to convert human brain-derived 
pericytes into neurons (Karow et al. 2012). The fate-switch from the mesodermal cell type to neurons 
requires the co-expression of the transcription factor SOX2, which acts synergistically with ASCL1 to 
induce a neural stem cell-like gene expression program that eventually leads to conversion into neurons 
(Karow et al. 2018). This synergistic action allows the modulation of different signalling pathways that 
contribute to direct reprogramming and the maintenance of induced neurons. Interestingly, in this 
context the ASCL1/SOX2-mediated conversion leads to the formation of two distinct neuronal 
populations: the activation of a Dlx-driven program gives rise to GABAergic neurons, while the activation 
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of a Neurog2-driven program generates glutamatergic neurons (Karow et al. 2018), suggesting that the 
direct conversion happens through a bipotent-progenitor state. Such context-dependent behaviour 
might hold true also for other transcription factors involved in forced lineage-conversion. 
Interestingly, also miRNAs have a role in direct cell fate-switch (Abernathy et al. 2017; Lee et al. 2018; 
Victor et al. 2014; Yoo et al. 2011). In fact, the expression of the neuronal-specific miR-9/9* and miR-
124 in human fibroblasts leads to changes in DNA methylation, chromatin accessibility and 
transcriptome that eventually result in the opening of neuronal-subtype specific loci (Abernathy et al. 
2017; Lee et al. 2018; Yoo et al. 2011). Interestingly, the two miRNAs don’t need co-expression with 
neuronal-specification factors to induce the cell fate-switch, meaning that non-translated elements 
such as miRNAs or long non-coding RNAs might have a role in forced neuronal mediation and 
specification (Abernathy et al. 2017; Karow et al. 2018; reviewed in Masserdotti et al. 2016). Moreover, 
co-expression of miR-9/9* and miR-124 with lineage-specific transcription factors induces formation of 
striatal medium spiny neurons human fibroblasts in vitro (Victor et al. 2014), thus further hinting at a 
role for miRNAs in forced neurogenesis. 
Another aspect of importance recently emerged for cell fate-switch is the metabolic state of cells. The 
forced conversion of fibroblasts or cortical astrocytes mediated by Neurog2 or Ascl1 seems in fact to 
activate a transcriptional program causing oxidative stress in the cells (Gascón et al. 2016). The action 
of reactive oxygen species thus generated leads to cell death and reduced reprogramming efficiency, 
which is consequent to the switch from a glycolytic metabolism to an oxidative phosphorylation-
sustained metabolism (Gascón et al. 2016; Kim et al. 2018). However, the co-expression of the proneural 
factors with Bcl2 or co-treatment with antioxidants helps the cells to overcome this metabolic hurdle 
by inhibiting a cell death program called ferroptosis, thus surviving and successfully converting into 
neurons (Gascón et al. 2016). 
1.3.3 Direct neuronal reprogramming: lessons from in vivo paradigms 
In vitro paradigms are useful to understand the mechanisms underpinning direct cell-lineage 
conversion, to screen for novel factors in the quest for the generation of specific neuronal subtypes and 
to investigate the functional properties and the integration of induced neurons after transplantation 
(reviewed in Heinrich et al. 2015; Torper et al. 2013; Yang et al. 2013). However, the necessity to find 
successful strategies to replace neuronal cells lost in the brain after traumatic or neurodegenerative 
stimuli, drove several groups to investigate the possibility of performing in vivo direct conversion of 
brain resident cells into neurons (reviewed in Amamoto and Arlotta 2014, Heinrich et al. 2015). One of 
the first studies to bridge in vitro direct reprogramming with in vivo paradigms, described transduction 
of fibroblasts or astrocytes with Cre-dependent lentiviral vectors expressing the BAM factors (Brn2, 
Ascl1, Myt1l). After injecting the viruses in the adult rodent striatum, they activated the transcription 
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factors and identified successful neuronal reprogramming of injected cells, specifically generating 
dopaminergic neurons (Torper et al. 2013). Following this report of the successful induction of direct 
neuronal cell-fate conversion of transplanted cells in the rodent brain, other studies described cell-fate 
conversion of non-neuronal brain resident cells into neurons (Heinrich et al. 2014; Liu et al. 2015; Niu 
et al. 2013, 2015; Su et al. 2014). 
 
 
 
 
 
 
Fig.1.5 Main advances in the field of direct neuronal cell fate-switch mediated by transcription factors in vivo. 
Direct conversion of brain resident cells into neurons has been successfully achieved from different starting 
populations: astrocytes, OPCs and newly generated neurons in the cortex; astrocytes in striatum and spinal 
cord. In most cases it is required to induce a reactive state of glial cells, e.g. via stab wound injury. Direct 
conversion of astrocytes in striatum and spinal cord goes through the formation of neuroblasts, which 
proliferate in situ, and mature when induced with valproic acid or BDNF.  
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A proneural factor prominently used in vitro to convert postnatal cortical astrocytes into neurons, 
namely ASCL1, fails to reprogram endogenous adult reactive cortical glia in vivo (Heinrich et al. 2014). 
However, expression of Ascl1 in reactive astrocytes of the dorsal midbrain induces neurons in vitro and 
in vivo (Liu et al. 2015). Moreover, by combining ASCL1 with the transcription factor SOX2 it is possible 
to convert transduced OPCs into doublecortin (DCX)-positive neuroblasts after stab wound injury 
(Fig.1.5) (Heinrich et al. 2014). Surprisingly, also Sox2 alone induces the generation of DCX-positive 
neuroblasts; such induced cells progressively mature through time and by 21 days post injection some 
of them actually express the mature neuronal marker NeuN (Heinrich et al. 2014; reviewed in Heinrich 
et al. 2015). Moreover, Sox2-induced cells do not seem to be significantly different in terms of 
morphology and maturation than the Ascl1/Sox2-induced cells, thus indicating the forced neurogenic 
potential of this factor in the adult injured murine cortex (Heinrich et al. 2014; reviewed in Heinrich et 
al. 2015). Exogenous expression of Sox2 can convert also adult striatal astrocytes into DCX-positive 
neuroblasts expressing ASCL1 protein (Niu et al. 2015, 2013). Noteworthy, conditional deletion of Ascl1 
hampers the formation of Sox2-induced neuroblasts, hinting at the requirement of the proneural factor 
for the switch to the neurogenic lineage (Niu et al. 2015). Such induced neuroblasts proliferate in situ 
and become postmitotic mature neurons, expressing NeuN, only after treatment with neurotrophic 
factors or valproic acid (Niu et al. 2015, 2013). The same group showed that SOX2 alone is able to force 
the fate-switch of astrocytes upon spinal cord injury both in situ and after transplantation (Su et al. 
2014). Induced DCX-positive neuroblasts mature into GABAergic neurons only when treated with the 
deacetylase inhibitor valproic acid (Su et al. 2014), indicating that the epigenetic state of the cells is 
involved in the maturation of induced neurons (Niu et al. 2015; Su et al. 2014). 
Some groups have successfully converted cortical glia into glutamatergic neurons in vivo, such as via the 
exogenous expression of NeuroD1 in adult cortical astrocytes after stab wound injury or in a model of 
Alzheimer disease (Guo et al. 2014), and via the expression of the proneural factor Neurog2 (Gascón et 
al. 2016) (Fig.1.5). Notably, Neurog2 alone fails reprogramming reactive adult cortical glia (Gascón et al. 
2016). However, when co-expressed with Bcl2 or upon associated treatment with vitamin E to reduce 
oxidative stress in cells undergoing direct reprogramming, Neurog2 successfully converts reactive adult 
cortical glia (Gascón et al. 2016). 
Coming to the fine-tuning of cellular identity, the work of the group of Paola Arlotta identified FEZF2, a 
transcription factor that during development specifies subcortical projection neurons, as sufficient for 
the direct conversion of one neuronal cell type into another (Rouaux and Arlotta 2013, 2010). After in 
utero electroporation at E14.5, the exogenous expression of Fezf2 converts progenitors fated to 
generate medium spiny neurons into corticofugal neurons (Rouaux and Arlotta 2010). Surprisingly, 
forced expression of Fezf2 in callosal projection neurons from layers II/III during embryonic 
development or at early postnatal stages induces their conversion into corticofugal projection neurons 
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of layers V/VI (Rouaux and Arlotta 2013). Converted neurons changed their axonal projections, directing 
them to ipsilateral subcortical structures (Rouaux and Arlotta 2013). The fact that it is possible to convert 
one neuronal subtype into another one at early developmental stages, means that also postmitotic cells 
might have a plasticity-window for the specification of their neuronal subtype (Rouaux and Arlotta 
2013). 
The plasticity of the starting population is of great importance to achieve conversion into neurons. In 
fact, the vast majority of in vivo studies require a pre-existing injury to induce a reactive phenotype of 
glial cells present in the brain (reviewed in Heinrich et al. 2015) (Fig.1.5). Some paradigms activate glia 
through mechanical means, such as cortical stab wound injury or spinal cord hemisection (Gascón et al. 
2016; Heinrich et al. 2014, 2015; Su et al. 2014), whereas others exploit pathological conditions that 
induce reactive astrogliosis, such as stroke models or neurodegeneration models (Guo et al. 2014; 
reviewed in Heinrich et al. 2015; Torper et al. 2013). The necessity of a reactive phenotype of cortical 
astrocytes in the brain is likely to depend on the fact that it coincides with the acquisition of neural stem 
cell-like properties (reviewed in Heinrich et al. 2015, Robel et al. 2011). Similarly, striatal astrocytes are 
able to spontaneously induce neurogenesis after stroke or in an Huntington’s disease model through 
activation of a neurogenic program which induces proliferating DCX-positive neuroblasts (Magnusson 
et al. 2014; Nato et al. 2015). While most experimental paradigms require a pre-existing injury, some 
studies performed by expressing SOX2 in striatal glia did not require an injury to induce a reactive 
phenotype of the starting cell population (Niu et al. 2015, 2013). 
1.4        Astrocytes 
1.4.1    Origin and function of astrocytes 
Astrocytes are glial cells that originate from the same developmental precursors of neurons, namely 
radial glia (RG). At perinatal stage, once radial glial cells (RGCs) have generated neurons and their role 
in the guidance of newly born neurons to their final position in the cortical plate is concluded, some 
RGCs undergo a series of transcriptional and morphological transformations to become astrocytes while 
others remain as neural stem cells in dedicated postnatal niches (Barry & McDermott 2005; Culican et 
al. 1990; Fuentealba et al. 2015; Furutachi et al. 2015; reviewed in Kriegstein & Alvarez-Buylla 2009). 
RGCs first lose the attachment to the ventricle, then migrate to the developing cortex via soma 
translocation (reviewed in Kriegstein and Alvarez-Buylla 2009). Here, newly generated astrocytes locally 
proliferate and divide symmetrically to generate more astrocytes until postnatal day 21 (P21) (Ge et al. 
2013). Astroglial cells generated postnatally in the cortex will also mature and integrate into the 
network, coupling with neighbouring astrocytes and oligodendrocytes via formation of gap-junctions 
(Ge et al. 2013; reviewed in Nagy & Rash 2007). Interestingly, progenitors generate neurons and 
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astrocytes in a columnar way (Magavi et al. 2012). Each cortical column contains pyramidal neurons and 
protoplasmic astrocytes, the latter usually in clusters containing several astroglial cells (Magavi et al. 
2012). 
As mentioned in section 1.1.2, proneural factors regulate neurogenesis and inhibit gliogenesis during 
embryonic brain development (Nieto et al. 2001). Several mechanisms are involved in the inhibition of 
gliosis. The signalling pathway most prominently involved in promotion of astrogenesis is the JAK/STAT 
pathway; its inhibition by bHLH factors, especially NEUROG1, during neurogenesis leads to the 
repression of astrogenesis (He et al. 2005; reviewed in Kanski et al. 2014; Sun et al. 2001). The 
modulation of JAK/STAT pathway activity goes through the physical sequestering of the acetyl-
transferase p300/CBP, which during neurogenesis binds NEUROG1, thus not being available for 
dimerization with STAT3 (reviewed in Kanski et al. 2014; Sun et al. 2001). However, given the presence 
of other proneural factors during development, such as NEUROG2 and ASCL1, known to inhibit 
astrogenesis (Nieto et al. 2001), it is possible that p300/CBP is sequestered by other bHLH proteins. 
Another pathway modulating proneural factors, namely RAS/ERK, has been described to regulate ASCL1 
functions via direct phosphorylation. The RAS/ERK pathway becomes transiently upregulated during late 
neurogenesis, at E15.5; in conditions of high RAS/ERK activity, ASCL1 is phosphorylated and promotes 
activation of a gliogenic program, inducing Sox9-expressing glial precursors (Li et al. 2014). 
One of the main changes permitting gliogenesis is the opening of chromatin at the promoter of the Glial 
Fibrillary Acidic Protein (GFAP) gene, expressing a protein involved in gliogenesis and widely used as an 
astroglial marker (Cheng et al. 2011; reviewed in Kanski et al. 2014, Sofroniew and Vinters 2010). 
Different factors contribute to a change in chromatin accessibility. To begin with, after the end of 
neurogenesis there is no more sequestering of p300/CBP from proneural factors, thus leading to 
dimerization of p300/CBP with STAT3 and to the activation of a gliogenic program (He et al. 2005; 
reviewed in Kanski et al. 2014). In addition to this, Notch signalling induces astrogenesis via its 
downstream target NFIA (reviewed in Kanski et al. 2014; Namihira et al. 2009), which contributes to 
demethylation of the GFAP promoter (Wilczynska et al. 2009). NFIA is also cooperating with SOX9 and 
ZBTB20 to regulate astrocytic specification via repression of the BRN2-mediated neurogenic program in 
neural progenitors (Nagao et al. 2016). It has recently been demonstrated that NFIA binds enhancer 
regions of their target genes that are primed, thereby switching them to an activated state (Tiwari et al. 
2018). The increased accessibility of chromatin in these regions results in transcription of genes driving 
astrocyte differentiation (Tiwari et al. 2018). 
After specification of progenitors into astrocytes, astrocytic fate-commitment is promoted by BMP 
signalling (Gross et al. 1996; reviewed in Kanski et al. 2014), which induces the transcriptional repressor 
REST (Gross et al. 1996; reviewed in Kanski et al. 2014; Kohyama et al. 2010). The repressor protein 
occupies the promoter of neuronal genes, thus suppressing neurogenesis (Kohyama et al. 2010; 
Introduction 
 
 24 
reviewed in Kanski et al. 2014), similarly to what was found in late-stage cultures of postnatal cortical 
astrocytes (Masserdotti et al. 2015). 
 
 
 
Astrocytes are organised in the cortex as individual domains in which one cell does not extensively 
overlap with the neighbouring astroglial cell but rather has only the most distal end-feet interdigitating 
with each other and forming gap junctions (Ge et al. 2013; reviewed in Sofroniew & Vinters 2010) 
(Fig.1.6B-B’). Cortical astrocytes contacts blood vessels and protoplasmic astrocytes envelope synapses, 
while fibrous astrocytes contact Ranvier nodes (Herrmann et al. 2008; reviewed in Sofroniew and 
Vinters 2010). Moreover, they exert many important functions, as reviewed by Sofroniew and 
colleagues (reviewed in Khakh and Sofroniew 2015, Sofroniew and Vinters 2010).  Astrocytes express 
on their membrane sodium and potassium channels (Higashi et al. 2001; Pappalardo et al. 2015; Tong 
et al. 2014), have low membrane resistance and can have evoked inward currents, albeit not being able 
to propagate an action potential (Higashi et al. 2001; reviewed in Khakh and Sofroniew 2015, Sofroniew 
and Vinters 2010). They also show excitability due to increase of intracellular calcium concentration, 
either via release from internal storage or triggered by neurotransmitters (Cornell-Bell et al. 1989; 
Fig.1.6 Morphology of protoplasmic 
astroglia. A, Hippocampal CA1 layer 
protoplasmic astrocytes exhibit very 
complex arborisation, as shown by 
labelling with Luciferin yellow. B, 
Individual domains of protoplasmic CA1 
astrocytes: cells do not invade each 
other’s domain. B’, Fluorescent labelling 
with dyes of different colours show that 
the green astrocyte has a minor overlap 
(5%) with the red ones. Figure modified 
from Khakh & Sofroniew, 2015. 
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reviewed in Khakh and Sofroniew 2015, Sofroniew and Vinters 2010). This elevated calcium 
concentration in astrocytes can be propagated to neighbouring astroglial cells and elicit release of 
neurotransmitters, thus evoking receptor-mediated currents in neurons (Ma et al. 2016; Sofroniew & 
Vinters 2010). This last effect is linked to the role that astrocytes have in the maintenance of transmitter 
homeostasis: they indeed uptake neurotransmitters released by neurons, thus clearing the synaptic 
space, and convert them into neurotransmitter precursors which they will release back in the synaptic 
space, whereby neurotransmitter precursor molecules are recycled via conversion into active 
transmitters (Clements et al. 1992; Norenberg and Martinez-Hernandez 1979; Yu et al. 1983). Astroglia 
also contributes to the maintenance of homeostasis of ions, pH and fluids, to neurovascular coupling, 
to guidance of axonal migration and to the formation of functional synapses (Powell and Geller 1999; 
reviewed in Sofroniew and Vinters 2010). The homeostatic control of water can be exerted via 
Aquaporine 4 (AQP4), a water channel expressed on the astrocytic membrane and densely expressed 
at contact with blood vessels (Schummers et al. 2008; Sofroniew & Vinters 2010). Given the fact that 
cortical astrocytes make contacts with blood vessels and synapses, the homeostatic control of fluids 
contributes also to the regulation of blood flow depending on the synaptic activity, as demonstrated via 
two-photon calcium-imaging (Schummers et al. 2008; Sofroniew and Vinters 2010). The increase in 
astrocytic calcium concentration that follows neuronal activity induces vasodilation or vasoconstriction: 
to a modest increase corresponds dilation of arterioles, whereas to a larger increase corresponds 
vasoconstriction (Girouard et al. 2009; reviewed in Mishra 2017). In addition to these roles, the 
metabolic state of astrocytes is very important too (reviewed in Sofroniew and Vinters 2010). In fact, 
astroglial cells have a glycolytic metabolism (Zhang et al. 2014) and constitute the major storage of 
glycogen granules in the central nervous system, which they can use to support neuronal activity during 
high activity or hypoglycaemia (Cataldo and Broadwell 1986).  
Astrocytes have also a role in pathological conditions, most notably through reactive astrogliosis and 
scar formation (reviewed in Dimou and Gotz 2014, Sofroniew and Vinters 2010, Sofroniew 2009). Upon 
invasive injury, such as a stab wound, ischemia, or inflammation, local astrocytes assume a “reactive” 
phenotype: they become hypertrophic and upregulate GFAP expression, proliferate and acquire neural 
stem cell-like properties (reviewed in Robel et al. 2011; Sirko et al. 2013; reviewed in Sofroniew and 
Vinters 2010, Sofroniew 2009). Moreover, they undergo a series of molecular changes mediated by 
different pathways, including JAK/STAT and Shh (Sirko et al. 2013; reviewed in Sofroniew 2009). In case 
of severe injury, reactive astrogliosis is accompanied by glial scar formation (Anderson et al. 2016; 
reviewed in Robel et al. 2011, Sofroniew 2009, Sofroniew and Vinters 2010). The scar is a dense and 
compact fibrotic tissue made of reactive scar-forming astrocytes derived from proliferation (Bardehle 
et al. 2013) (with overlapping domains and elongated morphology), fibrotic cells and inflammatory cells 
(reviewed in Sofroniew 2009; Wanner et al. 2013). The scar creates a barrier against inflammatory 
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agents and infectious agents, thereby protecting the healthy tissue. However, some consider the scar 
to have negative effects, via the formation of neurotoxic astrocytes induced by activated microglia, 
which inhibit axonal regeneration and induce death of neurons and oligodendrocytes (Liddelow et al. 
2017; reviewed in Sofroniew 2009; Sofroniew and Vinters 2010). In opposition to these data, it has been 
recently demonstrated that ablation of scar-forming astrocytes from a spinal cord injury site hampers 
axonal regeneration, and that the cells present at the lesion site upregulate molecules supporting axonal 
growth (Anderson et al. 2016; reviewed in Sofroniew 2009, Sofroniew and Vinters 2010), thus pointing 
at the fact that the actual mechanisms triggered by cell types and molecules involved in a glial scar 
formation are not yet completely understood. Interestingly, in the spinal cord a sub-population of a non-
glial cell type, namely pericytes, forms the core of the scar and gives rise to stromal cells (Goeritz et al. 
2011). The progeny of stromal cells invades the damaged tissue and deposits extracellular matrix, 
thereby contributing to the formation of the scar (Goeritz et al. 2011).  
1.4.2    Heterogeneity of astrocytes 
Astrocytes are a very heterogeneous population in terms of morphology, functions and reaction to 
injury. Mouse astrocytes are morphologically characterized as protoplasmic (Fig.1.6) and fibrous, which 
are located in the grey matter or white matter, respectively (Hu et al. 2016; reviewed in Sofroniew & 
Vinters 2010). Some astrocytes, at the border of the scar-forming area during reactive astrogliosis, 
acquire an elongated morphology which differentiates them from the others (Wanner et al. 2013), while 
astroglial cells of the cerebellum and retina (Mueller glia, Bergmann glia, Velate astrocytes) have region-
specific characteristics (Farmer et al. 2016; reviewed in Farmer & Murai 2017). Astrocytes make contacts 
with blood vessels; protoplasmic astrocytes make also contacts with synapses, while fibrous astrocytes 
contact Ranvier nodes, thus having different functions at the synapse and in myelination, respectively 
(Herrmann et al. 2008; reviewed in Sofroniew and Vinters 2010). 
Protoplasmic astrocytes are known to have a big arborisation, with branches, branchlets and leaflets 
constituting 90-95% of their volume (Bushong et al. 2002; reviewed in Khakh and Sofroniew 2015) 
(Fig.1.6A). They are organised in individual non-overlapping domains, with only about 5% of their surface 
(the leaflets) overlapping with nearby astroglial cells (Bushong et al. 2002; reviewed in Khakh and 
Sofroniew 2015, Sofroniew and Vinters 2010) (Fig.1.6B-B’). Interestingly, cortical layering seems to be 
required for the emergence of heterogeneity among cortical astrocytes. Their morphological and 
molecular properties depend in fact on cortical layers, such that deep layer astrocytes expand 
tangentially (horizontal, in relation to the pial surface) whereas upper layer astrocytes expand radially 
(vertical, in relation to the pial surface) (Lanjakornsiripan et al. 2018). Moreover, layer II/III astrocytes 
occupy a bigger volume and cortical astroglia exhibits layer-specific morphology (Lanjakornsiripan et al. 
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2018). Cortical layering influences also the formation of the tripartite synapse, as layer II/III astrocytes 
appear to have a broader ensheathment of the synapse (Lanjakornsiripan et al. 2018). 
In subcortical regions, astroglial cells behave differently depending on their location. Striatal astrocytes 
are in fact larger than hippocampal ones, and differ from the latter in terms of transcriptome, proteome, 
electrophysiological properties and proximity to the synapse (Chai et al. 2017). Moreover, Shh signalling 
displays differential effects on astrocytes of different brain areas (reviewed in Farmer & Murai 2017). 
For instance, neuronal induction of Shh signalling in hippocampal astrocytes translates into expression 
of the potassium channel Kir4.1 (Farmer et al. 2016), while in cerebellar Velate astrocytes (VA) it 
promotes a switch from expression of VA typical markers to markers of Bergmann glia (Farmer et al. 
2016). 
Astrocytes exhibit also diverse expression of markers used for their identification. GFAP is in fact 
expressed by some, but not all, astrocytes, by neural stem cells and by reactive astrocytes and is not 
detected in adult cortical astroglia (Levitt et al. 1981, 1983; reviewed in Kriegstein and Alvarez-Buylla 
2009, Sofroniew and Vinters 2010). The channel Kir4.1 is highly expressed in astrocytes of hippocampus 
and cerebellum, but not in the rest of the brain (Poopalasundaram et al. 2000); the expression of the 
glutamate transporter GLAST is higher in the cerebellum than in the rest of the brain, whereas the 
expression of the glutamate transporter GLT-1 is higher in cortex, hippocampus and striatum (Lehre et 
al. 1995); connexins are heterogeneously expressed and Connexin30 is expressed only in the grey 
matter, although with regional patterning (reviewed in Khakh & Sofroniew 2015; Nagy et al. 1999; 
reviewed in Nagy & Rash 2007).  
There is also increasing evidence of the regionalisation of astrocytic function, as suggested by 
transcriptional and activity-dependent diversity. First of all, the heterogenous distribution of connexins’ 
expression results in different density of gap junctions in different brain regions, which implies regional 
variations in the coupling of astrocytes (Houades et al. 2008). Astroglial cells can have also different 
responsiveness to Ca2+-signalling, with different types of Ca2+-signals observed (reviewed in Khakh and 
Sofroniew 2015). These signals can be spontaneous, mediated by neurons, arousal-evoked, specific to 
branches and branchlets or specific to the soma and large branches (Cornell-Bell et al. 1989; Ma et al. 
2016; reviewed in Khakh and Sofroniew 2015; Sasaki et al. 2014). At a molecular level, it has been 
recently demonstrated that there is a gradient of transcribed proteins in astrocytes, from the cortex to 
the thalamus, indicating heterogenous molecular footprints (Morel et al. 2017). The different 
transcriptional profile seems to be linked to the different region-selective functions of cortical and 
subcortical areas (Morel et al. 2017). 
Astrocytes are heterogeneous also in their response to injury. A fraction of the cells at the border with 
the injury site proliferates, possibly due to Shh-responsiveness, and generates the scar-forming 
astrocytes (Bardehle et al. 2013; Farmer et al. 2016; Sirko et al. 2013; Wanner et al. 2013).  Two-photon 
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imaging experiments performed by Bardhele and colleagues in 2013 showed how astrocytes at the site 
of injury behave after traumatic brain injury. Surprisingly, cells involved in reactive astrogliosis at the 
site of injury do not migrate and only a small proportion of reactive astrocytes proliferates (14%), while 
the rest of the astroglial cells polarize or simply acquire a hypertrophic morphology (45% and 47%, 
respectively) (Bardehle et al. 2013). Cells that polarize and extend towards the injury site, polarize 3-5 
days after injury and maintain the elongated processes for weeks. Interestingly, the majority of 
astrocytes that proliferate are juxtavascular, with their somata in contact with the glio-vascular 
basement membrane (Bardehle et al. 2013), which hints at the role of this sub-set of reactive astrocytes 
in limiting infiltration of other cells contributing to inflammation or fibrosis. 
1.5        PiggyBAC transposons 
1.5.1    PiggyBAC transposase: mechanism of action 
Part of the work presented in this thesis is aimed at adapting a clonal labelling system based on 
PiggyBAC-mediated transposition of genetic elements to be used for direct conversion of astrocytes 
into neurons. The piggyBAC transposon is an autonomous DNA element capable of moving itself from 
one location of the genome to another thanks to the enzyme transposase. Originally isolated from the 
cabbage looper moth (Trichoplusia ni), we know today that it belongs to a superfamily of elements found 
in several non-insect species, including Homo sapiens (reviewed in Yusa 2014; Yusa et al. 2011). The 
piggyBAC transposon originally contains: the gene for the transposase, flanked by 5’ and 3’ terminal 
inverted repeats (TIR) to signal where the enzyme should bind; the tetranucleotide TTAA for specific 
insertion (Fraser et al. 1985; reviewed in Yusa 2014). The transposase contains a DDE/D domain, 
necessary to catalyse all steps of transposition: nicking, hairpin resolution and target joining (reviewed 
in Yusa 2014; Yuan and Wessler 2011). At first, the transposase nicks the 3’ ends of the transposon at 
each strand, thus generating free 3’-OH ends. These free ends are then attached to the 5’ end of the 
flanking TTAA tetranucleotide on the complementary strand, forming a hairpin. While the genome is 
being repaired at the nicked sites via joining of the TTAA free ends, the transposase resolves the hairpin 
by nicking it and leaving again free 3’OH ends. At the new target site, the TTAA sequences are nicked at 
their 5’ end in each strand and the free 3’OH ends are joined via ligation of the 5’ overhangs (Mitra et 
al. 2008; reviewed in Yusa 2014) (Fig.1.7). Given the formation of overhanging TTAA ends, the piggyBAC 
transposase does not require DNA replication and does not leave a footprint (reviewed in Yusa 2014; 
Yusa et al. 2011). 
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1.5.2    PiggyBAC transposase: tool for mammalian expression systems 
In order to use the PiggyBAC transposase as a genetic tool, different versions have been engineered. 
The most prominent changes to the system are the generation of a hyperactive PiggyBAC transposase 
containing seven aminoacidic mutations that highly increase its transposition efficiency, the separation 
of the system in two independent elements (the transposon and the transposase) and the generation 
of an inducible transposase (Cadiñanos and Bradley 2007; Yusa et al. 2011; reviewed in Yusa 2014). The 
separation of enzyme and mobile element allows the use of this tool for integration of genomic 
elements that are up to 10Kb long (Li et al. 2011). The hyperactive form of the transposase, called 
hyPBase, does not affect genomic integrity and introduces about 1% of point mutations due to 
integration in unspecific (non-TTAA) sites (Li et al. 2013; Yusa et al. 2011). Studies on mouse embryonic 
stem cells revealed that the hyPBase integrates the transposon preferentially at TA-rich and GC-rich 
regions, thus indicating a preference for coding regions. Moreover, integration happens predominantly 
in regions with open chromatin, with H3K4me3 enrichment, DNase I-hypersensitivity and Polymerase II 
Fig.1.7 Transposition mechanism catalysed by the PiggyBAC transposase. The PiggyBAC transposase catalyses 
transposition via three different actions: nicking at the TTAA sites and formation of a hairpin containing the 
transposon, hairpin resolution, nicking of the target site for transposition and ends joining. Figure taken from 
Yusa, 2014. 
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binding (Li et al. 2013). Interestingly, transposons prefer to be mobilised in chromosomal locations at 
less than 5Kb of distance, upstream or downstream, to coding genes and they favour loci with genes 
that are highly expressed (Li et al. 2013). 
1.5.3    StarTrack clonal labelling system 
In order to track cells in vivo, it is useful to have a combinatorial labelling system which tags cells with 
fluorescent proteins and allows to follow them and their progeny. Among the most famous tools used 
in the mouse central nervous system, is the Brainbow (Livet et al. 2007). This tool is multi fluorophore-
based and it is possible to generate mouse lines stably expressing the Brainbow fluorophores under the 
control of cell type-specific promoters; moreover, the combinatorial expression of the fluorophores is 
Cre-dependent, thus allowing precise temporal induction of labelling (Livet et al. 2007). However, in 
order to achieve a resolution of combinatorial labelling that allows clonal analysis of treated cells, e.g. 
in gain/loss of function experiments, there would be no fluorescent channels left to identify them. In 
addition to this, the possible necessity to treat animals with tamoxifen for several days in order to 
activate a specific protein, would lead to Cre-dependent recombination of all Lox sites on the Brainbow 
constructs, thus reducing the possibilities of combinatorial labelling.  
An in vivo clonal analysis system that circumvents these problems is the StarTrack clonal labelling system 
(García-Marqués and López-Mascaraque 2013). It was established for tracking of astroglia, thanks to 
the human GFAP promoter-driven expression of the fluorophores, and exploits in utero electroporation 
for the delivery of the plasmids. Thus, there are no transgenic mouse lines generated but rather a series 
of plasmids encoding for six fluorophores (Fig.1.8A) that can be injected in the lateral ventricle of 
embryos or pups as a mix (Figueres-Oñate et al. 2015; García-Marqués & López-Mascaraque 2013). The 
plasmids are randomly internalised by the progenitors lining the ventricle through electroporation 
(García-Marqués and López-Mascaraque 2013). 
In order to stably integrate the genes to express in the genome of the host cell, the Startrack system 
exploits transposons. In fact, each gene is encoded by an operon containing also the promoter and a 
polyA sequence; such operon is part of the PiggyBAC transposon, as it is flanked by the 5’ and 3’ terminal 
repeats (TR) recognised by the PiggyBAC transposase (García-Marqués and López-Mascaraque 2013). 
Given the fact that transposition requires the catalytic activity of the enzyme, in the plasmid mixture 
there is also a plasmid encoding for the hyPBase (García-Marqués and López-Mascaraque 2013). 
Moreover, each fluorophore is present in two variants: one with cytoplasmic localisation and one with 
nuclear localisation, thanks to the fusion with the Histone 2B protein (García-Marqués and López-
Mascaraque 2013). Thus, the resolution power of the combinatorial labelling is determined by the 
number of fluorophores (six), their subcellular localisation (cytoplasmic or nuclear) and the stochastic 
integration in the genome of ventricular progenitors of different copies of each transposon (Figueres-
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Onãte et al. 2016). Due to genomic integration of the transposons, the progeny of targeted progenitors 
will express the same barcode, namely the same combination of fluorophores of the cell of origin. This 
allows lineage tracking and clonal analysis of electroporated cells by colour-barcoding and spatial 
location (García-Marqués & López-Mascaraque 2013; Garcia-Marques et al. 2014). 
Analysis of adult brains electroporated at E14 with the StarTrack system revealed for instance that 
astroglial progenitors are specialised to generate a very heterogeneous population (García-Marqués 
and López-Mascaraque 2013). Protoplasmic (grey matter) and fibrous (white matter) astrocytes were 
never clonally related, while cortical astrocytes exhibited different morphological characteristics. 
Cortical clones contained up to 50 cells and were bigger than callosal clones. Moreover, they were 
usually organised in columnar domains that associated to a single blood vessel. Pial clones were instead 
either made of protoplasmic astrocytes or of fibroblast-like astrocytes and expressed GFAP protein 
(García-Marqués and López-Mascaraque 2013). Similarly, the StarTrack system allowed the clonal study 
of OPCs, to reveal that the size of clones increases with life and clones grow up to hundreds of cells 
originating from pallial progenitors (Garcia-Marques et al. 2014). 
A more recent version of this tool, the ubiquitous StarTrack, allows tracking of cells from every lineage 
thanks to the human ubiquitin promoter (Figueres-Onãte et al. 2016) (Fig.1.8D). The generation of this 
method highlighted a caveat of the technique: since transposons are randomly transposed in the 
genome by the transposase, some of them are not integrated and remain as episoms in the cell 
(Figueres-Onãte et al. 2016; Figueres-Oñate et al. 2015). Episoms can be diluted or lost during cell 
proliferation, thus leading to a different amount of gene copies per each fluorophore in the cells of the 
same clone. This translates into an interference with clonal analysis of glial cells, which proliferate after 
electroporation, but not of neurons, which are postmitotic (Figueres-Oñate et al. 2015). In order to 
circumvent this, the ubiquitous StarTrack has been engineered in order to insert LoxP sites at strategic 
locations: one LoxP site is upstream of the gene (inside the transposon) and one LoxP site is downstream 
of the 3’TR (outside of the transposon) (Fig.1.8C). Cre-dependent recombination allows excision and 
loss of the genes that are present as episoms, but not of the genes stably integrated in the host genome 
(Figueres-Oñate et al. 2015). The ubiquitous StarTrack thus requires to include in the plasmid mixture 
also a plasmid encoding for a tamoxifen-dependent Cre recombinase (Figueres-Onãte et al. 2016). 
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As mentioned above, there are six fluorophores in the StarTrack clonal labelling system: mTSapphire, 
mCerulean, eGFP, eYFP, mKO, mCherry. The fluorescent proteins can be detected at a confocal 
microscope using acquisition settings that don’t overlap between each other (Figueres-Onãte et al. 
2016) (Fig.1.8B). Even though the probability of integrating each transposon should be the same, the 
percentage of detection of the six fluorophores in labelled cells is different, with eGFP, mTSaphhire and 
mCherry being the most frequently expressed ones. Conversely, eYFP and mKO are not frequently 
expressed (Figueres-Onãte et al. 2016). Thus, the StarTrack is a tool suitable for clonal analysis of cells 
in gain/loss of function experiments in vivo, or for other paradigms in which it is required to follow the 
progeny of specific cells. 
Fig.1.8 StarTrack clonal labelling system. A, The six fluorophores used by the StarTrack system, with their 
excitation and emission wavelengths. B, Spectral separation of the StarTrack fluorescent proteins. C, Overview 
of the location of the LoxP sites in plasmids of the ubiquitous StarTrack system that either integrated or not 
in the genome of the cell. Episomal copies that do not integrate are sensitive to Cre-dependent 
recombination, which excides the fluorophore. D, Illustration of the result of an electroporation performed 
at E12 with the ubiquitous StarTrack. Cre-mediated recombination was induced at P10 via one single 
intraperitoneal injection of tamoxifen and the clonal analysis was performed at P18. Astrocytes (asterisks) 
and neurons (arrowhead) can be distinguished by their characteristic morphology. Figure modified from 
Figueres-Onate et al., 2016. 
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1.6        Aim of the study 
Proneural transcription factors-mediated direct conversion of cortical glia into neurons in vivo has so far 
been achieved via modulation of different aspects, such as the choice of transcription factors (Heinrich 
et al. 2015) or the induction a reactive glial phenotype, either through stab wound injury or disease 
models (reviewed in Heinrich et al. 2015, Robel et al. 2011). Taking advantage of a model in which glial 
cells proliferate in the absence of injury (Ge et al. 2013) and can be converted into neurons using 
retrovirus-mediated forced expression of neurogenic transcription factors (unpublished data), namely 
the early postnatal mouse brain, we aimed in this study at deciphering the influence of specific biological 
aspects on the reprogramming outcome. Understanding the mechanisms underpinning forced cell fate-
switch will help improving the efficiency of this approach for generating new neurons for brain repair. 
The first aspect investigated was phosphorylation of ASCL1, a proneural factor which successfully 
converts cortical astrocytes into GABAergic interneurons when exogenously expressed alone in vitro 
(Berninger et al. 2007; Heinrich et al. 2011). Phosphorylation of ASCL1 on six serine/proline (SP) residues 
modulates its neurogenic ability both during development in vivo and in the context of direct conversion 
of human fibroblasts into neurons in vitro (Ali et al. 2014; Li et al. 2014). Thus, I studied whether the 
phosphorylation state of ASCL1 influences its ability to induce cortical glia-to-neuron conversion in the 
uninjured brain of postnatal mice. In order to do this, I first subcloned the coding sequences of: the wild 
type Ascl1 gene; a phospho-deficient Ascl1 mutant carrying S>A mutations at the six SP residues above 
mentioned; a phospho-mimetic Ascl1 mutant carrying S>D mutations at the six SP residues into a 
Moloney-Murine Leukaemia Virus (MoMLV) retroviral backbone. The three forms of ASCL1 with 
different phosphorylation states are collectively called pASCL1. The cell populations transduced by 
MoMLV retroviruses in the postnatal murine cortex correspond to astroglia and oligodendroglia 
(Fig.2.4), thus allowing the exogenous expression of transgenes in cortical glia. After injecting 
retroviruses encoding for pAscl1 in the postnatal cortex, I performed immunohistochemistry at 12 days 
post injection to assess the fate of transduced cells and determine the impact of the three different 
phosphorylation states on the reprogramming outcome: 
 Wild type ASCL1 alone has been shown to induce astrocyte-to-neuron conversion in vitro and 
to instruct developmental neurogenesis in vivo (Ali et al. 2014; Li et al. 2014). Thus, I expected 
to observe neuronal induction upon its exogenous expression (Fig.1.9, left). 
 ASCL1SA6, the phospho-deficient mutant, increases the efficiency of forced neurogenesis in 
vitro and developmental neurogenesis in vivo (Ali et al. 2014; Li et al. 2014). Thus, I expected to 
observe increased neuronal induction upon its exogenous expression (Fig.1.9, middle). 
 ASCL1SD6, the phospho-mimetic mutant, mimics constitutive phosphorylation of the protein. 
It has been shown that high levels of RAS/ERK signalling pathway activation, which directly 
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phosphorylates the six SP residues of ASCL1 during mouse cortical development, lead to 
increased transactivation of Sox9, expressed by glial progenitors (Li et al. 2014). Thus, I expected 
to observe increased gliogenesis upon its exogenous expression (Fig.1.9, right). 
 
Knowing whether the phosphorylation of ASCL1 modulates the neurogenic ability during in vivo cell fate-
switch can help improving forced conversion efficiency.  
Besides investigating the role of post-translational modifications, I adapted a tool used for in vivo clonal 
labelling, called StarTrack, to be used for conversion of postnatal cortical astrocytes into neurons. The 
StarTrack system allows clonal labelling of cells via in utero electroporation of plasmids encoding for 
different fluorophores. These plasmids encode the transgenes within transposons of the PiggyBAC 
transposase which, after injection in the lateral ventricle and electroporation, get randomly internalised 
in neural progenitors and randomly integrated by a hyperactive form of the PiggyBAC transposase 
(called hyPBase) in the genome of the host cell. This randomised integration of the fluorophores results 
in the acquisition of a specific colour-barcode of the cells (García-Marqués & López-Mascaraque 2013; 
García-Marqués et al. 2014). The StarTrack system offers the advantage of exploiting different 
Fig.1.9 Graphical abstract of the experimental hypothesis for section 2.1 By means of retroviral transduction, 
the pAscl1 genes have been exogenously expressed in cortical glia. To determine the fate of transduced cells, 
immunohistochemical analyses have been performed. More specifically, given prior knowledge on the effect 
of ASCL1 phosphorylation in vivo during Xenopus and mouse neural development, it was hypothesised that 
the wild type protein would induce neurogenesis (left side), while the phospho-deficient protein would induce 
increased neurogenesis (middle). Conversely, the working hypothesis for the function of the phospho-
mimetic mutant in glia-to-neuron conversion was that it would induce a non-neuronal, i.e. glial fate (right 
side). 
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promoters for the expression of the transgenes, thus allowing tracking of cells from different lineages 
(Figueres-Onãte et al. 2016; García-Marqués & López-Mascaraque 2013; García-Marqués et al. 2014).  
By electroporating a plasmid mix containing plasmids encoding for the proneural factors Neurog2 and 
Ascl1 and plasmids encoding for the fluorophores in E14 embryos, it is possible to combine forced 
conversion of astrocytes into neurons in the postnatal uninjured cortex with clonal analysis of induced 
neurons (Fig.2.18). The investigation of the clonal origin of induced neurons will allow to study the 
starting cell population and to determine whether the heterogeneity of astroglia influences the 
outcome of forced neurogenesis. This knowledge will help determining why different subpopulations of 
astroglia expressing the transcription factors fail or succeed to reprogram into neurons and, 
consequently, to improve strategies to force cortical astroglia to change lineage in vivo. 
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2    Results 
2.1       Influence of phosphorylation on ASCL1-mediated direct glia-to-neuron conversion 
2.1.1   In vitro conversion of postnatal cortical astrocytes into neurons by exogenous expression of 
differentially phosphorylated forms of ASCL1 
The use of Moloney Murine Leukaemia Virus (MoMLV)-based retroviral vectors to exogenously express 
proneural transcription factors is an established tool for direct conversion of cortical glia into neurons 
(Heinrich et al. 2010; Heinrich et al. 2011). Thus, in order to assess the influence of the phosphorylation 
state of ASCL1 on its ability to force fate-switch of cortical glia, I cloned retroviral constructs for 
exogenous expression of three forms of mouse Ascl1 encoding for proteins with different 
phosphorylation states (all together: pASCL1). The ASCL1 protein contains in fact six Serine/Proline (SP) 
sites that are phosphorylated by kinases of the RAS/ERK signalling pathway (Li et al. 2014). In the wild 
type form (Ascl1 wt), the SP residues are not mutated and therefore possible phosphorylation targets. 
In the phospho-deficient mutant (Ascl1SA6), a S>A mutation is present at all six sites, thus hindering the 
attachment of a phosphoryl group. Conversely, in the phospho-mimetic mutant (Ascl1SD6), there is a 
S>D mutation that mimics constitutive phosphorylation due to the presence of a negative charge (Fig.2.1 
and Fig. 4.1). 
 
 
 
Fig.2.1 Retroviral vectors for the exogenous expression of pAscl1. A, Schematic of the retroviral constructs 
cloned for mammalian expression of the pAscl1 genes. B, Structure of the amino acids present at the 
phosphorylation sites in the wild type and phospho-mutant constructs. 
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After cloning the constructs for the production of retroviruses, I assessed their ability to force cell fate-
switch of astrocytes in vitro in a preliminary study via lipofection. Thus, I transfected postnatal day 5-7 
(P5-7) cortical astrocytes 24 hours (24h) after seeding the cells on PDL-coated coverslips, as previously 
described (Heinrich et al. 2011). One day after transfection, the medium was gradually switched to a 
differentiation medium without serum, to support induced neurons (Fig.2.2A). I analysed the astrocyte-
to-neuron conversion rate one week after transfection, namely at 8 days in vitro (div), via 
immunostaining for the immature neuronal marker doublecortin (DCX) (Fig.2.2B-B’’). Surprisingly, the 
analyses revealed that all three phosphorylation states of ASCL1 are capable of converting astrocytes 
into DCX-positive immature neurons (Ascl1 wt 57.3±9.9%; Ascl1SA6 79.3±8.9%; Ascl1SD6 36.8±10.4%). 
However, the phospho-mimetic construct exhibited a significantly lower direct conversion efficiency 
compared to the phospho-deficient one (Fig.2.2C). 
These experiments show that the three pAscl1 constructs can all convert astrocytes into neurons in 
vitro. However, transfection has higher variability and lower efficiency than retroviral transduction. 
Thus, retroviral particles for the expression of all three exogenous genes were produced with the aim 
of further studying pAscl1-mediated direct neuronal reprogramming. I therefore transduced postnatal 
cortical astrocytes and analysed the expression of the pan-neuronal marker beta III-tubulin (bIIItub) at 
7div (Fig.2.3B-B’’’). As a control I used a virus expressing only a fluorescent reporter (pCAG-IRES-eGFP). 
Given the ability of MoMLV-based retroviruses to transduce only cells that are proliferating, due to the 
requirement of the breakdown of the nuclear envelope to access the nucleus (Roe et al. 1993), 
astrocytes were maintained in culture with mitotic factors inducing gliogenesis, namely EGF and FGF-2 
until 24h post transduction, when the medium was completely switched to medium for the support of 
induced neurons (Fig.2.3A). As expected, no induction of neurons was observed in cells transduced with 
the control retrovirus (Fig.2.3B). Consistently with previously published results (Berninger et al. 2007; 
Heinrich et al. 2010), the wild type form of Ascl1 converted astrocytes into neurons. In addition to this, 
both phospho-mutants successfully induced neuronal fate-switch of astrocytes (Fig.2.3C) and the 
phospho-deficient mutant had the highest conversion efficiency (Ctrl 0.1±0.1%; Ascl1 wt 27.3±3.8%; 
Ascl1SA6 51.1±7.0%; Ascl1SD6 37.2±3.6%). 
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Fig.2.2 Exogenous expression of pAscl1 converts astrocytes into neurons in vitro. A, Experimental design. Cells 
were cultured in a medium supporting astroglial proliferation until the day of transfection. Subsequently, it was 
gradually switched to a medium for the support of induced neurons. B-B’’, Microscopy pictures illustrating cells 
transfected with pAscl1 (green) expressing the immature neuronal marker DCX (red). Cultured cortical astrocytes 
express GFAP (white). C, Percentage of DCX-positive cells among transfected cells at 8div. p=0.005 (One-Way 
ANOVA for all quantifications of section 2.1); n=3. Means±SD. For numbers of cells quantified and all p-values 
see Appendix III and IV. AM=Astromedium.  
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In summary, my results show that, independently on its phosphorylation state, ASCL1 can convert 
astrocytes into neurons in vitro. Nonetheless, they also hint at a role of phosphorylation in modulating 
neurogenesis, as revealed by the higher conversion rate achieved by the phospho-deficient mutant. 
 
 
 
 
 
 
Fig.2.3 Retroviral expression of pAscl1 converts astrocytes into neurons in vitro. A, Experimental design. B-B’’’, 
Microscopy illustrations of cultures of postnatal cortical astrocytes (GFAP, white). Transduced cells (red) were 
converted into beta III-tubulin (green) positive neurons upon exogenous expression of pASCL1. C, Percentage 
of converted neurons at 7div. p<0.001; n=3. Means±SD. For numbers of cells quantified and all p-values see 
Appendix III and IV. AM=Astromedium. RV=Retrovirus. 
 
Results 
 
 40 
2.1.2  In vivo direct reprogramming of postnatal cortical glia: identification of cell populations transduced 
by the retroviruses and validation of pASCL1 expression 
In order to investigate whether the phosphorylation state of ASCL1 has a role in forced neurogenesis in 
vivo, the postnatal murine cerebral cortex was transduced with the three retroviruses validated during 
in vitro experiments. Injections were performed in P5 mice, when neurogenesis is over but gliogenesis 
is occurring and astrocytes are locally proliferating (reviewed in Miller & Gauthier 2007; Ge et al. 2013). 
This means that glial cells at P5 are susceptible to transduction by retroviruses. 
It has been proposed that a viral injection itself can be considered as an injury leading to astrogliosis in 
the adult mouse cortex (Guo et al. 2014). In order to determine whether the retroviral injection 
performed on P5 mice induced a reactive phenotype of cortical glia, I analysed cells transduced with a 
control retrovirus encoding for the fluorophore DsRed (pCAG-IRES-DsRed) (Fig.2.5A-A’). I performed 
immunohistochemistry for GFAP and SOX10 at 3 days post-injection (dpi). Cells transduced with the 
pCAG-IRES-DsRed retrovirus do not exhibit hyperregulation of GFAP expression and hypertrophy at 3dpi 
as compared to the contralateral, non-injected, hemisphere (Fig.2.4), thus excluding reactive 
astrogliosis. 
 
 
 
 
 
 
 
 
Fig.2.4 No signs of hypertrophy of GFAP-positive cells and reactive gliosis in the injected cortex at 3dpi. 
Immunohistochemistry analysis of cortices 3 days after transduction with the control retrovirus pCAG-IRES-
DsRed illustrate that there are no evident signs of reactive gliosis ongoing in the injected area. GFAP-positive 
astrocytes in the injected (ipsilateral) cortex are not hypertrophic and do not show signs of reactive 
astrogliosis, as compared to the non-injected (contralateral) cortex. Immunohistochemistry for SOX10, does 
not illustrate an increase in OPCs in the ipsilateral cortex, as compared to the contralateral one. 
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Subsequently, to determine the identity of cortical cells transduced by the MoMLV-derived retroviruses 
in vivo, I first performed immunohistochemistry for glial and neuronal markers on cells transduced with 
the control retrovirus at 3dpi and then analysed their expression (Fig.2.5B-B’’, C-C’’). A large number of 
reporter-positive cells were found throughout the cortex, as expected (Fig.2.5A’). The vast majority of 
them were GFAP-positive astrocytes and SOX10-positive cells of the oligodendroglial lineage (62.8±8.1% 
and 32.2±6.1%, respectively) (Fig.2.5B-B’’, D). A limited fraction of cells were Iba1-positive microglial 
cells (1.0±0.9%) and, importantly, no DCX-positive neurons were detected (Fig.2.5C-C’’, D). 
To test the ability of pAscl1 to convert cortical glia into neurons in vivo, pAscl1-encoding retroviruses 
were injected together with a control retrovirus at P5 and the cell fate-switch success was analysed at 
12dpi. I first determined whether cells transduced with pAscl1-encoding retroviruses were indeed 
exogenously expressing the proneural factor in vivo. To do this, I performed immunohistochemistry with 
a monoclonal antibody against ASCL1 (Fig.2.6A). ASCL1 was successfully detected in cells transduced 
with pAscl1 (Fig.2.6D’-D’’’). Conversely, cells transduced with the control virus did not express it 
(Fig.2.6D). 
In conclusion, I confirmed that retroviruses can very efficiently and specifically target glial cells, 
predominantly astrocytes, and that the retroviral vectors encoding for pAscl1 were successfully inducing 
expression of exogenous ASCL1 in the cells. 
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Fig.2.5 Analyses at 3dpi in the postnatal mouse cortex reveal that glial cells are specifically targeted by a control 
retrovirus. A, Experimental scheme. A’ Transduced cells detected in the cortex. B-B’’’, Confocal microscopy 
pictures showing that GFAP-positive astrocytes (green) and SOX10-positive oligodendroglial cells (cyan) are 
targeted by the pCAG-IRES-DsRed retrovirus at 3dpi. C-C’’’, DCX-positive neuronal cells (cyan) were never 
detected. Very rare Iba1-positive microglial cells (green) were found. D, Percentage of cells among 
transduced cells targeted by the retroviral vectors. n=3. Means±SD. For numbers of cells quantified see 
Appendix III. 
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2.1.3 In vivo direct reprogramming of postnatal cortical glia: effect of different phosphorylation states of 
ASCL1 
To investigate whether pASCL1 proteins (namely Ascl1 wt, Ascl1SA6 and Ascl1SD6) have an influence on 
forced neuronal fate-switch of glial cells in vivo, I analysed the fate of transduced cells 12 days after 
injection of pAscl1-encoding retroviruses (Fig.2.6A) via immunohistochemistry for the immature 
neuronal marker DCX (Fig.2.7). While no emergence of DCX-positive induced neurons was detected in 
control conditions, I found sporadic DCX-positive cells after exogenous expression of pAscl1 (Ctrl 
0.0±0.0%; Ascl1 wt 4.9±1.6%; Ascl1SA6 6.8±0.1%; Ascl1SD6 4.0±0.2%) (Fig.2.7C). In any case, although 
significantly different to control and higher with the phospho-deficient mutant than with the phospho-
mimetic one, the direct conversion efficiency was very low as compared to the in vitro results (Fig.2.3C 
and 2.7C). Moreover, the level of DCX expression was low and the morphology of most of the DCX-
positive cells was not convincingly resembling immature neurons (Fig.2.7D). 
 
 
Fig.2.6 Exogenous expression of pAscl1 in transduced cells at 12dpi. A, Experimental scheme. B-B’’’, Confocal 
microscopy pictures depicting the injection site in the cortex at 12dpi for the control retrovirus (B) and the 
pAscl1-encoding retroviruses (B’-B’’’). C-C’’’, High magnification of transduced cells (red) showing their glial 
morphology. D-D’’’, Magnifications of cells transduced with pAscl1 in C’-C’’’ revealing they express exogenous 
ASCL1. Conversely, ASCL1 expression was not detected in control conditions. 
Results 
 
 44 
 
 
 
 
 
 
 
 
 
 
Fig.2.7 Inefficient formation of neurons upon exogenous expression of pAscl1 in vivo. A-A’’’, Transduced cells 
(red) at 12dpi. B-B’’’, Few DCX-positive cells were found among Ascl1SA6 expressing cells and only in this 
condition they changed their morphology and looked like neuroblasts. Insets illustrate the DCX staining alone 
(white). C, Percentage of DCX-positive cells among transduced cells at 12dpi. D-D’, Examples of rare DCX-
positive cells (white in the insets) detected among Ascl1 wt and Ascl1SD6 expressing cells and do not exhibit a 
striking neuroblast-like morphology. P<0.001; n=3-4. Means±SD. For numbers of cells quantified and all p-
values see Appendix III and IV. 
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Given this overall unsuccessful glia-to-neuron fate-switch, I checked if Ascl1 was involved in inducing an 
alternative, non-neuronal, fate-switch in vivo. Thus, I performed immunohistochemistry for the two 
macroglial populations targeted by the retroviruses. More precisely, I verified if there was a change in 
the proportion of astrocytes and oligodendroglial cells by performing a co-immunostaining for GFAP 
and for the pan-oligo marker SOX10 (Fig.2.8). Surprisingly, exogenous expression of pASCL1 led to a 
consistent decrease of astrocytes, as revealed by the three-times lower percentage of cells expressing 
only GFAP compared to control (Ctrl 63.9±12.1%; Ascl1 wt 18.7±3.1%; Ascl1SA6 19.5±6.1%; Ascl1SD6 
23.1±6.3%) (Fig.2.8C). This decrease in GFAP-only expressing cells was accompanied by an increase of 
the percentage of cells expressing only SOX10 upon expression of wild type Ascl1, but not of the 
phospho-mutants (Ctrl 34.9±11.3%; Ascl1 wt 69.9±7.7%; Ascl1SA6 51.1±3.1%; Ascl1SD6 49.3±4.7%) 
(Fig.2.8C’). 
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Intriguingly, in cells transduced with pAscl1 I also detected a subpopulation that was not present in 
control conditions, namely cells co-expressing GFAP and SOX10 (Fig.2.9), suggesting a state of transition 
between the two lineages. Despite the fact that all three phosphorylation states induced the presence 
of these double-labelled cells, the two phospho-mutants (Ascl1SA6 and Ascl1SD6) yielded a higher 
proportion of them (Ctrl 0.1±0.1%; Ascl1 wt 4.5±2.6%; Ascl1SA6 17.6±6.0%; Ascl1SD6 11.9±3.4%) 
(Fig.2.9B), suggesting a role in increasing oligodendrogenesis. 
In light of these findings, I determined to investigate if, within the oligodendroglial population, there 
was a change in the proportion of oligodendrocyte progenitor cells (OPCs) and mature 
oligodendrocytes. To assess this and to identify these two subpopulations, I performed co-
immunohistochemistry for the pan-oligo marker SOX10 and for the oligodendrocyte-specific marker 
APC (Fig.2.10). I quantified as oligodendrocytes cells that were co-expressing SOX10 and APC and as 
OPCs cells that were expressing only SOX10. As in my former analyses (Fig.2.8C’), the proportion of cells 
expressing only SOX10 was affected by the wild type form of ASCL1 but not by the mutants (Ctrl 
36.8±5.5%; Ascl1 wt 56.3±3.3%; Ascl1SA6 33.5±3.4%; Ascl1SD6 44.3±6.5%) (Fig.2.10C). Interestingly, 
albeit not influencing the progenitors’ fraction (Fig. 2.10C), the phospho-mutants increased the 
oligodendrocytes’ fraction compared to the wild type (Ctrl 15.2±5.5%; Ascl1 wt 9.1±3.3%; Ascl1SA6 
19.4±3.4%; Ascl1SD6 20.3±6.5%) (Fig.2.10C’), suggesting a possible role in oligodendrocyte 
differentiation. Moreover, ASCL1 seems to slightly reduce the fraction of oligodendrocytes, even though 
the decrease was not significant (Fig.2.10C’). 
 
 
 
 
 
Fig.2.8 pAscl1 expression decreases the proportion of astrocytes and increases the oligodendroglial population. 
(See page before) A-A’’’, Overview of cells transduced with pAscl1 and control vector (red) at 12dpi in brain 
sections following co-immunohistochemistry for GFAP and SOX10. B-B’’’, Magnifications illustrating 
transduced cells expressing GFAP (green, arrows) or SOX10 (cyan, arrowheads). Insets show single channels; 
p=0.000. C, Percentage of transduced cells expressing only GFAP. C’, Percentage of transduced cells expressing 
only SOX10; p=0.001. n=3-4. Means±SD. For numbers of cells quantified and all p-values see Appendix III and 
IV. 
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Taken together, my results reveal that the exogenous expression of pASCL1 in the mouse postnatal 
cortex, independently on its phosphorylation state, is not capable of efficiently converting glia into 
neurons. They also hint at a role of Ascl1 in the maturation of cells within the oligodendroglial lineage, 
as highlighted by the higher percentage of OPCs detected upon expression of wild type ASCL1 and 
different maturation levels upon expression of the phospho-mutants. 
 
 
 
Fig.2.9 Some pAscl1-transduced cells co-express astroglial and oligodendroglial markers. A-A’’’, Confocal images 
of transduced cells (red) at 12dpi co-expressing GFAP (green, arrowhead in A) and SOX10 (cyan, arrow in A). B, 
Percentage of cells co-expressing macroglial markers among transduced cells (arrowheads in A’-A’’’). p=0.001; 
n=3-4. Means±SD. For numbers of cells quantified and all p-values see Appendix III and IV. 
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Fig.2.10 The phospho-mutants yields more mature oligodendrocytes than ASCL1 wt. A-A’’’, Confocal images of 
transduced cells (red) expressing APC (green) and SOX10 (cyan). B-B’’’, Magnifications illustrating 
oligodendrocyte progenitors (arrowheads) and oligodendrocytes (arrows). Insets show single channels. C, 
Percentage of oligodendrocyte progenitors expressing only SOX10 among transduced cells at 12dpi; p<0.001. 
C’, Percentage of oligodendrocytes co-expressing SOX10 and APC among transduced cells; p=0.003. n=3-4. 
Means±SD. For numbers of cells quantified and all p-values see Appendix III and IV. 
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2.1.4    In vivo direct reprogramming of postnatal cortical glia: co-transduction of pAscl1 and Bcl2 in the 
mouse postnatal cortex 
Due to the low glia-to-neuron conversion rate achieved upon exogenous expression of pASCL1 alone in 
vivo, it was not possible to determine whether phosphorylation of this proneural transcription factor is 
involved in the modulation of forced neurogenesis. Recently, it has been demonstrated that co-
transduction of the proneural factor Neurog2 with Bcl2 greatly increases the direct conversion of 
cortical glia into neurons in the adult lesioned cortex in vivo (Gascón et al. 2016). I therefore evaluated 
whether Bcl2 would similarly improve the neuronal fate-switch rate in postnatal cortical glia and 
analysed cells transduced with two retroviruses encoding for Bcl2-GFP and pAscl1-DsRed, respectively, 
at 12dpi (Fig.2.11A). With all three forms of Ascl1 (pAscl1), I observed several co-transduced cells which, 
with great surprise, had neuronal morphology (Fig.2.11B-B’’). Moreover, single transduced cells seemed 
to retain glial morphology (Fig.2.11B-B’’), confirming my previous observation that pAscl1 alone does 
not convert cortical glia into neurons and indicating that Bcl2 alone does not do it either. 
 
 
 
 
 
 
Fig.2.11 Co-transduction of pAscl1 and Bcl2. A, Schematic of the retroviral vectors used and of the experiment. 
B-B’’, Confocal images of cells co-transduced with pAscl1 (red) and Bcl2 (green), showing that while single 
transduced cells retain glial morphology, a majority of double-transduced cells (yellow) drastically change 
morphology and resemble neuronal cells. 
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I therefore determined whether phosphorylation of ASCL1 would modulate the level of forced 
neurogenesis in the context of Bcl2-facilitated direct reprogramming. For this purpose, I analysed the 
expression of the immature and mature neuronal markers DCX and NeuN, respectively, after co-
immunohistochemistry (Fig.2.12, 2.13). No Bcl2-only transduced cells and, in accordance with my 
previous results (Fig.2.7C), rare pAscl1-only transduced cells expressed DCX (Fig.2.12D). On the contrary, 
many co-transduced cells acquired expression of neuronal markers (Fig.2.12D and 2.13D), in line with 
the morphological alteration described above. Interestingly, while expression of either the wild type or 
phospho-deficient protein gave a similar abundance of DCX-only positive cells, the phospho-mimetic 
protein yielded a slightly but significantly higher proportion of immature neurons (Ascl1 wt 26.9±2.6%; 
Ascl1SA6 23.0±5.5%; Ascl1SD6 38.8±6.0%) (Fig.2.12D). In contrast, the induction of NeuN-only positive 
neurons was more prominent when expressing the phospho-deficient protein (Ascl1 wt 5.8±3.0%; 
Ascl1SA6 27.5±3.9%; Ascl1SD6 13.1±4.7%) (Fig.2.13D). Notably, some cells expressing only the 
fluorescent reporter DsRed presented neuronal morphology and expressed NeuN (Fig.2.13D), an 
observation that was never made upon pAscl1-only transduction (Fig.2.7). Rather than suggesting the 
ability of pAscl1 alone to generate mature neurons from glia, this may result from non-detectable levels 
of transgene (Bcl2-gfp) expression and may suggest that low levels of Bcl2 expression are sufficient to 
promote Ascl1-mediated glia-to-neuron conversion. 
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Fig.2.12 Successful forced neuronal fate induction in cells co-transduced with pAscl1 and Bcl2. A-A’’’, Confocal 
illustrations of co-transduced cells. B-B’’, Insets show single channels for the retroviral reporters of pAscl1 (red) 
and Bcl2 (green). C-C’’, Single channel images revealing that co-transduced cells in B-B’’ are also expressing the 
immature neuronal marker DCX (cyan). D, Percentage of cells expressing DCX among transduced cells. p<0.001; 
n=3. Means±SD. Hashtags indicate significance of the percentage of co-transduced cells compared to cells 
transduced with pAscl1 only. Asterisks compare double-transduced conditions. For numbers of cells quantified 
and all p-values see Appendix III and IV. 
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Transient expression of DCX in newly generated neurons in the hippocampus of two months old rats is 
rapidly downregulated around one week after emergence of the cells; simultaneously, NeuN expression 
starts being upregulated, indicating the transition of the cells to a more mature stage (Brown et al. 
2003).  The expression of these two markers between day 7 and day 21 overlaps (Brown et al. 2003). 
Interestingly, further analyses of co-stainings for DCX and NeuN at 12dpi (Fig.2.14) revealed that a 
proportion of cells co-transduced by pAscl1 and Bcl2 were expressing both neuronal markers (Ascl1 wt 
12.7±3.6%; Ascl1SA6 23.2±4.4%; Ascl1SD6 18.3±2.5%) (Fig.2.14D), indicating the presence of cells in 
Fig.2.13 Forced cell fate-switch mediated by pAscl1 and Bcl2 leads to mature neurons. A-A’’, Confocal images 
show an overview of the injected area with NeuN-positive cells (cyan). B-B’’, Magnifications illustrating double-
transduced cells expressing NeuN. C-C’’, Single channel images of cells in B-B’’ (arrowheads). D, Percentage of 
cells expressing NeuN among transduced cells. p<0.001; n=3. Means±SD. Hashtags indicate significance of the 
percentage of co-transduced cells compared to cells transduced with pAscl1 only. For numbers of cells 
quantified and all p-values see Appendix III and IV. 
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transition between their immature stage and a more mature one. Of note, the phospho-deficient 
mutant induced a percentage of DCX/NeuN-double positive cells higher than wild type ASCL1 
(Fig.2.14D). 
 
 
Fig.2.14 Some converted neurons co-express DCX and NeuN. A-A’’, Confocal images show an overview of the 
injected area with DCX-positive (cyan) and NeuN-positive cells (white). B-B’’, Magnifications illustrating double-
transduced cells co-expressing DCX and NeuN. C-C’’, Single channels of insets in B-B’’ (arrowheads). D, 
Percentage of cells expressing NeuN among transduced cells. p<0.001; n=3. Means±SD. Hashtags indicate 
significance of the percentage of cells co-transduced by pAscl1 and Bcl2 compared to cells transduced with 
pAscl1 only. For numbers of cells quantified and all p-values see Appendix III and IV. 
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To summarise, I have here demonstrated that co-transduction of pAscl1 and Bcl2 promotes pASCL1-
mediated glia-to-neuron fate-switch, thus allowing the investigation of the influence of phosphorylation 
of ASCL1 on its ability to induce neuronal fate conversion in cortical glia. Moreover, the collected results 
highlight an overall higher glia-to-neuron conversion rate upon expression of the phospho-deficient or 
phospho-mimetic mutants (Table 2.1). In particular, mimicking constitutive phosphorylation yielded 
more immature neurons at 12dpi, while a deficiency in phosphorylation resulted in a higher percentage 
of mature neurons (Fig.2.12, 2.13, 2.14). Interestingly, the overall neurogenic potential of the two 
phospho-mimetic mutants was similarly higher compared to the wild type protein, as revealed by the 
sum of the percentage of double-reporter positive cells expressing neuronal markers (Ascl1 wt 
45.5±9.1%; Ascl1SA6 73.7±2.6%; Ascl1SD6 70.3±6.5%) (Table 2.1). 
 
Table 2.1    Total percentage of neuronal cells among cells co-transduced with pAscl1 and Bcl2. The mean values for 
each subpopulation quantified were considered. 
 Ascl1 wt + Bcl2 Ascl1SA6 + Bcl2 Ascl1SD6 + Bcl2 
DCX 26.9 ± 2.6%  23.0 ± 5.5% 38.8 ± 6.0% 
NeuN 5.8 ± 3.0% 27.5 ± 3.9% 13.1 ± 4.7% 
DCX/NeuN 12.7 ± 3.6% 23.2 ± 4.4% 18.3 ± 2.5% 
Total 45.5 ± 9.1% 73.7 ± 2.6% 70.3 ± 6.5% 
 
Ascl1 regulates the specification of GABAergic interneurons during development (Casarosa et al., 1999). 
Neuronal cells derived from Ascl1-mediated conversion of in vitro-expanded adult neural stem cells 
(Berninger et al. 2007) or from Dlx2-mediated conversion of astrocytes in vitro  (Heinrich et al. 2010) 
were shown to express GABA or the GABAergic transporter vGaT, respectively, which confirmed their 
interneuronal identity. I therefore investigated whether neurons derived from pAscl1/Bcl2-mediated 
fate-switch in vivo were expressing interneuronal markers. Given the fact that a considerable proportion 
of neurons induced by pAscl1 and Bcl2 already expresses the maturation marker NeuN (Fig.2.13 and 
2.14), I sought to determine whether they were also expressing GABA via immunohistochemistry. Even 
though some co-transduced cells were already expressing GABA, only a small proportion was positive 
at 12dpi (Ascl1 wt 1.2±0.1%; Ascl1SA6 9.2±2.4%; Ascl1SD6 3.0±0.4%) (Fig.2.15). The phospho-mutants 
exhibited more GABA-positive co-transduced cells and the phospho-deficient, which was also promoting 
the highest fraction of NeuN-positive cells (Fig.2.13D), induced three times more neurotransmitter-
positive cells (Fig.2.15). This suggests that pAscl1/Bcl2-induced neurons might not yet be functionally 
mature, despite the expression of the mature neuronal marker NeuN. 
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Co-expression of ASCL1 and SOX2 in the adult injured cortex induces direct conversion of OPCs into 
neurons expressing DCX at 10dpi, some of which further mature into NeuN-expressing neurons and by 
24dpi exhibit electrophysiological properties similar to immature neuronal phenotypes (Heinrich et al. 
2014). While the morphology of pAscl1/Bcl2-induced neurons at 12dpi (Fig.2.11) and the markers they 
expressed (Fig.2.13, 2.14, 2.15) suggest that the majority of reprogrammed cells become mature 
neurons, these elements are not proof of their functional maturation and integration in the cortical 
networks. Thus, in order to determine whether pAscl1/Bcl2-induced neurons were functional and to 
determine their degree of maturation, whole-cell patch-clamp electrophysiological recordings were 
performed on acute brain slices at 4 weeks post injection (wpi) (Fig.2.16A). Given the finding that co-
Fig.2.15 Some converted neurons express GABA. A-A’’, Confocal images showing cells transduced by pAscl1 
(red) and Bcl2 (green). B-B’’, Single channels illustrating GABA expression of some co-transduced cells 
(arrowheads). C, Percentage of cells expressing GABA among transduced cells. p<0.001; n=3. Means±SD. 
Hashtags indicate significance of the percentage of cells co-transduced by pAscl1 and Bcl2 compared to cells 
transduced with pAscl1 only. For numbers of cells quantified and all p-values see Appendix III and IV. 
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expression at 12dpi of Bcl2 in cells expressing the phospho-deficient protein ASCL1SA6 induces the 
highest percentage of cells positive for neuronal markers (Table 2.1) and for the neurotransmitter GABA 
(Fig.2.15), a first set of experiments were performed to determine the functional properties and 
maturation of Ascl1SA6/Bcl2-induced neurons at 4wpi (Fig.2.16B). Current-clamp recordings showed 
that some co-transduced cells had the ability to generate high-frequency repetitive action potential in 
response to a depolarising current pulse (Fig.2.16C), resembling the functional phenotype of fast-spiking 
cortical interneurons (Kepecs and Fishell 2014). Moreover, sustained depolarising current steps (5 
seconds long) showed that induced neurons were able to maintain their high firing frequency 
(Fig.2.16D), suggesting that these cells have acquired a substantial degree of functional maturation. 
Subsequently, voltage-clamp recordings were performed to determine whether Ascl1SA6/Bcl2-induced 
neurons integrated in the cortical circuitry and received synaptic inputs from surrounding neurons. 
Interestingly, five over six recorded cells exhibited spontaneous synaptic inputs (Fig.2.16E), suggesting 
a certain level of integration in the local pre-existing neuronal circuitry. Taken together, 
electrophysiological recordings of Ascl1SA6/Bcl2-induced neurons at 4wpi suggest that these cells 
become mature functional neurons resembling interneurons with high firing frequency and that they 
receive synaptic inputs, which indicates their integration in the postnatal cortical circuitry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
 57 
 
 
 
 
 
 
 
Fig.2.16 ASCL1SA6/Bcl2-expressing cells mature into high-frequency firing neurons. A, Experimental scheme. B, 
Epifluorescent pictures of an ex vivo cortical slice showing a cell transduced by Ascl1SA6 (red) and Bcl2 (green) 
(arrow). Arrowheads indicate the process of the cell. Notably, a cell transduced only with Ascl1SA6 (red, 
asterisk) retains glial morphology. C, Current-clamp recording of co-transduced cell shown in B. A depolarising 
current step of 60pA and a hyperpolarising step current of -50pA were applied for 500ms. Interestingly, the 
recorded cell exhibits high firing frequency (114Hz). D, Current-clamp recording after applying a 20pA 
depolarising current for 5s show that the cells maintains a high firing frequency for long time. E, Voltage-clamp 
recordings revealed the presence of spontaneous synaptic inputs in induced neurons. n=3. For numbers of 
cells quantified see Appendix III. 
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2.2      Development of a novel paradigm for clonal analysis of astrocytes converted into neurons in vivo 
2.2.1    Cloning of constructs for in vivo exogenous expression of proneural transcription factors via a 
transposable system 
Astrocytes are known to be heterogeneous in terms of morphology and function (reviewed in Farmer 
and Murai 2017). However, it is still unknown to what extent the heterogeneity of cortical astrocytes 
influences the outcome of forced fate-switch. Thus, to investigate the role of astroglia heterogeneity in 
direct reprogramming, I adapted a transposition- and in utero electroporation-based technique that was 
developed at the Instituto Cajal (Madrid, Spain) – the StarTrack clonal labelling system (see also section 
1.5.2).  
The StarTrack system exploits transposable elements to stably integrate them into the host cell’s 
genome. Such transposons are administered to the cells as plasmids via in utero electroporation and 
contain the operons for the expression of genes of interest (promoter, genes, transcription termination 
sequences). Their transposition is catalysed by a hyperactive version of the PiggyBAC transposase, called 
hyPBase (Fig.4.6). 
In order to study the clonal origin of induced neurons, I adapted to my purpose the plasmids of the 
original version of the StarTrack system, developed for clonal labelling of astroglia. I therefore subcloned 
tamoxifen-dependent forms of the proneural transcription factors Neurog2 and Ascl1 (Neurog2ERT2 
and Ascl1ERT2, respectively) in transposons with the human GFAP (hGFAP, in the constructs referred to 
as GFAP) promoter, thus to ensure the induction of cell fate-switch at the desired timepoint and 
specifically in astrocytes, respectively (Fig.2.17). To be able to detect the subpopulation of astrocytes 
electroporated with the plasmids for expression of the proneural factors, I subcloned in the transposon 
also the coding sequence of a fluorescent reporter preceded by an Internal Ribosome Entry Sequence 
(IRES) for enhanced transcription. Given the prior knowledge that Neurog2-mediated and Ascl1-
mediated cell fate-switch in vivo both greatly improve upon co-expression of Bcl2 and Sox2, respectively 
(Gascón et al. 2016; Heinrich et al. 2014), I subcloned in transposons also the genes for these two 
factors, again under the control of the hGFAP promoter (Fig.2.17). In light of the results I presented in 
section 2.1, combination of Ascl1 and Bcl2 is currently planned. 
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As explained in section 1.5.2, the StarTrack system allows clonal labelling of cells thanks to six 
fluorescent reporters: mTSapphire, mCerulean, eGFP, eYFP, mKO, mCherry. Each fluorescent reporter 
is expressed by a different plasmid and has either cytoplasmic or nuclear localisation (due to the fusion 
with the Histone 2B (H2B) gene) (Fig.4.5). Thus, there are in total twelve constructs, which greatly 
increases the resolution power for clonal labelling. For the purpose of achieving clonal labelling of 
electroporated cells even if they are not reprogrammed, I use the ubiquitous StarTrack system, with the 
human Ubiquitin promoter (Figueres-Onãte et al. 2016). Since each of the six fluorophores has a 
different intensity and frequency of presence in the clonal labels (Figueres-Oñate et al. 2016), I opted 
to maintain the clonal labelling system as powerful as possible and to use one of the least represented 
fluorescent proteins in the clonal labels, namely eYFP, as a fluorescent reporter for the plasmids 
expressing Ascl1ERT2 and Neurog2ERT2. Thus, the clonal labelling plasmids with ubiquitous promoter 
used in this study are ten instead of twelve. 
Fig. 2.17 Maps of the transposable constructs for direct conversion of astrocytes into neurons in vivo. The four 
constructs I cloned contain the tamoxifen-dependent genes for astrocyte-to-neuron conversion (Ascl1ERT2 and 
Neurog2ERT2) within the transposon. To avoid effects of constitutive expression of Bcl2, an antiapoptotic 
factor, and make it strictly dependent on tamoxifen, I subcloned upstream to the gene a loxed STOP cassette 
(LSL). 
 
pGFAP-Sox2 
6961bp 
pGFAP- LSL-Bcl2 
7641bp 
pGFAP-Ascl1ERT2-IRES-eYFP 
9013bp 
pGFAP- Neurog2ERT2-IRES-
eYFP  
9119bp 
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To determine the role of astroglial heterogeneity in astrocyte-to-neuron conversion, I performed in 
utero electroporations. I therefore injected embryonic stage 14 (E14) embryos with a mix containing: 
plasmids for the expression of tamoxifen-dependent versions of proneural factors; plasmids for the 
expression of their cofactors; plasmids of the ubiquitous StarTrack clonal labelling system, including one 
for transposase’s expression and one for Cre recombinase expression. To electroporate cells, I applied 
positive electric current. After birth I treated electroporated animals with tamoxifen, which ensured 
removal of the episomal copies of the ubiquitous StarTrack (Figueres-Oñate et al. 2015), activation of 
the proneural factors and activation of the transcription of Bcl2. On one hand, transcriptional activation 
of the targets of either NEUROG2 or ASCL1 is aimed at forcing direct conversion of astrocytes into 
neurons. On the other hand, labelling with the ubiquitous StarTrack plasmids allows clonal analysis of 
induced neurons, even after they have lost eYFP labelling due to inactivation of the hGFAP promoter 
(Fig.2.18). 
 
Fig.2.18 Graphical abstract of the project. A plasmid mixture containing both the transcription factors for cell 
fate-switch and the StarTrack system for integration of the plasmids and clonal analysis is injected in the 
lateral ventricles of E14 embryos. In order to internalise the plasmids in the neural progenitors lining the 
ventricle, I electroporated them. After birth, I induced activation of the factors for astrocyte-to-neuron 
conversion via tamoxifen administration. At the collection of the brains I can analyse the success of the cell 
fate-switch as well as the clonal origin of the induced neurons. XFP= Fluorescent protein. 
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2.2.2.   Confocal detection of cloned constructs after in utero electroporation 
The first step to determine the success of this method was to assess whether the constructs I cloned for 
exogenous expression of Ascl1ERT2 and Neurog2ERT2 can be detected. Thus, I first co-electroporated 
the pGFAP-Ascl1ERT2-IRES-eYFP plasmid and the ubiquitous construct pUbq-LoxP-H2BmKO-LoxP, to 
ensure correct identification of the electroporated area. I analysed the expression of the fluorophores 
via confocal imaging shortly after in utero electroporation, at E18 (Fig.2.19A). Upon detection, the eYFP 
signal appeared to be localised only in the soma despite the lack of the H2B-fusion for nuclear 
localisation (Fig.2.19B-B’). 
 
 
 
Fig.2.19 Detection of the plasmid for the exogenous expression of Ascl1ERT2. A, Experimental scheme. B, 
Confocal picture depicting cells electroporated in the cortex at E18. B’, Magnification of the inset shown in B. 
The signal of the mKO is nuclear, due to the fusion with the H2B protein. The plasmid mix included the 
hyPBase-encoding plasmid. 
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Subsequently, I analysed the brains of animals electroporated with the pGFAP-Neurog2ERT2-IRES-eYFP 
plasmid and the ubiquitous construct pUbq-LoxP-mCherry-LoxP (Fig.2.20B-B’). This time, the 
electroporation was performed on newborn pups at P0 and the expression of fluorophores was analysed 
at P6 (Fig.2.20A). I could detect eYFP signal at the lateral ventricle, even though at a low level (Fig.2.20B-
B’). 
 
The expression of the YFP reporter after in utero electroporation of the pGFAP-Neurog2ERT2-IRES-eYFP 
and the pGFAP-Ascl1ERT2-IRES-eYFP plasmids (Fig.2.19 and 2.20) is different to the expression pattern 
detected in cells electroporated with the control plasmid pPB-hGFAP-eYFP (Fig.2.21). In fact, confocal 
imaging of cells electroporated with the control plasmid and analysed at E18 shows that many cells have 
internalised the plasmid and some of them express eYFP also in their radial processes (Fig.2.21). 
 
Fig.2.20 Detection of the plasmid for the exogenous expression of Neurog2ERT2. A, Experimental scheme. This 
electroporation was performed in collaboration with the Instituto Cajal (Madrid, Spain). B, Confocal picture 
depicting cells electroporated in the cortex at P6. B’, Magnification of the inset shown in B. The signal of the 
eYFP is quite low, as opposed to the one of mCherry. The plasmid mix included the hyPBase-encoding plasmid. 
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During these preliminary experiments to find whether the pGFAP-Ascl1ERT2-IRES-eYFP and pGFAP-
Neurog2ERT2-IRES-eYFP constructs can be detected (Fig.2.19 and 2.20), the plasmids encoding for the 
tamoxifen-inducible proneural factors, the plasmid encoding for the hyPBase and the ubiquitous 
StarTrack-plasmid used to detect the electroporated area were present in the mix with a 1:1:1 
proportion. In order to determine whether a higher concentration of plasmids encoding for the 
transcription factors will give a stronger expression of eYFP, thus allowing a better identification of 
electroporated cells, a test has been performed in newborn mice. P1 mice were electroporated with a 
mix containing the plasmid encoding for Neurog2ERT2 (pPB-hGFAP-Neurog2ERT2-IRES-eYFP), one 
plasmid from the ubiquitous StarTrack system (pPB-Ubq-mCherry) and the hyPBase. The hyPBase 
constituted one-third of the mix; the remaining two-thirds contained GFAP-Neurog2ERT2-IRES-eYFP 
and Ubq-mCerry in different proportions (Fig.2.22). Confocal analysis to detect the fluorescent proteins 
was performed at P6. Cells electroporated with two times more Neurog2ERT2 than mCherry expression 
plasmid (2:1:1 dilution) (Fig.2.22, left) have higher levels of fluorescence than cells electroporated with 
a 1:1:1 proportion of plasmids (Fig.2.20, for comparison). Thus, for future experiments, a higher 
concentration of the plasmids encoding for the transcription factors will be used, hoping to achieve a 
higher expression of the reporter eYFP and therefore to better identify cells expressing them. 
Interestingly, cells electroporated with five times more Neurog2ERT2- than mCherry-expressing 
plasmids (5:1:1 dilution) have a lower level of fluorescence (Fig.2.22, right), suggesting that a too high 
concentration of the plasmid might not improve the expression efficiency. 
In summary, I could detect the eYFP reporter signal of the plasmids that express Ascl1ERT2 and 
Neurog2ERT2. Nevertheless, they both displayed unsatisfactory signal levels. The late embryonic-stage 
expression of pGFAP-Ascl1ERT2-IRES-eYFP is restricted to the soma, despite the fact that the fluorescent 
Fig.2.21 Morphology of cells electroporated with the pPB-hGFAP-eYFP plasmid. Cells electroporated at E14 
with a control plasmid (pPB-hGFAP-eYFP), express a higher amount of fluorescent protein at E18 (right), as 
compared to cells electroporated with plasmids encoding for Ascl1ERT2-IRES-eYFP (Fig.2.19) and 
Neurog2ERT2-IRES-eYFP (Fig.2.20). Moreover, it is possible to observe their radial processes directed 
towards the pial surface (left). 
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protein should be localised in the cytoplasm thereby labelling the whole cell (Fig.2.19B-B’). Similarly, the 
postnatal expression level of pGFAP-Neurog2ERT2-IRES-eYFP is very low and does not highlight the 
processes of the radial glia-like cells targeted, as opposed to the mCherry signal (Fig.2.20B-B’) and to 
the expression of eYFP from a control plasmid (Fig.2.21).  
 
2.2.3    In utero electroporation for the clonal analysis of induced neurons 
In order to convert postnatal cortical astrocytes into neurons for their subsequent clonal analysis in vivo, 
I performed in utero electroporation at E14, when radial glia is targeted by the plasmid mixture. 
Exogenous expression of Ascl1 alone fails to reprogram adult cortical glia into neurons after injury in 
vivo, but co-expression of Ascl1 with Sox2 induced cell fate-switch of adult OPCs into DCX-positive 
neurons (Heinrich et al. 2014). Thus, I co-electroporated the plasmid encoding for Ascl1ERT2, the 
plasmid encoding for Sox2 and the StarTrack plasmids (Fig.2.23A). The proneural factors fused to the 
ERT2 protein are able to induce cell fate-switch in vitro only when activated by tamoxifen administration 
(Masserdotti et al. 2015). Thus, starting at P5 I treated the newborn pups with tamoxifen for 5 
consecutive days and analysed the cell fate-switch 10 days after the end of tamoxifen administration 
(Fig.2.23A’). A successful electroporation should result in random internalisation of the plasmids in the 
cells and integration in the genome (Fig.2.23B). This implies that cells might not express all fluorescent 
reporters, and that they might express different levels of each reporter due to a different number of 
copies integrated (Figueres-Onãte et al. 2016). As a consequence of this, the number of possible 
labelling combinations to be analysed, is greatly increased. Moreover, I confirmed that it is possible to 
Fig.2.22 Cells electroporated with different dilutions of the Neurog2ERT2-encoding plasmid. The 
electroporation was performed at P1 with the GFAP-Neurog2ERT2-IRES-eYFP, the Ubq-LoxP-mCherry-LoxP 
and the CMV-hyPBase plasmids with, respectively, 2:1:1 or 5:1:1 dilution. At P6, cells containing double the 
amount of Neurog2ERT2-encoding plasmid compared to the mCherry encoding one (left) express a higher 
level of eYFP than cells containing five times the amount of Neurog2ERT2-encoding plasmid compared to the 
mCherry-encoding one (right). The quantity of the hyPBase in the plasmid mix is the same one as the quantity 
of the mCherry-encoding plasmid. The electroporations and the confocal imaging were performed in 
collaboration with the Instituto Cajal (Madrid, Spain). 
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perform immunohistochemistry for the detection of DCX-positive induced neurons without losing the 
fluorescent signal of the six reporters (Fig.2.23B’-B’’). With great disappointment I was not able to detect 
DCX-positive induced neurons labelled with the StarTrack system, but this may be related to the low 
levels of expression presented in section 2.2.2. 
To conclude, I have adapted a clonal labelling system to be used for direct conversion of astroglia into 
neurons. After cloning the vectors for the expression of transcription factor-mediated cell fate-switch, I 
performed preliminary experiments in vivo to determine whether electroporated cells can be easily 
detected. Even though such experiments have not yet allowed conversion of astrocytes into neurons 
and clonal analysis of induced neurons, they highlighted limitations of the technique as of now, which 
will be discussed in section 3.2. This will serve as basis for the further improvement of the system and 
successful completion of the project.  
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Fig.2.23 Example of in utero electroporation for clonal analysis of induced neurons. A, Experimental scheme. 
The proneural factor Ascl1ERT2 and Sox2 were co-electroporated, in addition to the ubiquitous StarTrack. 
Astrocyte-to-neuron conversion was initiated at P5, with daily tamoxifen injections until P9. Analysis were 
performed at P19, 10 days after the end of tamoxifen administration. B, Confocal overview of an 
electroporated cortex. B’, Magnification of the inset shown in B. B’’, DCX-positive cells in the striatum, where 
there are no electroporated cells, serve as a control for DCX immunohistochemistry. B’’’, Micrographs 
illustrating single channels of the inset shown in B’. 
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3       Discussion and outlook 
3.1        Cell extrinsic and cell intrinsic factors in direct cell fate-switch 
In this study, I have investigated the role of cell extrinsic and cell intrinsic factors in determining 
competence for direct glia-to-neuron conversion in the postnatal murine brain (Fig.3.1). 
First, I studied the role that signalling pathways leading to phosphorylation of transcription factors have 
on direct reprogramming. In recent years, it has been shown that RAS/ERK signalling controls Ascl1 
proneural function through the phosphorylation of ASCL1, thereby controlling developmental neural 
cell fate selection (Li et al. 2014). This opens the question of whether such kind of cell extrinsic control 
directed by signalling pathways can influence the outcome of direct cell fate-switch in the postnatal 
brain. The role of the phosphorylation of ASCL1 in forced cell fate-switch in vivo was investigated via 
exogenous expression of coding sequences encoding for the ASCL1 protein with three different states 
of phosphorylation (all together, pASCL1): wild type ASCL1 (ASCL1 wt or ASCL1), which can 
phosphorylated at six serine/proline (S/P) sites (Fig.4.3); phospho-deficient ASCL1 (ASCL1SA6 mutant), 
which cannot be phosphorylated due to S>A mutation of the S/P sites; phospho-mimetic ASCL1 
(ASCL1SD6 mutant), which mimics constitutive phosphorylation due to S>D mutation of the S/P sites 
(Fig.2.1). 
Second, I investigated the influence that the heterogeneity of the starting cell population has on direct 
astrocyte-to-neuron conversion. The cell population of origin (e.g. mouse cortical astrocytes, human 
brain pericytes, mouse cortical OPCs) is indeed an intrinsic factor playing an important role in the 
promotion of forced neurogenesis (reviewed in Falk and Karow 2018) (see sections 1.3.2 and 1.3.3). 
Astrocytes constitute an heterogeneous population in terms of morphology, transcriptome and function 
(reviewed in Farmer and Murai 2017). Moreover, Karow and colleagues recently published a study in 
which they identified subpopulations of pericytes with different competence for neuronal 
reprogramming (Karow et al. 2018). It is therefore of interest to understand whether an intrinsic factor, 
such as the heterogeneity of mouse cortical astrocytes, is associated to different outcomes of forced 
neurogenesis. This knowledge will provide fundamental information that might help improving direct 
astrocyte-to-neuron conversion strategies in vivo. In order to determine whether the heterogeneity of 
astroglia (reviewed in Khakh and Sofroniew 2015, Sofroniew 2009) influences the susceptibility of 
astrocytes to neuronal fate-switch, I have adapted an in utero electroporation-based clonal analysis 
system to suit the needs of in vivo direct conversion of cortical astrocytes into neurons. 
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3.2        Role of the phosphorylation state of ASCL1 in directing glia-to-neuron reprogramming 
3.2.1     pAscl1 converts postnatal cortical glia into neurons in vitro but not in vivo 
First, I determined whether the pASCL1 proteins had different ability to induce forced cell fate-switch 
in vitro. In the past decade, it has been shown that retroviral-mediated or lipofection-mediated forced 
expression of  the proneural gene Ascl1 in cultured astrocytes isolated from the cortex of P5-7 mice 
successfully induced conversion into neurons (Berninger et al. 2007; Heinrich et al. 2010, 2011; 
Masserdotti et al. 2015). Consistent with these data, I observed about 30% of induced neurons 
generated after transduction of cortical postnatal astrocytes with a retroviral vector encoding for the 
wild type Ascl1 gene (Fig.2.3C). Moreover, the phospho-deficient mutant yielded a higher proportion of 
induced neuronal cells among transduced cells (circa 51%, Fig.2.3C) compared to wild type Ascl1, thus 
highlighting a more efficient forced neurogenic effect in vitro. Increased neurogenesis upon expression 
of the Ascl1SA6 mutated gene was already observed during embryonic development, first in Xenopus 
after injections of lentiviruses in the oocyte, and then in the embryonic cortex of mice after in utero 
electroporation (Li et al. 2014; Ali et al. 2014). The phospho-deficient mutant was also found to have a 
higher forced-conversion efficiency of human fibroblasts into neurons in vitro when co-expressed with 
Fig.3.1 Cell intrinsic and cell extrinsic factors in direct glia-to-neuron conversion. The role of cell extrinsic 
factors, such as the phosphorylation status of proneural transcription factors exogenously expressed to 
induce cell fate-switch (right side), and cell intrinsic factors, such as the heterogeneity of the starting cell 
population (left side), in direct reprogramming of mouse postnatal cortical glia into neurons in vivo has been 
investigated in this study. TF= Transcription Factor. 
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Neurog2 or Brn2 and Myt1l (Ali et al. 2014). Interestingly, the phospho-mimetic mutant yields lower 
forced neurogenesis compared to the phospho-deficient one (37% of induced neurons among 
transduced cells, Fig.2.3C). A more pronounced difference in neurogenesis induced by phospho-mutant 
proneural proteins was observed by Quan and colleagues, who mutated a residue within the bHLH motif 
of mouse Neurog2, which is target of phosphorylation, either into an alanine (A) or into an aspartic acid 
(D) residue. They found that the phospho-deficient mutant induces neurogenesis, while the phospho-
mimetic functions as a strong loss of function allele (Quan et al. 2016). This seems to be due to the fact 
that the location of the residue in the protein influences its DNA binding abilities, introducing a repulsion 
between the transcription factor and the DNA in presence of the negatively charged aspartic acid (Quan 
et al. 2016). However, the six S/P residues targeted in the Ascl1-expressing plasmids used in this study 
are located outside of the bHLH domain, thus hinting at a possible different mechanism, as will be 
discussed in more detail later. 
Surprisingly, the overall efficiency of direct glia-to-neuron conversion was higher in transfection 
experiments than in transduction ones, but was also accompanied by a higher dispersion of the data 
values upon transfection (Fig.2.2D and 2.3D). The reason for this higher percentage of induced neurons 
quantified in transfected cultures could be due to the fact that transfection is less efficient and gives a 
less stable reporter-signal. In fact, plasmids internalised by the cell via lipofection need to enter the 
nucleus for transcription (Dean et al. 1999). Once in the nucleus, they can undergo nuclear exclusion 
upon cell proliferation and be relocated in the cytoplasm of daughter cells, where the exogenous genes 
cannot be transcribed (Ludtke et al. 2002). Moreover, cell proliferation leads to a dilution of the copy-
number per cells (Ludtke et al. 2002; Dean et al. 1999), which means that daughter cells of proliferating 
cells will express less fluorescent reporter protein. Transfected cultures will therefore tend to give an 
overestimate of the number of induced neurons, which don’t proliferate, versus the number of 
astrocytes, which proliferate and can lose fluorescent signal. Conversely, the retroviral vector used for 
this study integrates its DNA in the genome of the host cell (Naviaux et al. 1996), thus leading to stable 
and inheritable expression of the inserted genes. 
After determining that the pASCL1 proteins can induce astrocyte-to-neuron conversion in vitro, I 
transduced cortical glia of P5 mouse cortices with pAscl1-expressing retroviruses and the outcome was 
analysed at 12 days post injection (dpi) (Fig.2.6A). Exogenous pASCL1 expression resulted in very low 
percentage of induced neurons among transduced cells (Fig.2.7C). The unsuccessful neuronal cell fate-
switch might be due to the lack of injury in the experimental paradigm. In fact, transcription factors-
mediated direct conversion of adult cortical glia into neurons in vivo has been so far achieved in the 
presence of a pre-existing injury, such as a stab wound, or degeneration, such as Alzheimer’s Disease 
(Fig. 1.5) (Gascón et al. 2016; Guo et al. 2014; Heinrich et al. 2014). Cells around the injury site react to 
the stimulus by assuming a so called “reactive” phenotype ( reviewed in Robel et al. 2011, Sofroniew 
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2009) and acquire characteristics typical of neural stem cells (Buffo et al. 2008). Three days after stab 
wound injury, cortical astroglia upregulates the expression of GFAP (Buffo et al. 2008) and by day 7 
some resident astrocytes around the injury site start to proliferate (Bardehle et al. 2013; Buffo et al. 
2008). GFAP-positive cells isolated from the injured cortex are able to form multipotent neurospheres 
(Buffo et al. 2008), a property typical of neural stem cells (Morshead et al. 2003), while cells derived 
from the uninjured cortex do not. Thus, reactive astrocytes acquire a progenitor-like state that allows 
them to change their lineage fate (reviewed in Robel et al. 2011). Even though Guo and colleagues 
proposed that the viral injection itself can be considered as an injury in the adult mouse cortex (Guo et 
al. 2014), immunohistochemistry for GFAP shows that cells transduced with the pCAG-IRES-DsRed 
control retrovirus do not exhibit signs of hypertrophy at 3dpi as compared to the non-injected 
hemisphere (Fig.2.4). This is in contrast to what observed by Heinrich and colleagues, who detected 
reactive astrogliosis in the ipsilateral adult cortex after stab wound injury (Heinrich et al. 2014). The pool 
of cells becoming “reactivated” has been identified with genetic fate mapping as quiescent astrocytes 
(Buffo et al. 2008). However, postnatal cortical astrocytes proliferate (Ge et al. 2013), thus pointing at 
a possible partial lack of reactive astrogliosis in the postnatal brain. Moreover, as described in section 
2.1.4, pAscl1 does not require reactive astrogliosis to convert cortical glia into neurons. 
Noteworthy, direct reprogramming of cortical glia into neurons seems to be context-dependent. In fact, 
Ascl1 alone fails to convert glia into neurons in the injured adult cortex, while it successfully does it 
when co-expressed with Sox2 (Heinrich et al. 2014). In the absence of injury, striatal astrocytes can be 
converted into neurons through expression of Sox2 only (Niu et al. 2015, 2013) and hippocampal glial 
neural progenitors can be converted into oligodendrocytes through expression of Ascl1 (Braun et al. 
2015; Jessberger et al. 2008). In the postnatal cortex, as opposed to the adult one, astrocytes are still 
actively proliferating (Ge et al. 2013). Thus, the cortical postnatal environment is different from the 
adult one and proliferating postnatal astroglia differs from the quiescent adult one, which might lead to 
a different neurogenic response. Nevertheless, there might be other barriers hampering forced cell fate-
switch in the postnatal cortex, and the fact that local astrocytes proliferate until P21 (Ge et al. 2013) 
seems to not be sufficient to induce pAscl1-mediated glia-to-neuron conversion. 
3.2.2     pAscl1-induced change in the proportion of OPCs and oligodendrocytes in vivo 
Despite the lack of conversion into neurons, cells transduced with pAscl1 exhibited a change of 
phenotype within the glial lineages, as revealed by four observations. Firstly, all three proteins induced 
a sharp reduction in the proportion of cells expressing GFAP (from 63.9% with a DsRed-expressing 
vector, to about 20% with each of the pAscl1-expressing vectors, Fig.2.8C). Secondly, some cells 
expressing the phospho-mutants co-express the astroglial marker GFAP and the pan-oligodendroglial 
marker SOX10 (Fig.2.9B). The lower proportion of GFAP-positive astrocytes and higher proportion of 
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oligodendroglial cells (Fig.2.8C-C’) could be due to cell fate-switch of astrocytes into cells of the 
oligodendroglial lineage. The surprising emergence of GFAP/SOX10-double positive cells upon 
expression of pAscl1, a population that is absent in controls (Fig.2.9C), would also point to astrocyte-to-
OPCs conversion. Notably, retrovirus-mediated expression of Ascl1 in the dentate gyrus of adult mice 
demonstrated a capacity of Ascl1 in forced oligodendrogenesis. At 4 weeks after transduction, cells 
expressing exogenous ASCL1 protein were located in the hilus of the uninjured dentate gyrus, have glial 
morphology and express markers typical of OPCs and mature oligodendrocytes (Braun et al. 2015; 
Jessberger et al. 2008). The expression of Ascl1 exhibited also a much higher conversion rate of 
hippocampal neuronal progenitors into OPCs than Olig2 or Sox10, it induced formation of mature 
myelinating oligodendrocytes and rescued hilar myelination in a demyelination model (Braun et al. 
2015). However, despite this published evidence of the forced conversion of glial neural progenitors 
into OPCs by Ascl1, it is not possible to establish yet the identity of the cell population influenced by the 
exogenous expression of pAscl1.  In fact, the two main cell populations I found to be transduced by the 
MoMLV-derived retrovirus are GFAP-positive astrocytes and SOX10-positive oligodendroglial cells (Fig. 
2.4D), which both proliferate at this stage of cortical development (Ge et al. 2013; Nakatani et al. 2013) 
and are therefore susceptible to transduction with the retroviral vector used (Roe et al. 1993). Heinrich 
and colleagues showed by means of lineage tracing that the cell population they converted into neurons 
by co-expression of Sox2 and Ascl1 was NG2-positive glia, namely OPCs, rather than reactive astrocytes 
(Heinrich et al. 2014). Thus, lineage tracing experiments will help to determine whether pAscl1-induced 
oligodendroglial cells derive from direct conversion of astrocytes. Knowing if the oligodendroglial cells 
quantified at 12dpi derive from astrocytes or from OPCs will be of importance, to understand if pAscl1 
indeed induces astrocyte-to-OPC conversion. 
Thirdly, there is an increase in the proportion of SOX10-positive cells of the oligodendroglial lineage 
when transduced cells express the pASCL1 proteins (Fig.2.8C’). Fourthly, the wt ASCL1 protein induces 
an increase in the proportion of SOX10-positive OPCs (Fig.2.10C), while expression of the phospho-
mutants increases the proportion of APC-positive oligodendrocytes (Fig.2.10C’). An alternative 
explanation to the astrocyte-to-oligodendrocyte conversion interpretation for the changes in the 
proportion of glial cells in pAscl1-transduced cell population is that pASCL1 could have an effect on 
proliferation and differentiation, given the higher proportion of OPCs and of oligodendrocytes induced 
by ASCL1 wt and the phospho-mutants, respectively (Fig.2.9C-C’). In fact, it is known that Ascl1 is 
expressed in a subset of OPCs during mouse cortical embryonic development and after birth (Parras et 
al. 2007; Parras et al. 2004). However, the presence of ASCL1 is required only for the generation of the 
first wave of OPCs, around E12.5 (Parras et al. 2007), while at later stages it is not necessary, perhaps 
due to the expression of other genes mediating oligodendrogenesis (Li et al. 2014; Parras et al. 2007). 
Interestingly, tamoxifen-induced ablation of Ascl1 at P5 or P8-9 showed that after 7 days, OPCs of the 
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subependymal zone proliferate more, and asymmetric divisions generating one OPC and one 
oligodendrocyte (OPC/OL) are reduced in favour of symmetric divisions generating two OPCs (OPC/OPC) 
(Nakatani et al. 2013). Interestingly, the rate of symmetric divisions generating two oligodendrocytes is 
not affected by loss of Ascl1 (Nakatani et al. 2013). Thus, Ascl1 controls proliferation and differentiation 
of OPCs, favouring asymmetric divisions at the expense of symmetric OPC/OPC divisions. Such control 
of proliferative events would be expected to result in more reporter-positive OPCs and oligodendrocytes 
upon expression of wild type Ascl1. However, the effect of ASCL1 on cortical cells at 12dpi illustrated in 
this study leads to an increase only in the proportion of OPCs among transduced cells (Fig.2.10C), 
suggesting a possible increase in symmetric OPC/OPC divisions. This different proportion of 
oligodendroglial cells might depend on other mechanisms compensating in the long term the Ascl1-
mediated effect, as suggested by a return to proportions of OPCs and oligodendrocytes similar to wild 
type conditions in Ascl1-/- mice at 28dpi (Nakatani et al. 2013) or on the fact that cortical OPCs behave 
differently than their counterparts in the subependymal zone. It could also be that Ascl1 increases the 
survival of transduced OPCs. Lineage tracing experiments with a GLAST::CreERT2 (Buffo et al. 2008) and 
a Sox10-iCreERT2 (Simon et al. 2012) are required to determine whether pAscl1-induced 
oligodendroglial cells derive from direct conversion of astrocytes or from OPCs, respectively, and the 
use of BrdU/EdU paradigms could aid to unravel the proliferative behaviour of cells transduced with 
pAscl1-expressing retroviruses. 
3.2.3     Role of ASCL1 phosphorylation in the induction of OPCs and oligodendrocytes 
Immunohistochemical analysis of brains 12 days after injecting the pAscl1-expressing retroviruses 
revealed that the ASCL1-mediated effect on cells of the oligodendroglial lineage appears to be 
phosphorylation-dependent (Fig.3.2). First, the phospho-mutants do not increase the proportion of 
SOX10-positive cells compared to a control expressing only the fluorescent reporter DsRed (Fig.2.9C’ 
and 2.10C). Recent work demonstrated that the RAS/ERK signalling pathway modulates the decision 
between gliogenesis and neurogenesis by directly phosphorylating ASCL1 during mouse development 
(Li et al. 2014). The wild type protein has gliogenic potential when RAS/ERK signalling is activated at high 
levels, inducing predominantly oligodendrogenic fate, while at low levels of RAS/ERK signalling ASCL1 
transactivates the Dlx1/2 genes (Li et al. 2014), hinting that high levels of ASCL1 phosphorylation are 
driving formation of OPCs while lower levels drive neurogenesis. The observation that wild type ASCL1 
induces higher OPCs formation compared to control-injected postnatal brains (Fig.2.10C), suggests that 
the niche environment allows phosphorylation of ASCL1. However, this would not explain why the 
phospho-mutants increased the proportion of oligodendroglial cells (Fig.2.8C’, 2.10C’). Expression of 
the phospho-deficient ASCL1SA6 protein in the mouse embryonic brain at E12.5 or in the oocytes of 
Xenopus resulted in increased neurogenesis (Ali et al. 2014; Li et al. 2014) and showed that the lack of 
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phosphorylation on ASCL1 has a neurogenic effect in a Dlx-independent manner (Li et al. 2014). 
However, constitutively active RAS is able to induce in Ascl1-/- embryos a proportion OLIG2-positive 
cells similar to the one induced in wild type embryos (Li et al. 2014). Thus, it is possible that if the niche 
conditions are supporting high RAS/ERK activity, the high level of RAS pathway activity are compensating 
for the lack of phosphorylation of ASCL1 and determine an oligodendrogenic fate. The fact that between 
P15 and P18 the levels of phosphorylated ERK (pERK) are elevated (Galabova-Kovacs et al. 2008) 
supports this interpretation. 
Second, the phospho-mutants induce a higher proportion of APC-positive oligodendrocytes compared 
to wild type ASCL1 (Fig.2.10C’). Third, the phospho-mimetic mutant had an effect similar to the one of 
the phospho-deficient (Fig.2.8C-C’, 2.9C and 2.10C-C’). Co-expression of ASCL1SA6 in human fibroblasts 
with either NEUROG2 or BRN2/MYT1L resulted higher maturation of induced neurons, as compared to 
expression of wild type ASCL1 (Ali et al. 2014). Moreover, exogenous expression of Ascl1 has already 
been shown to induce gradual maturation of Ascl1-derived oligodendroglia in the adult hippocampus 
(Jessberger et al. 2008). Thus, it is possible that loss of phosphorylation leads to increased maturation 
of the oligodendroglial cells transduced by a pAscl1-expressing retrovirus. Notably, rather than having a 
loss-of-function effect like the phospho-mimetic mutant of mouse NEUROG2 (Quan et al. 2016), 
ASCL1SD6 had an effect similar to the one of the phospho-deficient mutant, inducing an increase in the 
proportion of oligodendrocyte (Fig.2.10C’). It is possible that, despite mimicking the presence of 
negatively charged phosphorylation-moieties, the six aspartic acid residues on ASCL1SD6 modify the 
binding of the proneural factor to DNA target sites or co-factors, thus leading to the activation of 
different pathways downstream of Ascl1. A bHLH transcription factor that is not classified as a proneural 
factor but is expressed in oligodendroglial cells, OLIG2, is phosphorylated at S147 during embryonic 
development of the spinal cord, thus forming homodimers and leaving NEUROG2 available for binding 
to E47 and induction of motor neuron formation. However, when oligodendrogenesis begins it is de-
phosphorylated and binds preferentially to other bHLH transcription factors, consequently inducing 
OPCs generation (Li et al. 2011). The role of the zinc-finger protein ZFP24 in proliferation and 
differentiation of OPCs is regulated by phosphorylation too. When the transcription factor is de-
phosphorylated, it binds target genes that specify OPCs, while upon phosphorylation it binds to target 
genes specifying oligodendrocyte maturation (Elbaz et al. 2018). These studies point to a 
phosphorylation-dependent choice of dimerization partners and DNA binding for transcription factors, 
as described for OLIG2 and ZFP24. This raises the possibility that, despite mimicking the constitutive 
presence of phosphorylation, the conformation of the ASCL1SD6 protein is modifying its binding abilities 
hampering binding to the targets of wt phosphorylated ASCL1. Moreover, the elevated levels of pERK in 
the postnatal murine brain (Galabova-Kovacs et al. 2008) could be determining an oligodendrogenic 
fate also in cells expressing the phospho-mimetic mutant. Further experiments to determine the DNA-
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binding abilities of the pASCL1 proteins, or their preference of binding partner will help understanding 
the mechanisms underpinning their role in postnatal cortical glia. 
 
Fig.3.2 pASCL1-mediated cell fate-switch: graphical abstract. Cortical glia of P5 mice transduced with 
retroviruses encoding for pAscl1 (left panel, red) or for pAscl1 and Bcl2 (right panel, yellow). Exogenous 
expression of pASCL1 only affects the glial population. The wild type protein (wt) increases the proportion of 
OPCs, while the phospho-deficient (SA6) and phospho-mimetic (SD6) mutants favour oligodendrocytes 
production. When co-expressed with Bcl2, pAscl1 successfully converts cortical glia into neurons. ASCL1 wt 
expression results in production of a lower percentage of DCX-positive immature neurons (Table2.1), 
compared to the phospho-mutants. The two mutant ASCL1 proteins result in high efficiency of neuronal 
conversion but also higher maturation of induced neurons. 
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3.2.4    Role of ASCL1 phosphorylation in the pAscl1/Bcl2-mediated neuronal conversion of postnatal 
cortical glia 
Co-expression of Bcl2 with the proneural transcription factor Neurog2 successfully converts adult 
cortical glia into neurons in the presence of injury (Gascón et al. 2016). In order to investigate whether 
Bcl2 has a role in pAscl1-induced cell fate-switch in the postnatal uninjured cortex, I have analysed cells 
co-transduced with pAscl1- and Bcl2-expressing retroviruses at 12dpi (Fig.2.11). Immunohistochemistry 
for the neuronal markers DCX and NeuN showed abundant generation of induced neurons in cells co-
transduced with pAscl1- and Bcl2-expressing retroviruses (Fig.2.12 and 2.13, Table 2.1). Notably, upon 
co-expression of wild type Ascl1 and Bcl2 I have quantified at 12dpi about 26% of DCX-positive immature 
neurons (Fig.2.12D) and about 5% of NeuN-positive mature neurons (Fig.2.13D). Interestingly, I have 
observed also about 12% of cells co-expressing DCX and NeuN among reporter-positive ones 
(Fig.2.14D), indicating the presence of neuronal cells undergoing maturation (Brown et al. 2003). The 
ability of ASCL1 to force direct conversion of postnatal cortical glia co-expressing Bcl2 into neurons 
seems to be phosphorylation-dependent.  
Firstly, the phospho-mutants exhibit a direct cell fate-switch rate of circa 70% when co-expressed with 
Bcl2, as compared to circa 45% for wild type Ascl1 (Table 2.1). The higher neurogenic ability of the 
phospho-deficient mutant confirms previous findings obtained upon ectopic expression of ASCL1SA6 in 
vivo, in which it increased neurogenesis during Xenopus and mouse development (Ali et al. 2014; Li et 
al. 2014). Moreover, in vitro conversion of human fibroblasts into neurons led to increased neuronal 
conversion of ASCL1/NEUROG2- or BAM-induced neurons upon Ascl1SA6 exogenous expression (Ali et 
al. 2014). Notably, the work of Li and colleagues demonstrated that ASCL1 phosphorylation in the 
murine embryonic cortex is mediated by RAS/ERK signalling in a dosage-dependent way (Li et al. 2014). 
By placing Ras gene under the control of the EF1-alpha promoter, the level of activation of Ras is low 
and RAS has reduced ability to induce phosphorylation of ERK (Li et al. 2014). Upon low level of Ras 
activation, Ascl1 induces GABAergic neurogenesis, while upon constitutive activation of Ras (achieved 
by exogenous expression of the constitutively active protein RASV12 in a pCIG2 vector) Ascl1 induces 
gliogenesis (Li et al. 2014). Thus, it is likely that ASCL1 is less successful in inducing forced neurogenesis 
than ASCL1SA6 because of the presence of increasing RAS/ERK signalling in the postnatal brain between 
P5 and P10, that would phosphorylate ASCL1. The potential involvement of signalling mechanisms in 
pAscl1-mediated glia-to-neuron conversion are discussed more in depth in session 3.2.5. 
Secondly, the SD6 mutation induces an intermediate phenotype between that of the wild type protein 
and that of the phospho-deficient protein, exhibiting higher levels of forced neurogenesis than ASCL1 
wt (Table 2.1). The levels of neurogenesis induced by ASCL1SD6 could be linked to a higher resistance 
to NOTCH-mediated lateral inhibition of the phospho-mimetic mutant. In fact, Ascl1 is sensitive to 
lateral inhibition and its expression in the Xenopus oocyte fails to induce neurogenesis (Ali et al. 2014). 
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However, loss of phosphorylation in the SA6 mutant results in resistance to NOTCH-mediated lateral 
inhibition and induction of neuronal differentiation (Ali et al. 2014). Lateral inhibition is involved in the 
oscillatory expression of Ascl1 and Hes1 in neural progenitors: high and low levels of Ascl1 expression 
correspond to low and high levels of Hes1 expression, respectively, in a negative-feedback loop of gene 
regulation (Imayoshi et al. 2013). When neural progenitors differentiate into neurons, ASCL1 protein is 
expressed in a sustained manner (Imayoshi et al. 2013). If the SD6 mutation confers ASCL1SD6 binding 
properties different than the ones of ASCL1, it could be resistant to NOTCH-mediated lateral inhibition, 
thereby inducing neuronal differentiation (Ali et al. 2014). It would be interesting to determine whether 
the three pASCL1 proteins are actually binding different co-factors, via pull-down assays. Another 
possible explanation for the phenotype of Ascl1SD6/Bcl2-transduced cells might be that the binding 
affinity of ASCL1SD6 is not the same one of the wild type ASCL1 protein, whereby the mutant protein 
cannot bind the same targets of phosphorylated ASCL1. It would be thus interesting to investigate the 
DNA-binding ability of the pASCL1 proteins via ChIP-sequencing (ChIP-seq) experiments. In ChIP-seq, 
after the creation of protein-protein and DNA-protein cross-links, the DNA is sonicated and then 
immunoprecipitated (Milne et al. 2009). The analysis of the precipitated DNA allows the identification 
of histone modifications and DNA binding sites for proteins (Milne et al. 2009). This would help 
elucidating the transcriptional programs initiated by pASCL1 and whether they differ in the specification 
or maturation of neurons. A study involving ChIP-seq of BAM-expressing and ASCL1-expressing 
fibroblasts revealed that ASCL1 binds in both cases the same targets on the genome, without needing 
cooperation with BRN2 and MYT1L, thereby acting as a “pioneer factor” (Wapinski et al. 2013). 
Interestingly, upon Ascl1-mediated direct reprogramming, the genomic region of Brn2 gene becomes 
accessible around 5 days after Ascl1 induction (Wapinski et al. 2017). In fact, ASCL1 induces rapid 
chromatin changes after binding to its targets, opening chromatin at neuronal genes-associated regions 
and increasing chromatin accessibility within 12 hours after induction of the proneural gene, thus 
leading to a cascade of transcription factors’ activation that, by day 5, transitions to late neuronal 
programs (Wapinski et al. 2017). Thus, given the role of ASCL1 as pioneer factor and in inducing 
chromatin accessibility during cell fate-switch, it will be interesting to determine whether the phospho-
mutants induce the same chromatin-remodelling events and activate the same transcription factor 
cascades as the wild type protein. Another possible difference in the phenotype of Ascl1/Bcl2 and 
Ascl1SD6/Bcl2-transduced cells could be that the phospho-mimetic mutant is less susceptible to 
ubiquitination. Noteworthy, phosphorylation can function as a signal for ubiquitination (Hunter 2007). 
It has been recently demonstrated that chromatin-bound ASCL1 is post-translationally modified by 
addition of short ubiquitin chains that confer lower susceptibility to proteasomal degradation, while 
cytoplasmic ASCL1 carries long ubiquitin chains (Gillotin et al. 2018). The different type of ubiquitination 
results in about double half-life of chromatin-bound ASCL1 (Gillotin et al. 2018). In case of involvement 
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of phosphorylation in the ubiquitination of the protein it is possible that the phospho-mimetic construct 
exhibits lower susceptibility to the degradation-mechanism, thus remaining for longer time in the cell 
nucleus. Further experiments to determine the half-life of the phospho-mutants and their ubiquitination 
state will help understanding whether the phosphorylation of ASCL1 has an impact on its degradation. 
Thirdly, the phospho-deficient mutant induced a higher percentage of NeuN-positive and DCX/NeuN-
positive cells, as compared to the phospho-mimetic (Table 2.1). Fibroblast-derived neurons induced by 
ASCL1SA6/NEUROG2 or BAM factors containing ASCL1SA6 showed also a higher level of maturation, 
with increased branching and neurite length, than the ones induced by ASCL1 (Ali et al. 2014), thus 
indicating that loss of phosphorylation on ASCL1 could promote neuronal maturation. Notably, the 
expression of the interneuronal marker GABA I observed at 12dpi is barely detectable or at low levels in 
cells transduced with pAscl1/Bcl2 (Fig.2.15), thus indicating that while cells expressing the phospho-
mutants reach morphological maturation (Fig.2.13A’-A’’) and show increased expression of the mature 
neuronal marker NeuN (Fig.2.13D, Table 2.1), they might not yet be functionally mature or might acquire 
an alternative neuronal fate. It has recently been shown that pericytes-derived neurons induced by 
forced expression of Ascl1, Sox2 and Dlx1 (ASD) first transition to a neural stem cell-like state and then 
bifurcate into two alternative lineages: the majority of reprogrammed cells express interneuronal genes, 
while a smaller set of cells expresses genes of the glutamatergic specification program (Karow et al. 
2018). Interestingly, one of the genes induced during ASD-mediated reprogramming is Myt1 (Karow et 
al. 2018), which acts downstream of Ascl1 to repress Notch signalling and the progenitor state of the 
cells, thus promoting neuronal differentiation (Vasconcelos et al. 2016). MYT1L, a transcription factor 
related to MYT1 and used in the combination of factors BAM (Brn2, Ascl1, Myt1l) to induce direct 
conversion of fibroblasts into neurons, represses many somatic lineage programs, except the neuronal 
one, during reprogramming (Mall et al. 2017). Moreover, the transcriptional repressor REST competes 
with NEUROG2 for binding on the regulatory regions of NEUROG2 targets, making them no longer 
accessible and thereby hampering the unravelling of the alternative non-astrocytic lineage program 
(Masserdotti et al. 2015). Thus, the fact that direct neuronal reprogramming requires silencing of 
alternative lineage programs to promote neuronal differentiation, and that induced neurons can acquire 
alternative transmitter identities, points to the possibility that pAscl1/Bcl2-induced neurons could 
acquire a glutamatergic rather than GABAergic identity. The finding that some pAscl1/Bcl2-induced 
neurons express the mature neuronal marker NeuN at 12dpi suggests that these reprogrammed cells 
could reach functional maturation at later time points. Heinrich and colleagues showed in 2014 that 
adult cortical OPCs co-expressing Sox2 and Ascl1 can be converted into neurons after stab-wound injury. 
By 24dpi, some of these induced neurons exhibit action potential-like spikes in response to injected 
depolarising currents and received some spontaneous synaptic inputs (Heinrich et al. 2014), indicating 
that they acquired neuronal functional properties but remained rather immature after almost one 
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month from the retroviral transduction. However, Ascl1SA6/Bcl2-transduced cells exhibit high-
frequency firing pattern and spontaneous synaptic inputs at 4wpi (Fig.2.16), pointing out that co-
expression of Bcl2 and the phospho-deficient mutant induces the reprogramming of cortical glia into 
neurons that can functionally mature and integrate in the cortical circuitry. Interestingly, the higher 
firing frequency recorded in current-clamp (Fig.2.16C, Heinrich et al. 2014 for comparison), indicates 
that Ascl1SA6/Bcl2-induced neurons reach a higher level of functional maturation than Sox2/Ascl1-
induced neurons, which show instead functional features typical of immature neurons. Additional 
electrophysiological recordings at 4wpi will help determining whether Ascl1/Bcl2- and Ascl1SD6/Bcl2-
induced neurons can reach a functional maturation similar to the one of Ascl1SA6/Bcl2-induced 
neurons. 
The in situ formation of induced neurons in the murine cortex, together with the transplantation of 
induced neurons, is an emerging strategy that could help in the future to replenish the pool of neuronal 
cells lost and to ameliorate circuits disfunctions during neurodegenerative diseases, e.g. epilepsy or 
Parkinson Disease (reviewed in Heinrich et al. 2015, Dehorter et al. 2017). To this purpose, it will be 
important also to specify different subtypes of interneurons. To date, the formation of specific 
interneuronal subtypes via direct reprogramming of cortical glia in vivo has not yet been achieved 
(reviewed in Dehorter et al. 2017). However, cell fate-switch of OPCs into neurons via 
Ascl1/Lmx1a/Nurr1 in the striatum yielded induced neurons that reached functional maturation by 
12wpi (Pereira et al. 2017). The majority of these induced neurons became fast-spiking parvalbumin 
(PV)-positive interneurons (Pereira et al. 2017). Similarly, neurons derived by conversion of fibroblasts 
with Ascl1/Sox2/FoxG1/Dlx5/Lhx6 in vitro mature and become express PV by 21div (Colasante et al. 
2015). Interestingly, the majority of these induced neurons die after transplantation in the adult murine 
hippocampus and the surviving cells express GABA but not PV; the surviving neurons successfully 
integrated in the host circuitry and exhibited inhibitory activity of endogenous granule neurons 
(Colasante et al. 2015). It is possible that the cortical circuitry maintains the homeostasis of the network 
and limits the survival of transplanted or reprogrammed interneurons, for instance by controlling their 
integration and survival in an activity-dependent manner (reviewed in Dehorter et al. 2017; Wong et al. 
2018). It will be interesting to determine whether Ascl1SA6/Bcl2-induced neurons that exhibit high firing 
frequency at 4wpi become PV-expressing interneurons, and whether other subtypes of interneurons 
are specified by Ascl1 in the postnatal cortex. 
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3.2.5    Pathways potentially involved in pASCL1-mediated glia-to-neuron reprogramming 
Given the role of pAscl1 in forced cell fate-switch illustrated in this study, it will be interesting to 
understand which signalling pathways are taking place in the postnatal brain and mediating pAscl1-
induction of neurogenesis. Phosphorylation of ASCL1 has been described to be mediated by CDK2 in the 
Xenopus oocyte (Ali et al. 2014), or by RAS/ERK signalling in mouse embryonic cortical development (Li 
et al. 2014) (Fig. 3.3). RAS/ERK signalling activates cell proliferation-related programs and, in the 
postnatal brain, is required for oligodendrocyte differentiation (Galabova-Kovacs et al. 2008; reviewed 
in Molina and Adjei 2006), while CDK2 is required for the S/G2 transition of the cell cycle (Rosenblatt e 
al. 1992). 
 
 
 
 
 
Fig. 3.3 Signalling pathways potentially involved in pASCL1-mediated glia-to-neuron conversion. A, The 
phosphorylation of ASCL1 has so far been described to be mediated by RAS/ERK pathway (Li et al. 2014) and 
CDK2 (Ali et al. 2014). Activation of RTKs by their ligands, lead to phosphorylation of ERK or AKT (Li et al. 2014; 
Maddika et al. 2008). Active RAS/ERK signalling leads to phosphorylation of ASCL1 in the mouse embryonic 
cortex (Li et al. 2014). AKT phosphorylates and activates CDK2 (Maddika et al. 2008), which has been implied 
in the regulation of ASCL1 phosphorylation in Xenopus oocyte (Ali et al. 2014). However, it is not known what 
is the role of CDK2 in ASCL1 phosphorylation. B, In the nucleus, ASCL1 exerts its activity of transcriptional 
control. Depending on the level of activity of RAS/ERK pathway, ASCL1 activates a gliogenic or a neurogenic 
program during embryonic cortical development (Li et al. 2014). RTK= Receptor Tyrosine Kinase. 
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CDK2 is phosphorylated and thereby activated by AKT, in a signalling cascade activated by EGF (Maddika 
et al. 2008). However, exogenous expression of an active form of Akt revealed that AKT does not induce 
phosphorylation of ERK (Li et al. 2014), an effector of the RAS/ERK pathway (Li et al. 2014; reviewed in 
Molina and Adjei 2006), and confirmed that the RAS/ERK pathway, but not AKT, is mediating ASCL1 
phosphorylation in the embryonic murine cortex (Li et al. 2014). 
The increase of phosphorylated ERK (pERK) between P5 and P15 in the mouse brain (Galabova-Kovacs 
et al. 2008) introduces the intriguing possibility that RAS/ERK signalling could have a role in the pAscl1-
induced effects described in this study. B-Raf is the main effector of RAS/ERK signalling in the postnatal 
brain, and its genetic ablation leads to loss of pERK, dismyelination, and reduced oligodendrocyte 
differentiation (Galabova-Kovacs et al. 2008), thus indicating a role for the RAS/ERK signalling pathway 
in the differentiation of myelinating oligodendrocytes in the postnatal brain. Interestingly, Ras activation 
levels influence the neurogenic activity of Ascl1: when Ras is constitutively expressed and there is high 
pERK, Ascl1 induces gliogenesis; when the Ras gene has low activity and there is low phosphorylation of 
ERK, Ascl1 induces GABAergic neurogenesis (Li et al. 2014). It is possible that the wild type ASCL1 protein 
is phosphorylated by RAS/ERK signalling in the postnatal cortex, thus leading to the observed increase 
in the percentage of SOX10-positive OPCs (Fig. 2.10C), as suggested by the pro-gliogenic effect of high 
RAS/ERK activity and the fact that exogenous expression of Ascl1 increases expression of Dll and Sox9, 
markers of proliferating progenitors and glial progenitors, respectively (Li et al. 2014). Interestingly, 
exogenous expression of Ascl1SA6 induces higher proportion of OPCs (Fig. 2.10C’), which is in contrast 
with the role described for RAS/ERK signalling in promoting oligodendrocyte differentiation in the 
postnatal brain (Galabova-Kovacs et al. 2008). Thus, it is likely that other mechanisms are involved in 
mediating the differentiation of oligodendrocytes upon pAscl1 expression. Remarkably, Ascl1SA6/Bcl2 
co-expression successfully induces forced neurogenesis in transduced cells (Table 2.1). The fact that 
ASCL1SA6 seems to mediate oligodendrogenesis rather than neurogenesis when expressed alone, could 
be due to the fact that the lack of Bcl2 effect in promoting neuronal reprogramming (discussed in section 
3.2.6) leads to occupation by pASCL1 of genomic regions regulating gliogenesis. Alternatively, it could 
be that in the absence of Bcl2 neurons do not survive during cell fate-switch, thus making it possible to 
detect only glial cells via immunohistochemistry. 
The RAS/ERK pathway is activated by receptor tyrosine kinases (RTKs), a family of transmembrane 
receptors with a cytoplasmic tyrosine kinase domain and an extracellular ligand-binding domain 
(reviewed in Lemmon and Schlessinger 2010). Among the family of RTKs there are the ErbB receptors 
and EGFR, whose ligand is EGF, and FGF receptors (FGFR), whose ligand is FGF (reviewed in Lemmon 
and Schlessinger 2010). EGF and FGF have been described to activate RAS/ERK pathway and induce 
pERK both in the embryonic cortex (Li et al. 2014) and in the postnatal brain (Galabova-Kovacs et al. 
2008), thus making them likely candidates for the activation of RAS/ERK signalling and subsequent 
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induction of pAscl1-mediated effects described in this study. Intriguingly, EGF and FGF-2 are used to 
treat postnatal cortical astrocytes in vitro and induce gliogenesis in culture (Heinrich et al. 2011; 
reviewed in Oliveira et al. 2013). Thus, it would be interesting to determine whether withdrawal of the 
mitogens from the culture changes the reprogramming efficiency of pAscl1 in vitro. This, united with 
experiments in which the receptors activated by EGF and FGF are inhibited (reviewed in Lemmon and 
Schlessinger 2010) could help shed light on the mechanism leading to phosphorylation of ASCL1 in the 
postnatal brain during forced neurogenesis. 
 
3.2.6    Role of Bcl2 in direct glia-to-neuron reprogramming 
The role of Bcl2 in facilitating Neurog2-mediated conversion of cortical glia into neurons was shown to 
be exerted through alleviation of the excess of reactive oxygen species (ROS) produced during cell fate-
conversion, rather than being mediated by its anti-apoptotic function (Gascón et al. 2016). In fact, the 
process of direct cell fate-switch forces the cells to change their metabolic state from glycolysis to 
oxidative phosphorylation (OxPhos) (Gascón et al. 2016; Kim et al. 2018), thereby inducing 
mitochondrial defects typical of cellular aging and loss of ATP to almost half in converted neurons, due 
to the increased workload (Kim et al. 2018). Moreover, forced neurogenesis induces high levels of ROS, 
which can be attenuated by administration of anti-oxidants, such as vitamin E, calcitriol and alpha-
tocopherol, or by Bcl2 expression (Gascón et al. 2016). This increase in the presence of ROS in cells 
undergoing lineage conversion is due to a mechanism of programmed cell death called ferroptosis 
(Gascón et al. 2016; Dixon et al. 2012), which is iron-dependent and doesn’t have the same 
morphological and molecular features of apoptosis, autophagy, necrosis and other known cell death 
pathways (Dixon et al. 2012; reviewed in Xie et al. 2016). During ferroptosis, mitochondria appear 
smaller than usual, have higher membrane density and intracellular ATP is depleted (Dixon et al. 2012). 
Ferroptosis induces accumulation of ROS, which can be reverted by iron chelators (Dixon et al. 2012; Yu 
et al. 2015). Accumulation of high levels of ROS eventually leads to cell death (Dixon et al. 2012). 
Exogenous expression of Bcl2 or vitamin E treatment reduce the levels of lipid peroxidation in cultured 
postnatal astrocytes undergoing Ascl1-mediated cell fate-switch (Gascón et al. 2016), which might 
promote the survival of induced neurons. It is likely that the role of Bcl2 in the direct conversion of 
pAscl1-transduced cortical glia into neurons is similar to the one described by Gascón and colleagues. 
An interesting perspective into the role of Bcl2 in facilitating neuronal reprogramming comes from the 
recent finding that the phosphatase PTEN is involved in the programmed cell death of GABAergic 
interneurons between P5 and P10, thus sculpting the cortical neuronal network composition (Wong et 
al. 2018). The mechanism is mediated by the activity of pyramidal neurons, which inhibit – in a non-cell-
autonomous manner – PTEN in GABAergic interneurons (Wong et al. 2018). Inhibition of PTEN results 
in activation of the kinase AKT and subsequent inhibition of apoptosis (Stambolic et al. 1998; Wong et 
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al. 2018). Thus, given the heterogeneous activity pattern of pyramidal neurons, and the fact that PTEN 
is active in sparse cells around the cortex at P5-10, there is a wave of programmed cell death of 
GABAergic interneurons sculpting the cortical circuit (Wong et al. 2018). The presence of active RAS/ERK 
signalling in the postnatal brain at P5-10 (Galabova-Kovacs et al. 2008) and the fact that RAS kinase 
activates also the PIP3/AKT pathway (Zalckvar et al. 2009), united with the fact that in my experiments 
co-transduction with pAscl1 and Bcl2 was performed at P5, suggests that pAscl1/Bcl2-induced neurons 
might undergo a similar PTEN-mediated regulation, assuming they are specified into GABAergic 
interneurons. However, induced neurons positively selected during this wave of programmed cell death 
could later succumb to ferroptosis-induced accumulation of ROS, and the exogenous expression of Bcl2 
could likely promote their survival. Interestingly, 75% of Neurog2/Bcl2-induced neurons among co-
transduced cells were NeuN-positive cells as early as 10dpi (Gascón et al. 2016). It could be that the 
anti-oxidant effect accelerates the maturation of induced neurons, through increased cell survival 
(Gascón et al. 2016).  
Interestingly, the function of BCL2 can also be regulated by phosphorylation. In fact, the non-
phosphorylated BCL2 protein can bind to BECLIN1 or its activators, thus inhibiting the autophagic 
process, while phosphorylation of BCL2 disrupts the BECLIN1:BCL2 complex and allows BECLIN1-
mediated initiation of autophagy (reviewed in Marquez and Xu 2012; Wei et al. 2008). Upon prolonged 
phosphorylation of BCL2, the cell eventually undergoes apoptosis mediated by caspase 3 (reviewed in 
Marquez and Xu 2012; Wei et al. 2008). The main kinase responsible for phosphorylation of BCL2 at the 
endoplasmic reticulum is JNK1; phospho-deficient and phospho-mimetic BCL2-mutants exhibit lower 
anti-apoptotic and autophagic effect, and higher anti-apoptotic and autophagic effect, respectively (Wei 
et al. 2008). Moreover, such mutated constructs revealed that a lack of phosphorylation of BCL2 induces 
more Neurog2-mediated conversion of glia into neurons (Gascón et al. 2016). Given that ROS are 
generated during forced conversion of astrocytes into neurons (Gascón et al. 2016), and that ROS are 
an activator of JNK signalling (reviewed in Marquez and Xu 2012; Wei et al. 2008), it is possible that 
during Ascl1/Bcl2-mediate cell fate-switch BCL2 is phosphorylated. 
Thus, the role of BCL2 seems to be related to protection of cells from ROS generated during forced 
lineage conversion via ferroptosis, and might be related to its phosphorylated status. It would be 
interesting to determine whether there is phosphorylation of BCL2 undergoing in transduced cells, and 
if so, whether it is key determinant of the success of pASCL1-mediated direct neuronal reprogramming 
and of the maturation of induced neurons.  
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3.3       Clonal analysis of induced neurons: establishment of a system for the study of forced cell fate-
switch in the context of astroglial heterogeneity 
3.3.1     An in utero electroporation system to study the role of astroglial heterogeneity in direct 
reprogramming 
In order to determine whether the heterogeneity of astroglia (reviewed in Khakh and Sofroniew 201, 
Sofroniew 2009) influences the susceptibility of astrocytes to neuronal fate-switch, I have adapted an 
in utero electroporation-based clonal analysis system to suit the needs of in vivo direct conversion of 
cortical astrocytes into neurons. Such system, called StarTrack, has been developed as an in vivo clonal 
labelling system (García-Marqués and López-Mascaraque 2013). It holds different advantages: 
 Cell type-specific conditional activation of the transcription factors: the factors used to induce 
astrocyte-to-neuron conversion were subcloned in plasmids with the hGFAP promoter (Fig. 
2.17), thus restricting their expression in astrocytes (García-Marqués and López-Mascaraque 
2013). Upon electroporation, the plasmids are internalised by the neural stem cells and neural 
progenitors of the VZ/SVZ, which can give rise to both glial and neuronal populations (Figueres-
Onãte et al. 2016; Fuentealba et al. 2015; Kriegstein & Alvarez-Buylla 2009). Thus, the presence 
of the hGFAP promoter will allow to restrict cell fate-switch only in one postnatal cortical cell 
population, namely astrocytes.  
 Temporal conditional activation of NEUROG2ERT2 and ASCL1ERT2: the proneural factors 
NEUROG2 and ASCL1 are fused to a modified version of the oestrogen receptor (Fig.2.17), which 
allows their activation only upon treatment with tamoxifen (Littlewood et al. 1995; Masserdotti 
et al. 2015). 
 Integration into the genome of the host cell: the StarTrack system exploits transposons of the 
PiggyBAC transposase, which can stably integrate in the host genome (García-Marqués and 
López-Mascaraque 2013). 
 Pairing to a clonal labelling system: the StarTrack system allows clonal labelling of cells in vivo 
(García-Marqués and López-Mascaraque 2013). More specifically, I was using the ubiquitous 
StarTrack for clonal labelling, which labels cells of every lineage because the fluorophores are 
under the control of the hUbiquitin promoter (Figueres-Onãte et al. 2016).  
To establish this new method for direct reprogramming, I have first subcloned tamoxifen-inducible 
forms of NEUROG2 and ASCL1 (NEUROG2ERT2 and ASCL1ERT2, respectively) (Masserdotti et al. 2015) 
in plasmids containing the transposons of the PiggyBAC transposase (Fig.2.17). Some issues arose during 
preliminary in utero electroporation experiments.  
Discussion 
 
 84 
First, the eYFP reporter of the pPB-hGFAP-NEUROG2ERT2-IRES-eYFP and pPB-hGFAP-ASCL1ERT2-IRES-
eYFP plasmids was expressed at very low level and seemed to be mostly localised at the soma of the 
cells (Fig.2.19 and 2.20). This could be due to the fact that the quantity of plasmid electroporated is too 
low to reach sufficient signal to detect the processes of cells. It is also important to consider that the 
plasmids expressing the factors for direct reprogramming do not contain LoxP sites; they thereby remain 
in the nucleus or cytoplasm of the cells when they are not integrated in the host cell’s genome, as 
explained in section 1.5.2 (Figueres-Oñate et al. 2015). Episomal copies are diluted within the progeny 
of proliferating astrocytes and, as a consequence of the lower number of copies in the daughter cells, 
their transgenes’ expression is also lower (Figueres-Oñate et al. 2015; Ludtke et al. 2002). Interestingly, 
cells electroporated with a control plasmid exhibit radial morphology, with processes that are directed 
towards the pial surface (Fig.2.21). 
Second, I have not detected DCX-positive cells among the progeny of Ascl1ERT2/Sox2 co-electroporated 
cells to date (Fig.2.23). The too low concentration, possible dilution and nuclear exclusion of episomes 
could be factors leading to low transgene expression and therefore lack of reprogramming. In fact, the 
amount of proneural factor required to induce astrocyte-to-neuron conversion might not be adequate 
in the current experimental setting. Alternatively, in the light of the finding that co-expression of Ascl1 
and Bcl2 in the postnatal cortex induces forced neurogenesis, it is possible that the absence of Bcl2 
leave induced cells to succumb to the effects of ferroptosis, which hinders direct reprogramming 
(Gascón et al. 2016). Thus, in the future Bcl2 will be co-electroporated with both proneural factors. It is 
also not known for how long the transcription factors should be expressed in order to induce direct 
conversion of astrocytes into neurons. The induction of astrocyte-to-neuron conversion mediated by 
Ascl1ERT2 and Neurog2ERT2 in vitro was possible via a transient activation of the proneural factors 
(Masserdotti et al. 2015). In fact, four days of tamoxifen treatment were sufficient to promote direct 
reprogramming (Masserdotti et al. 2015). So far, I have treated pups with tamoxifen for five consecutive 
days, but such a short treatment might not be sufficient in vivo. The levels of tamoxifen administered 
via intraperitoneal injection are strongly decreased after 24h (Wilson et al. 2014), thus the need for 
multiple applications to maintain relatively stable levels of the compound in the system of the animal. 
Even though a longer duration of activation of the proneural factors might be necessary, it is yet to be 
determined for how long the factors should remain active in the cells in order to induce direct neuronal 
reprogramming and if a transient expression is sufficient, as opposed to a prolonged one. Noteworthy, 
when using retroviral vectors for the exogenous expression of factors under the control of a strong 
ubiquitous CAG promoter to induce cell fate-switch, the expression is maintained active throughout the 
whole experiment, while with a hGFAP promoter the expression would be lost upon downregulation of 
the promoter in case of successful lineage conversion. Moreover, the proneural factors are co-injected 
with co-factors that have been previously shown to increase the glia-to-neuron conversion efficiency, 
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namely Sox2 and Bcl2 (Heinrich et al. 2014; Gascón et al. 2016). The possibility of remaining in the 
cytoplasm of the cell as an episome applies to them too. 
To improve the strategy and its success chances, an “all-in-one” construct is under preparation (Fig.3.4). 
Such construct contains multiple elements within the terminal repeats: 
 hGFAP promoter, for expression of the transgenes specifically in GFAP-expressing astrocytes. 
 Tamoxifen-inducible Cre-recombinase, fused to the modified oestrogen receptor domain. The 
recombinase is located upstream of a floxed Stop-cassette. 
 Internal Ribosomal Entry Site (IRES), followed by the coding sequence of Neurog2 or Ascl1. 
Notably, the coding sequences of the proneural factors in this construct won’t be tamoxifen-
inducible. 
 pA, for termination of transcription. 
This construct can be electroporated in a transgenic mouse line, such as the Ai3 line (Rosa-CAG-LSL-
eYFP-WPRE, The Jackson Laboratory). The Ai3 mouse line contains in the Rosa26 locus the eYFP 
transgene downstream of a floxed Stop cassette (LSL). The Cre-recombinase of the all-in-one construct 
will be expressed upon tamoxifen treatment only in electroporated astrocytes. Its activation will ensure 
excision of the Stop-cassettes present in the transposon and in the Rosa26 genomic locus, thus allowing 
consequent transcriptional activation of the transcription factor and of the eYFP reporter, respectively. 
The expression of the eYFP fluorescent reporter will be stable and inheritable in the progeny of 
electroporated cells. Moreover, the expression of eYFP will be active also in induced neurons, because 
the transgenes in the Rosa26 locus are under the control of the ubiquitous CAG promoter. The use of 
the Ai3 mouse line with the all-in-one construct (Fig.3.4) would also limit the tamoxifen treatment to 
just one injection and yield stable expression of the proneural factors until cell fate-switch. 
 
 
The co-expression of transcription factors and ubiquitously expressed fluorophores to label 
electroporated cells allows clonal analysis of induced neurons based on their colour barcoding (Fig.2.18) 
and on their proximity to the astroglial clone from which they originated. In fact, sibling astrocytes 
belonging to the same clone detected through ubiquitous StarTrack labelling are closed to each other 
and occupy tight domains (Figueres-Onãte et al. 2016). Conversely, neurons belonging to a mixed 
neuronal and glial clone derived from the same ventricular progenitor during cortical development are 
Fig.3.4 All-in-one plasmid for the electroporation in a transgenic mouse line. TF=transcription factor, here 
indicating Neurog2 or Ascl1. 
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located in different domains one week after electroporation, distant from the sibling astrocytes 
(Figueres-Onãte et al. 2016). Thus, in mixed clones containing induced DCX-positive neurons, we expect 
to detect induced neurons as sibling cells closely related to the other cells of the clone rather than 
located in distant cortical regions. 
3.3.2    Role of astroglial heterogeneity in direct reprogramming 
Direct reprogramming seems to be influenced by the heterogeneity of reprogrammed cells. First of all, 
there is heterogeneity of response within the same population. A recent study showed that pericytes, 
brain-resident cells of mesodermal origin, constitute an heterogeneous population of cells that do not 
reprogram and cells that reprogram into neurons (Karow et al. 2018). Moreover, pericytes undergoing 
Ascl1/Sox2-mediated direct conversion in vitro bifurcate in two different neuronal lineages during 
differentiation: a subset of cells expresses genes of the glutamatergic program, while another subset 
expresses genes of the GABAergic program (Karow et al. 2018). This, together with the fact that cells 
undergoing neuronal reprogramming activate non-neuronal programs that are silenced to allow 
neuronal differentiation (Mall et al. 2017), suggests that cells belonging to the same population might 
respond to the induction of cell fate-switch in different ways. Second, transcription factors inducing 
neuronal reprogramming might elicit different differentiation programs in different cell populations. 
Ascl1 exogenous expression in neural stem cells isolated from the subependymal zone in vitro induces 
neuronal differentiation in GABAergic interneurons (Berninger e al. 2007), while pericytes induced by 
Ascl1/Sox2 induce an intermediate stem cell-like state that precedes neuronal differentiation in 
GABAergic or glutamatergic neurons (Karow et al. 2018). Third, the same cell type might have different 
reactions to in vivo reprogramming: OPCs in the adult murine cortex do not respond to Ascl1/Sox2-
induction, but they reprogram into DCX-positive neurons upon cortical injury (Heinrich et al. 2014); 
conversely, striatal OPCs are susceptible to reprogramming also in the absence of injury (Pereira et al. 
2017). Moreover, the presence of cortical injury and subsequent reactive gliosis does not guarantee 
that a cell type will be reprogrammed. In fact, Ascl1/Sox2-induction does not convert adult cortical 
reactive astrocytes into neurons, but rather converts OPCs (Heinrich et al. 2014). Reactive gliosis seems 
also to not be necessary for direct conversion of cortical glia into neurons at postnatal stages, as 
described in this study. 
Given the multitude of heterogeneous responses of cells to forced cell fate-switch, it is of interest to 
understand whether the heterogeneity of mouse cortical astrocytes is associated to different outcomes 
of forced neurogenesis. This knowledge will provide fundamental information that might help improving 
direct astrocyte-to-neuron conversion strategies in vivo. Coupling direct conversion of astrocytes into 
neurons with clonal analysis of induced neurons will help elucidating whether the outcome of direct 
reprogramming in vivo is influenced by the heterogeneity of astrocytes. Many factors contribute to 
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astroglial heterogeneity. The variety of different morphological and functional properties of astrocytes 
(reviewed in Khakh and Sofroniew 2015) might hint at a different cell plasticity during fate-conversion. 
Various aspects can be thus investigated in mixed clones containing astrocytes and neurons. Firstly, it 
will be interesting to determine whether clones containing induced neurons are located in specific areas 
of the cortex. In fact, cortical astrocytes are generated in a columnar way (Magavi et al. 2012) and have 
layer-specific properties, including cell orientation, arborisation and volume occupied by the cell 
(Lanjakornsiripan et al. 2018). Besides being reflected by different morphology, layer distribution of 
astrocytes hints at different functional properties, as astrocytes of layer II/III contact a higher fraction 
of synaptic axon-dendrite surface than astrocytes of layer VI (Lanjakornsiripan et al. 2018). 
Second, astrocytes exhibit different Ca2+ signalling activity, thus mediating a variety of functions, 
including contribution to neuromodulation, uptake of electrolytes and neurotransmitters, coordination 
of neuronal synchronisation and control of vasodilation and vasoconstriction among others (reviewed 
in Khakh and Sofroniew 2015, Mishra 2017; Sasaki et al. 2014). Available genetic tools encoding for 
fluorescent Ca2+ indicators (reviewed in Khakh and Sofroniew 2015, Mishra 2017; Sasaki et al. 2014) can 
help dissecting the functions of Ca2+ signalling in astrocytes, and perhaps to determine whether the type 
of Ca2+ signalling exhibited by astroglia is peculiar to cells successfully (or unsuccessfully) converting into 
neurons or to the induction of neurons with different functional properties. 
Third, given the requirement to induce reactive astrogliosis in most direct neuronal conversion 
paradigms (Gascón et al. 2016; Guo et al. 2014; Heinrich et al. 2014; reviewed in Heinrich et al. 2015), 
the size of clones is another factor that can be analysed, to determine whether proliferation of astroglia 
is a prerequisite for direct neuronal conversion. 
Fourth, it would be of interest to analyse the proximity of astrocytes to the vasculature. Neurovascular 
coupling, which is the coupling between neuronal activity and cerebral blood flow, is in fact an important 
aspect of astroglial function (reviewed in Mishra 2017, Khakh and Sofroniew 2015) because the blood 
flow and astrocytes are the two sources of energy in the brain (reviewed in Mishra 2017). Astrocytes 
control the resting tone of cerebral vasculature in a mechanism mediated by the Ca2+-channel TRPV4, 
which is expressed by astrocytes and modulates the intracellular concentration of Ca2+, thus modulating 
the extracellular concentration of ATP (Kim et al. 2015; reviewed in Mishra 2017). These changes in 
intracellular Ca2+ concentration mediated by TRPV4 are triggered by changes in the pressure and flow 
of arterioles (Kim et al. 2015; reviewed in Mishra 2017). 
Fifth, changes in intracellular Ca2+ concentration in astrocytes influence neuronal function (Araque et al. 
2014). In fact, besides blood flow and pressure astrocytes can sense pH and Na+ concentration and can 
release gliotransmitters upon Ca2+-dependent signalling (Araque et al. 2014; reviewed in Mishra 2017). 
The release of gliotransmitters modulates neuronal activity (Araque et al. 2014). This Ca2+-regulated 
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astrocyte-mediated control on neuronal function might have an impact on the control of interneuronal 
cell death orchestrated by pyramidal neurons during postnatal cortical development (Wong et al. 2018). 
Sixth, storage of glycogen granules in the cytoplasm of astrocytes is not only linked to their function in 
providing energy to the brain, but also to their metabolic state (reviewed in Khakh and Sofroniew 2015; 
Zhang et al. 2014). A transcriptomic analysis performed on brain cells revealed that glycolytic 
components are enriched in astrocytes, while neurons rely predominantly on OxPhosph (Zhang et al. 
2014). This provides evidence for the fact that astrocytes transitioning to a neuronal fate undergo a 
series of forced metabolic changes, which can eventually hamper the conversion into neurons (Gascón 
et al. 2016; Kim et al. 2018). Thus, it would be interesting to find whether the amount of glycogen 
storage in the starting cells influences direct neuronal conversion, provided it is homogeneous among 
cells of the same clone. 
Another interesting aspect of astroglial heterogeneity is raised by the work of Morel and colleagues, 
who determined the transcriptional profile of astrocytes isolated from different brain regions (Morel et 
al. 2017). Surprisingly, astrocytes exhibit a dorso-ventral gradient of transcribed mRNA in the mouse 
brain (Morel et al. 2017), suggesting not only different function, but also possible different chromatin 
states at genomic loci targeted by factors for direct lineage conversion. Supporting the existence of 
heterogeneous chromatin states in astroglia, the work of Tiwari and colleagues demonstrated that, 
during the process of astroglial differentiation in vitro, different genetic programs underlie different 
stages of astrogliogenesis (Tiwari et al. 2018). At an early stage of differentiation, astrocytes express 
genes involved in nervous system development, while at a late stage of differentiation, corresponding 
to mature astrocytes, astroglial cells express genes involved in signalling and cytokine response (Tiwari 
et al. 2018). Interestingly, for each stage of astroglial differentiation there is a specific profile of 
chromatin activation, with enrichment of H3K27ac at stage-specific distal regulatory regions (Tiwari et 
al. 2018). These sites are primed by presence of H3K4me1 before their stage-specific acquisition of 
H3K27ac and transcriptional activation (Tiwari et al. 2018). Notably, two main effectors of early 
astrogliogenesis have been identified, namely Nfia and Atf3, which are likely responsible for repression 
of the neurogenic program and promotion of cell cycle exit, respectively (Tiwari et al. 2018). Runx2 has 
instead been identified as a gene involved in late astrogliogenesis, likely through repression of the 
acquisition of a reactive phenotype (Tiwari et al. 2018). Binding of these transcription factors to their 
primed stage-specific target elements is required for the acquisition of H3K27ac and the increase of 
chromatin accessibility on the targets (Tiwari et al. 2018). Knowing that astrocytes exhibit stage-specific 
transcriptional and epigenetic signatures, with unique priming and activation at regulatory elements is 
a first step towards understanding the heterogeneity of astroglia at a genomic level. In the future, 
transcriptome analysis and ChIP-seq data of cells electroporated and expressing the proneural factors 
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will help understanding if targeted astrocytes exhibit expression profiles and chromatin states favouring 
or disfavouring direct neuronal conversion. 
3.4       Conclusive remarks and future perspectives 
The direct conversion of cortical glia into neurons in vivo is of great importance as a potential brain 
repair strategy, to replenish the neuronal population depleted after traumatic brain injury or in the 
presence of neurodegeneration (reviewed in Heinrich et al. 2015). However, researchers face many 
challenges in order to find the best design for cell fate-switch, exhibiting high efficiency of conversion 
and integration of induced neurons in the pre-existing circuitry. In fact, different aspects are 
determining whether cells will be converted and which neuronal subtype will be generated, such as the 
choice of transcription factors exogenously expressed, the starting cell population targeted and its 
susceptibility to reprogramming. Moreover, cells undergoing forced cell fate-switch face several 
constraints both during lineage conversion and after, when induced neurons have to integrate in the 
circuitry. Thus, it is important to understand the mechanisms underpinning direct neuronal 
reprogramming in order to design more efficient strategies. In this section I will give a brief overview of 
the aspects that I find of greatest interest when it comes to finding new experimental designs for the 
improvement of the efficiency and efficacy of direct reprogramming in vivo. 
Cells that exogenously express transcription factors to induce neuronal fate-switch are subjected to 
both intrinsic and extrinsic influences determining the outcome of reprogramming. Among the most 
important intrinsic ones are the mechanisms triggered by forced expression of transcription factors and 
the heterogeneity of the starting cell population, which determines its susceptibility to reprogramming. 
ChIP sequencing experiments show on which targets the transcription factors are binding (Milne et al. 
2009), while RNA sequencing studies are providing insights into the transcriptional programs triggered 
by the expression of transcription factors, such as the presence of alternative fates (non-neuronal ones 
or inducing different neuronal subtypes) or the activation of possible cytotoxic pathways (Gascón et al. 
2016; Karow et al. 2018). Knowing the genome-wide binding of transcription factors and the difference 
between the transcriptional state of cells undergoing forced lineage conversion at different timepoints 
could help identifying subpopulations of cells susceptible and cells refractory to neuronal 
reprogramming. This could allow the sorting of cell populations that are productively reprogramming 
(Karow et al. 2018), thus increasing the reprogramming success. Moreover, the information on the 
genome accessibility in cells undergoing cell fate-switch, which can be provided by FAIRE sequencing 
(Giresi et al. 2007) or the more recent ATAC sequencing (Buenrostro et al. 2016), would be another 
important cue on the heterogeneity of the starting population. Such knowledge will help determining 
the proper choice of transcription factors, to be expressed alone or in combination with other 
transcription factors, for the induction of a specific type or subtype of neurons. It will also allow the 
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strategic design for the improvement of direct conversion efficiency by the development of ways to 
increase susceptibility to neuronal reprogramming, e.g. through increased chromatin accessibility at 
specific loci. The locus-specific induction of chromatin accessibility could be achieved thanks to the use 
of the CRISPR/dCas9 system, which increases accessibility at the genomic sites surrounding the sgRNA 
thus altering local transcription factor binding (Barkal et al. 2016). 
Noteworthy, the discovery that posttranslational modifications are modulating the neurogenic capacity 
of some proneural factors should pave the way to the identification of the modifications that induce 
glia-to-neuron conversion more efficiently in vivo. Given the finding reported in section 2.1.4 that, 
despite all having neurogenic potential, mutants of the ASCL1 protein with different states of 
phosphorylation induce different levels of neuronal maturation, it is important also to identify a 
combination of transcription factors which yields mature neurons. So far, in vivo glia-to-neuron 
conversion resulted in the generation of mostly DCX-positive neurons, with few NeuN-positive mature 
neurons. However, the co-expression of Neurog2 with Bcl2 not only induced a proportion of induced 
neurons among co-transduced cells higher than 90%, but also yielded about 70% of NeuN-positive 
neurons when coupled to anti-oxidant treatments (Gascón et al. 2016). Similarly, treatment with 
valproic acid and BDNF in the striatum and in the spinal cord induced maturation of the DCX-positive 
neurons induced by exogenous expression of Sox2 (Niu et al. 2015; Su et al. 2014). This suggests that a 
boosted maturation of induced neurons can be achieved via additional treatments aimed at 
counteracting constraints to neuronal maturation. As mentioned above, identification of transcriptional 
programs triggered during forced cell fate-switch will be of advantage in the determination of the stimuli 
repressing maturation of induced neurons.  
Besides intrinsic influences, there are also extrinsic ones involved in the modulation of susceptibility of 
cells to reprogramming and in the functional integration of induced neurons in the neuronal network. 
Among such stimuli are signals derived from the niche and the intercellular communication of cells 
undergoing reprogramming with other cell types. Astrocytes are one of the cell types used as a starting 
population for direct neuronal conversion, together with OPCs. Astrocytes maintain contacts with both 
neurons and blood vessels, consequently mediating neurovascular coupling (reviewed in Mishra 2017). 
Two-photon calcium imaging allows the monitoring of networks activity through recordings of Ca2+ 
transients (Stosiek et al. 2003; Wang et al. 2009). Neuronal activity corresponds to increased blood flow 
(Girouard et al. 2009; reviewed in Mishra 2017). In the future, it will be of interest to exploit the blood 
flow-dependent regulation of astrocytic Ca2+ transients to determine whether there is a correlation 
between the regulation of neuronal activity and the susceptibility to lineage conversion. Moreover, 
neuronal activity might have an important role in the modulation of the integration of induced neurons. 
As recently reported, the activity of pyramidal neurons in the postnatal cortex modulates a PTEN-
mediated mechanism of regulated cell death of newborn GABAergic interneurons (Wong et al. 2018). 
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Thus, it will be important to determine if cortical activity exerts such regulatory activity also in induced 
neurons, thereby determining their chance of surviving and consequently integrating in the pre-existing 
cortical circuitry. The high efficiency of direct conversion into neurons, achieved for instance via co-
expression of pAscl1 and Bcl2, coupled to the use of chemogenetic tools like DREADDS (reviewed in 
Roth 2017), could help determining whether the postnatal cortical environment is indeed modulating 
survival and integration of induced neurons. 
Another aspect to not be overlooked is concerning the possibility that transduced cells expressing 
neuronal markers might not derive from direct reprogramming of cortical glia into neurons. In fact, 
oligodendrocytes and astrocytes are both secreting extracellular vesicles called exosomes (Goetzl et al. 
2016; Krämer-Albers et al. 2007; Willis et al. 2017), which mediate glia-neuron communication (Frühbeis 
et al. 2013; Krämer-Albers et al. 2007; reviewed in White and Krämer-Albers 2014). Exosomes contain 
small cytoplasmic molecules, lipids, proteins, mRNAs and miRNAs (Krämer-Albers et al. 2007; Frühbeis 
et al. 2013; Valadi et al. 2007). Neurons can uptake exosomes released by glial cells and internalise their 
content, which can in turn support neuronal metabolism during oxidative stress (Frühbeis et al. 2013). 
Thus, in the future it will be interesting to determine whether neuronal cells expressing the reporter 
gene actually derive from cell fate-switch or from exosome-mediated internalisation of transcripts 
transferred from transduced cortical glia. 
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4    Methods 
4.1     In vitro methods 
4.1.1 Preparation of postnatal cortical astrocytes’ cultures 
Postnatal cortical astrocytes were isolated from cortices of 5-7 days old C57Bl6/J mice (stage P5-7). After 
decapitating the mice, brains were transferred in a 6cm dish containing ice cold 1xPBS (Phosphate Buffer 
Saline) for dissection. The two hemispheres were separated and hippocampus, cerebellum and midbrain 
were removed.  The meninges were then carefully removed using fine Dumont #5 Fine Forceps (FST). 
Finally, hindbrain structures and the developing white matter were eliminated under a stereotactic 
dissection microscope, to avoid contaminations of the culture from oligodendroglial progenitors. The 
frontal cortex was thereby isolated and kept in 15ml tubes with ice cold 1xPBS until further treatment. 
Dissected cortices were mechanically dissociated using a P1000 pipette and the homogenised tissue 
was spun down at 150xg/5min at 4°C. After carefully removing the supernatant, cells were resuspended 
with a serological pipette in 5ml of Astromedium (see Table 4.3) supplemented with 10ng/µl Epidermal 
Growth Factor (EGF) and 10ng/µl basic-Fibroblast Growth Factor (FGF-2). Cells were kept in culture and 
expanded to 7-10 days in a T25 flask, incubated at 37°C with 5% CO2. 
 
4.1.2  Passaging postnatal cortical astrocytes for experiments 
Cells were prepared for passaging when they reached 70-80% confluency (after ca. 1 week from 
preparation). One day before passaging the cells, the necessary amount of 24-well plates with glass 
coverslips (12mm, Menzel-Gläser) were prepared. To favour the attachment of induced neurons, the 
glass surface was coated with Poly-D-Lysine hydrobromide (PDL) (Sigma) dissolved in sterile dH2O at the 
concentration of 1mg/ml (PDL 1:100). Coverslips were incubated 4h at room temperature (RT) with the 
PDL solution and washed 3 times with sterile dH2O. The plates were then let to dry overnight. 
Cells were trypsinised with trypsin 0.05% for 5min at 37°C. Trypsinisation was stopped by adding 
Astromedium. The cell suspension was spun down at 150xg/5min at 4°C and resuspended with 
Astromedium. To count cells, cell suspension and Trypan Blue were mixed at a 1:1 ratio. 10µl of the mix 
was used to count the number of cells in an improved Neubauer chamber (VWR). Dead cells were not 
considered. Cells were seeded at a density of 50000-80000 cells/well in 500µl Astromedium 
supplemented with EGF and FGF-2. Before any other treatment, they were incubated for at least 4h so 
that they could attach to the surface of the coverslips. 
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4.1.3 Transfection of postnatal cortical astrocytes 
To prepare cells for transfection, conditioned medium was substituted with 300µl of Transfection 
Medium (TM) (see Table 4.3) 24h after seeding. The collected conditioned medium and cells in TM were 
equilibrated in the incubator at 37°C with 5% CO2 for at least 1h. 
Cells were transfected by lipofection with 0.5µg plasmid DNA and 0.7µl Lipofectamine™2000 in TM, 
according to manufacturer’s instructions. The mix of DNA and Lipofectamine™2000 was added dropwise 
to the cultured cells. Cells undergoing transfection were left in the incubator for 4h, during which the 
lipofection took place. Briefly, the positively charged lipids of Lipofectamine™2000 bind the negatively 
charged backbone of DNA, forming vesicles that can merge with the phospholipid bilayer of the cell 
membrane. This leads to internalisation of the exogenous DNA in the cell. 
After 4h, the Transfection Medium was removed and substituted with new pre-warmed Astromedium 
supplemented with EGF and FGF-2. Cells were moved to incubation with 8%CO2. One day after 
transfection, half of the conditioned medium was replaced with an equal volume of B27 Differentiation 
Medium (see Table 4.3), which supports the growth of induced neurons. The next day the whole 
medium was substituted with 1ml of new pre-warmed B27 Differentiation Medium. Cells were kept in 
culture up to 8 days in vitro starting from the day of seeding. 
For immunocytochemical analyses, cells were fixed with ice cold 4% Paraformaldehyde (PFA) for 10-
15min and washed with 1xPBS three times. Fixed cells were stored at 4°C with 1xPBS until further 
analyses.  
4.1.4 Transduction of postnatal cortical astrocytes 
After seeding the cells and letting them attach for 4h in the incubator, cells were transduced with 
retroviruses. In order to maximise the resuspension of the retrovirus in the medium and to avoid 
possible toxicity effects, retroviral particles were not directly applied to the cells. Instead, half of the 
volume of Astromedium was collected from each well in separate 2ml tubes and each tube received 1µl 
of retrovirus per well. The mixture was resuspended and the treated conditioned medium was gently 
added to the cells. The incubation conditions were changed to 37°C with 8% CO2. The day after, the 
treated Astromedium was removed and substituted with pre-warmed B27 Differentiation Medium, that 
was already inoculated and mixed with 1µl/well of retrovirus. On the third day, the culture volume was 
brought to 1ml/well with fresh B27 Differentiation Medium. Cells were kept in culture for a total of 
7days in vitro and fixed for immunocytochemical analyses with 4% PFA, as described in section 4.1.3. 
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4.1.5 Preparation of 4% Paraformaldehyde (PFA) 
To prepare 4% PFA, a volume of milliQ H2O corresponding to one fourth of the final volume of the 
solution was heated up. Once it reached 65°C, 4% PFA (w/v) was added and stirred for about 5min until 
partial dissolution of the powder, carefully checking that it would not boil. To allow full dissolution of 
the Paraformaldehyde, the pH of the solution was slowly raised with 5M Sodium Hydroxide to 
approximately 6.9, when the appearance of the solution became completely clear.  At this point a 
volume of 0,4M Phosphate Buffer (see Table 4.3) was added while the solution was still stirring. Final 
volume was reached with millQ H2O. To remove microcrystals of undissolved powder, the 4% PFA was 
filtered with Whatman paper filters. 
For fixation of cells in culture, the solution was aliquoted and stored at -20°C until use.  For perfusion of 
animals, 4% PFA was prepared fresh and maintained on ice until the end of the tissue’s fixation. 
4.1.6 Immunocytochemistry 
Since antibodies might weakly bind to non-antigen proteins mimicking their binding epitope, which 
causes higher background or unspecific signal, cells were treated with a Blocking Solution containing 3% 
Bovine Serum Albumin in 1xPBS. Moreover, the Blocking Solution was supplemented with 0.5% Triton 
X-100 to permeabilise membranes and allow penetration of the antibodies in the cells. Coverslips were 
thereby covered with Blocking Solution and incubated 1h at RT. Meanwhile, primary antibodies were 
diluted in Blocking Solution and stored at 4°C. After the blocking step, cells were incubated with the 
primary antibodies’ solution for 2-3h at RT. After washing 3 times with 1xPBS, cells were incubated with 
fresh secondary antibodies’ solution prepared in Blocking Solution for 1h at RT at the dark. In order to 
be able to visualise cell nuclei, cells were treated with DAPI diluted in Blocking Solution for 5min at RT. 
Finally, cells were washed 3 times in 1xPBS and mounted with Aqua Polymount (Polysciences). The 
mounting medium was left to dry for at least 24h before imaging. 
4.2 Molecular Cloning 
4.2.1 Cloning of retroviral vectors: Gateway® cloning system 
The retroviral vectors used for this study are based on Moloney Murine Leukemia Virus (Mo-MLV) and 
were originally obtained in the laboratory of Inder Verma (Naviaux et al. 1996). They contain the 
following elements (Fig.4.1): 
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CMV: cytomegalovirus early-immediate enhancer; 
R-U5: Moloney Murine Sarcoma Virus fused to the U3 region, a viral transcriptional enhancer; 
MLV-PBS: Mo-MLV primer binding site, a target of retroviral repression after integration in the host 
genome; 
Extended PSI: retroviral packaging signal; 
CAG: ubiquitous strong promoter for mammalian expression; 
IRES: internal ribosome entry site, to enhance the translation of the fluorescent reporter; 
eGFP or DsRed Express2: fluorescent reporters, derived from Aequorea victoria or Discosoma 
respectively. DsRedExpress2 will be indicated in this manuscript as DsRed; 
WPRE: Woodchuck Hepatitis Virus Post-translational Regulatory Element, to enhance viral gene 
expression; 
MLV PPT: Mo-MLV Poly-Purine Tract, a primer for DNA synthesis during reverse transcription; 
MLV 3’LTR: Mo-MLV 3’ Long Terminal Repeat, for integration in the genome of the host cell; 
pUC ori: bacterial origin of replication, for synthesis of the plasmid DNA; 
AmpR: gene encoding for β-lactamase, which confers resistance to the antibiotic ampicillin, for positive 
selection of bacterial clones. 
Additionally, the vectors contain the following elements required for molecular cloning:  
attR1 and attR2 sites: recombination sites, to perform LR recombination with the Gateway® kit 
(Invitrogen); 
CmR-ccdB cassette: dual selection cassette containing the chloramphenicol acetyltranspherase, an 
effector of the resistance to chloramphenicol in bacteria, and the ccdB gene, encoding for a protein 
toxic to bacteria. 
The retroviral plasmids were cloned using the Gateway® kit (Invitrogen®). It consists of a series of 
plasmids containing specific recombination sites, called att sites, deriving from the Lambda phage 
mechanism of integration in the host genome. 
 
Fig.4.1 Schematic of the retroviral backbones used for mammalian exogenous expression in this study. 
Fig. 4.2 Schematic of the main features of the plasmid pENTRY1A Dual Selection. 
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The general cloning strategy consists of sub-cloning the insert in the multiple cloning site of the 
pENTRY1A Dual Selection, thus generating the so-called donor vector. This plasmid contains attL and 
attB sites, which allow the recombination with the retroviral destination vectors. The use of appropriate 
restriction enzymes consents the excision of the CmR-ccdB cassette and the ligation with the insert of 
interest. After generation of this intermediate construct (pENTR-, the donor vector), an LR 
recombination catalysed by the LR Clonase® II was performed between the pENTR- construct and the 
destination vector (in this case the retroviral plasmid depicted in Fig.4.1). This resulted in the excision 
of the CmR-ccdB cassette present in the destination vector and the subsequent insertion of the gene of 
interest. 
The retroviral construct for the expression of human Bcl2 (pMIG-hBcl2-IRES-GFP) was a kind gift of the 
Gascón lab (Universidad Complutense, Madrid) and contains a 5’LTR that functions as a strong promoter 
for the gene of interest (Fig.4.1). 
4.2.2 Cloning of retroviral vectors: Plasmids generated 
In order to investigate the role of phosphorylation of ASCL1 on the modulation on forced neurogenesis, 
I cloned three retroviral constructs for the exogenous expression of pAscl1. The three genes I used were 
encoding respectively for the following proteins (Fig.4.3, see also Fig.2.1): 
 Wild type form of mouse ASCL1: contains six SP residues, which are targeted by 
phosphorylation; 
 Phospho-deficient form of mouse ASCL1: six S>A mutations had been inserted at the SP sites, 
to hamper phosphorylation due to the presence of alanine; 
 Phospho-mimetic form of mouse ASCL1: six S>D mutations had been inserted, to mimic 
constitutive phosphorylation via the negative charge of aspartate. 
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The coding sequences were originally inserted in the pCIG2 vector and kindly provided by Carol 
Schuurmans (Sunnybrook Research Institute, Toronto, ON, Canada). In order to sub-clone them into the 
pENTRY1A Dual Selection vector, I excided all three coding sequences via XhoI/SalI double restriction 
and inserted them into the intermediate backbone previously opened via SalI single restriction. I thereby 
generated the donor constructs pENTR-Ascl1, pENTR-Ascl1SA6 and pENTR-Ascl1SD6. Each of these 
intermediate constructs was recombined with the destination vector, to generate the final retroviral 
plasmids for exogenous expression of Ascl1 in mammalian cells (Fig.4.4). For all coding sequences were 
cloned: one expression vector with eGFP fluorescent reporter; one expression vector with 
DsRedExpress2 reporter. All plasmids were sequenced at GATC Biotech GmbH. 
 
 
 
 
Fig.4.3 Alignment of the secondary structure of the proteins encoded by the three forms of Ascl1. The nucleotide 
sequences were translated with Ape (A Plasmid Editor, by M. Wayne Davies). The alignment’s analysis of the 
three proteins was performed online with Clustal Omega (EBL-EBI), using a Multiple Sequence Alignment. 
Results were manually aligned for visual representation. Asterisks indicate multiple alignment. Mismatches, 
corresponding to the S>A and S>D mutations, are highlighted in orange. mAscl1= mouse Ascl1. 
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4.2.3 Cloning of transposon-based constructs 
To perform in utero electroporation experiments, I obtained the plasmids of the StarTrack clonal 
labelling system from the Instituto Cajal (Madrid, Spain) in the frame of a collaboration. The StarTrack 
system exploits PiggyBAC-transposition to stably integrate transposons into the host cell’s genome. 
Transposons are flanked by Terminal Repeats at the 5’ and 3’ sides (5’TR and 3’TR). The vectors 
containing transposons have the following elements (Fig.4.5): 
hUbc: human Ubiquitin promoter, for expression in every cell type; 
5’TR and 3’TR: Terminal Repeats, elements that are recognised by the PiggyBAC transposase and 
determine the integration site in the genome of the host cell. 
LoxP: recombination sites that are recognised by the Cre recombinase. 
pCAG-Ascl1-IRES-DsRed 
9001bp 
pCAG-Ascl1SA6-IRES-DsRed 
9001bp 
pCAG-IRES-DsRed 
8188bp 
pCAG-Ascl1SD6-IRES-DsRed 
8904bp 
Fig.4.4 Maps of the retroviral constructs cloned for the exogenous expression of Ascl1. (see next page) The 
maps illustrate location, proportional size and directionality of the elements present in the retroviral plasmids 
I cloned. The fourth map depicts the control retroviral plasmid encoding only for the fluorescent reporter 
DsRed, pCAG-IRES-DsRed. This construct, together with the pCAG-IRES-eGFP, was already available in the lab. 
While these maps are showing only the construction of the plasmids with DsRed as fluorescent reporter, they 
all have been cloned with the green fluorescent reporter eGFP too. 
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pA: bovine growth hormone polyadenylation sequence, for termination of transcription; 
pUC ori: bacterial origin of replication, for synthesis of the plasmid DNA; 
AmpR: gene encoding for β-lactamase, which confers resistance to the antibiotic ampicillin, for positive 
selection of bacterial clones. 
 
A hyperactive form of the PiggyBAC transposase (hyPBase) is expressed by an additional plasmid with 
CMV promoter (Fig.4.6). In addition to these constructs, it is necessary to have another one to express 
the Cre recombinase fused to the oestrogen receptor element (ERT2) for tamoxifen-dependent 
activation (Fig.4.6). The presence of active Cre recombinase is in fact necessary to induce recombination 
of the LoxP sites for removal of episomal copies of the plasmids (see section 1.5.2).  
 
To exogenously express proneural transcription factors for forced fate-switch of electroporated 
astrocytes into neurons, I subcloned the coding sequences of tamoxifen-dependent NEUROG2 and 
ASCL1 into the transposon of a plasmid with human GFAP promoter (Fig.4.7). Tamoxifen-dependent 
activation is ensured by the fusion of the proneural genes with the ERT2 gene. The original fused coding 
sequences were previously cloned at the LMU Munich (Masserdotti et al. 2015). To insert the coding 
sequence of Ascl1ERT2, the pGFAP-eGFP vector was opened via EcoRI restriction and blunted. 
Ascl1ERT2 was obtained via PCR and subcloned via blunted ClaI-ends. 
Fig.4.5 Schematic of the main features of the plasmids for expression of the StarTrack fluorescent proteins. The 
transposon, namely the part of the plasmid that is integrated in the host cell via retrotransposition, is flanked 
by the 5’TR and the 3’TR. 
Fig.4.6 Schematic of the main features of the plasmids for expression of the transposase and of the Cre 
recombinase. The Cre recombinase is fused both upstream and downstream to the ERT2 element, for 
tamoxifen-dependent activation.  
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To insert Neurog2ERT2, I opened the vector via EcoRI and BamHI restriction and blunted the EcoRI end. 
Neurog2ERT2 was obtained via PCR and subcloned via ClaI+blunting and BamHI restriction. Similarly, to 
subclone Sox2 I prepared the vector via EcoRI/BamHI double-restriction and blunted both ends. The 
insert with the coding sequence for Sox2 was obtained via PCR and inserter via blunted BamHI-ends. 
For the expression of BCL2, an antiapoptotic protein, it was necessary to add upstream of the gene a 
STOP cassette flanked by LoxP sites, to induce transcriptional activation only upon tamoxifen-dependent 
Cre recombination (Fig.4.7 and 2.17). Thus, I first prepared an intermediate construct containing only 
the STOP cassette and then subcloned Bcl2. For this purpose, I opened the pGFAP-eGFP vector via 
BamHI and EcoRI restriction and I blunted only the BamHI ends. The loxed STOP cassette was inserted 
via AccI blunted end and EcoRI end. To finally add the Bcl2 coding sequence, I linearized the 
intermediate construct  (pPB-GFAP-LSL) via EcoRI; Bcl2 was obtained via PCR and inserted via EcoRI. 
All plasmids were sequenced at GATC GmbH. 
4.2.4 Preparation of DNA for retroviral production and for in utero electroporation  
To prepare DNA for experiments, plasmids generated via ligation or recombination were first 
transformed into a competent strain of Escherichia coli, called DH5alpha, for amplification. Positive 
transformants were inoculated in liquid Luria Bertani medium containing Ampicillin and expanded for 
12-16h at 37°C, shaking at 210rpm. 
To isolate the expression plasmids, bacterial suspensions were first pelleted by centrifugation 
20min/4500xg at RT. Subsequently, the DNA plasmids were extracted and purified via anion-exchange 
column chromatography using commercial kits, according to the manufacturers’ instructions. They were 
finally resuspended in Tris-EDTA pH8.0. 
Fig.4.7 Schematic of the main features of the plasmids for expression of the proneural factors and of their 
cofactors. The STOP cassette consists in a series of repeated SV40 polyA sequences.  
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For transfections and for the production of retroviral particles, I used the PureLink™ HiPure Plasmid DNA 
Maxiprep kit (Invitrogen™), which allows the preparation of high-quality and high-purity DNA. 
Nevertheless, this kit yields a DNA preparation with an endotoxin content of 0.1-1.5EU/µg Plasmid DNA. 
Endotoxins, namely lipopolysaccharides, are present in the inner membrane of the wall of the E.coli 
strain used to amplify the plasmids. For some applications, such as in utero electroporation, in which 
the plasmids are directly injected in the organism of the experimental animal, their presence can be 
unwanted and even harmful, with potential toxic or inflammatory effects. Thus, in order to purify DNA 
for in utero electroporation, I used the NucleoBond® Xtra Maxi EF kit (Macherey-Nagel). This kit is an 
anionic-exchange chromatography kit that yields DNA preparations containing an endotoxin level of less 
than 0.05EU/µg Plasmid DNA. Plasmids were resuspended in endotoxin free Tris-EDTA pH8.0. 
For in utero electroporation experiments, the plasmid mix was prepared by mixing all plasmids at a 
concentration of 1µg/µl. The relative proportion of plasmids was thus divided: 
 one third of the total amount in micrograms: factors for direct conversion of astrocytes into 
neurons (Fig. 4.7), transposase and Cre recombinase (Fig.4.6); 
 two thirds of the total amount in micrograms: ubiquitous StarTrack (Fig.4.5). 
In order to be able to see the plasmid mix during ventricular injections, I added about 1µl of FastGreen 
(Sigma) diluted at 1mg/ml in milliQ H2O. 
4.3       Production of retroviruses 
4.3.1   Cells 
 Retroviruses were produced using 1F8 cells, a monoclonal line derived from a batch of 293GPG cells 
(Ory et al., 1996). These cells are derived from HEK293T cells modified via Adenoviruses-5 to stably 
express the retroviral gag-pol polycistronic element. This sequence encodes for the VSV-G protein, 
which is toxic for HEK cells. In order to avoid cytotoxicity, the system is maintained under the control of 
a Tetracycline-repressed (tetO) minimal promoter and a Tetracycline-responsive (tetR)/VP16. The 
genomic composition of this cell line allows the production of VSVG-pseudotyped retroviruses with a 
single transfection. 
1F8 cells were cultured in Growth Medium (see Table 4.3) supplemented with antibiotics: 2µg/ml 
Puromycin for selection of the integrated VSVG gene and the transactivator tetR/VP16; 0.3 mg/ml G418 
Sulfate (Geneticin) for selection of the MLV genome (gag-pol); 2µg/ml Tetracyclin for inhibition of the 
VSVG gene. Cells were kept in culture at 37°C with 5%CO2 and passaged via trypsinisation and 
resuspension when at 70-80% confluency. 
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4.3.2    Retroviral packaging 
In order to prepare cells for transfection, they were gently washed with 1xPBS and trypsinised with 
0.05% Trypsine-EDTA. Trypsinisation was stopped with pre-warmed Plating Medium (see Table 4.3) and 
cells were plated on 10cm dishes at a density of about 1x105-1x107 cells/dish. Cells were transfected 
when they reached 70-80% confluency. Briefly, a DNA mix and a reagent mix were prepared in 
Transfection Medium (DMEM; 1x Glutamine). Usually, 6x10cm dishes per each construct were 
transfected with 150µg plasmid DNA and the reagent mix with 250µl of GenJet Plus or with 1mg/µg of 
PEI. While incubating the transfection mix, Plating Medium was removed from the cells and substituted 
with Packaging Medium (see Table 4.3). At this point, because of the Tetracycline withdrawal, the VSVG 
expression is induced. The transfection mixture was then added dropwise to the cells. One day later, 
cells were washed with Packaging Medium and fed with 10ml of new Packaging medium. 
4.3.3    Retroviral harvesting and titering 
To harvest the viral particles released by transfected cells, supernatants were collected 3 days after 
transfection and spun 15min/350xg at 4C° to pellet cell debris. Cleared supernatants were filtered with 
a 0.44µm PVDF filter and transferred on SW28 tubes for ultracentrifuge. A cushion of 300µl Opti-PREP 
was added at the bottom of each tube and viral supernatants were centrifuged in pre-cooled 
ultracentrifuge with pre-cooled SW28 rotor 2h/24000rpm at 4°C. Supernatants were carefully removed 
and the Opti-PREP embedded pellet was washed with circa 30ml sterile ice-cold TBS-5 buffer (see Table 
4.3). Viral pellets were ultracentrifuged again 2h/24000rpm at 4°C. The supernatant was removed and 
the viral pellet was resuspended in 50µl TBS-5 buffer. The viral suspension was kept on ice until the next 
day and aliquoted for storage at -80°C. Three rounds of viral harvests were performed, each at 2 days 
from the previous one. First and second harvest were usually mixed together and used for in vitro 
experiments. 
Each harvest of each production was tested and titered using HEK293 cells. Briefly, HEK293 cells were 
trypsinised with 0.05% Trypsin-EDTA when they reached 70-80% confluence and seeded at a density of 
50000-80000 cells per well of a 24-well plate. 4-12h after seeding them, cells were transduced with the 
following dilutions: 1µl virus/well; 10-3µl virus/well; 10-5µ virus/well.  
The day after transduction, cells were fixed with 4% Paraformaldehyde and analysed via 
immunocytochemistry. Six random pictures of each coverslip were taken at the 20x objective at an 
AxioVision fluorescent microscope (Zeiss). The reporter-positive cells were counted over the total 
number of cells, indicated by DAPI-positive nuclei. The viral titer was calculate as it follows:                                  
𝑣𝑖𝑟𝑎𝑙 𝑡𝑖𝑡𝑒𝑟 =
(𝑟𝑒𝑝𝑜𝑟𝑡𝑒𝑟 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠)𝑥100
𝐷𝐴𝑃𝐼 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠
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Viral titers of 5-9x107 were considered suitable for viral injections in vivo. 
4.4       Animal experiments 
4.4.1   Animals 
All animal procedures were conducted in accordance to Policies on the Use of Animals and Humans in 
Neuroscience Research, revised and approved by the Society for Neuroscience and the state of 
Rheinland-Pfalz under licence number 23 177 07-G15-1-031 and licence number 23 177 07-G17-1-067, 
and carried on under the supervision of the licence holder (University Medical Center Mainz, Germany). 
For in vitro cultures, C57Bl6/J at the age of P5-7 were kindly provided by the Institute of Microscopy and 
Microscopic Anatomy (University Medical Center Mainz, Germany). All in vivo experiments were 
performed on C57Bl6/J mice obtained from Janvier. For retroviral injections, P5 mice were ordered with 
the mother, to ensure their survival until the end of the experiment. Retroviral injections were 
performed by the licence holder. For in utero electroporation experiments, timed pregnant mice 
(ordered from Janvier) at the E14 stage were operated. The day of detection of vaginal plug was 
considered day zero. Postnatal electroporations at P0 and P1 were performed by our collaborator at the 
Instituto Cajal (Madrid, Spain). 
4.4.2    Retroviral injections 
Before surgery, P5 pups were treated with analgesia (Rimadyl® 4mg/Kg of body weight in 0.9% NaCl). 
Anaesthesia was administered via intraperitoneal injection of 0.5mg/Kg body weight Medetomidin + 
5mg/Kg body weight Midazolam + 0.025mg/Kg body weight Fentanyl. Reflexes were checked and once 
mice were in deep anaesthesia, viruses were injected in the cerebral cortex using borosilicate glass 
capillaries (0.8-0.9mm diameter, World precision Instruments Inc.) pulled with a micropipette puller to 
have a tip diameter of about 20µm. Briefly, a small incision was made on the skin with a surgical blade 
and the skull was carefully opened with a needle. Each pup received a volume of 0.5-1µl of retroviral 
suspension injected in the cortex. After injection the wound was closed with surgical glue and 
anaesthesia was antagonised via intraperitoneal injection of 2.5mg/k body weight Atipamezol + 
0.5mg/Kg body weight Flumazenil + 0.1mg/Kg body weight Buprenorphin. Pups were left on a hot plate 
at 37°C to recover before reuniting them to the mother. The recovery state was daily checked for one 
week after the operation. 
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4.4.3    In utero electroporation and tamoxifen administration 
Timed pregnant mothers were operated as previously described (Baumgart and Grebe 2015). Half an 
hour before surgery, mice were analgesized subcutaneously with Rimadyl® (5mg/Kg of body weight in 
0.9% NaCl). To perform surgery, they were initially anesthetised per inhalation with 2.5% Isoflurane in 
pure O2. After fixing the limbs on the operation table and checking that mice were in full anaesthesia, 
the Isoflurane level at the inhalation mask was reduced to 2%. The abdomen was cleaned with a sterile 
gauze with 0.9% NaCl containing the bacteriostatic benzyl alcohol (0.9%), and with 70% Ethanol. The 
surgical area was surrounded by sterile gauze and the abdominal cavity was opened with a 2-2.5cm 
wide incision at the skin and a slightly smaller one at the muscle. The uterine horns were carefully 
extracted using ring loops (FST) and the area of the incision was kept moist with the solution of 0.9% 
NaCl and benzyl alcohol for the whole procedure. 
The plasmid mix was injected in the lateral ventricles of the embryos with borosilicate glass capillaries 
(0.8-0.9mm diameter, World Precision Instruments Inc.) pulled with a micropipette puller to have a tip 
diameter of about 20µm. The lateral ventricles were filled with 1-1.5µl plasmid mix (prepared as 
described in section 4.2.4), namely until when the ventricular cavity looked filled by the coloured dye 
Fast Green. Five electric current pulses (30mV, 50ms cycles length, 950ms interval pause) were applied 
via platinum electrodes (3mm diameter, Nepagene) connected to an electroporator. After 
electroporation, the uterine horns were carefully put back into the abdomen with ring loops. The muscle 
was sutured with surgical 5-0 PermaHand Silk (Ethicon) and the skin was sutured with 4/0 Safil® self-
resorbing silk (Braun). If necessary, mice were analgesized again the day after surgery (5mg/Kg body 
weight Rimadyl®, subcutaneous). Mice were visually controlled until they woke up. The recovery state 
was checked daily for one week after the surgery. The day of delivery was considered postnatal day zero 
(P0). 
Beginning at the age of P5, pups were injected intraperitoneally with 25mg/Kg body weight of Tamoxifen 
(Sigma) diluted in corn oil for five consecutive days. 
4.4.4    Fixation and preparation of tissue 
Prior to sacrifice, animals were lethally anesthetised with Ketamine (120mg/Kg body weight) and 
Xylazine (16mg/Kg body weight). Reflexes were checked and once animals reached the state of deep 
anaesthesia their limbs were fixed and their thoracic cavity was opened to expose the heart. They were 
transcardiacally perfused with pre-warmed 0.9% NaCl supplemented with heparin (1000U/ml), 
papaverine (4mg/ml) and polyvinylpyrrolidon (2.5%), to remove the blood from the vessels. Then, they 
were perfused with freshly prepared, ice-cold 4% PFA to fix the tissues. After fixation, the brains were 
taken out and post-fixed overnight in 4% PFA at 4°C.  
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The next day, brains were washed in 1xPBS and prepared for vibratome sectioning. The brains were 
coronally sliced with a thickness of 40µm for retrovirus-injected brains and 50µm for electroporated 
brains. Slices were separated into six series per each brain, each series containing one slice every six. 
Thus, one series is a representative sample of the brain along the rostro-caudal axis every 240 or 300µm. 
Brain slices were put in cryoprotective solution (see Table 4.3) and stored at -20°C. 
4.4.5    Immunohistochemistry 
For immunohistochemistry, one series obtained as in section 4.4.5 was stained as it follows. To remove 
the cryoprotective solution, slices were first washed three times for 15min with filtered 0.1M TBS, pH7.6 
(hereafter, 1xTBS). Subsequently they were incubated for 1,5h in blocking solution (5% Donkey Serum; 
0.1-0.3% Triton X-100 in 1xTBS). After the blocking step, slices incubated with the primary antibodies 
diluted in blocking solution for 2-3h at RT, followed by an overnight incubation at 4°C. After washing 
three times with 1xTBS, they were incubated with the secondary antibodies diluted blocking solution 
for 1h at RT. Slices were washed twice with 1xTBS and incubated with DAPI dissolved in 1xTBS for 5min 
at RT. Every excess of DAPI was removed by washing three times with 1xTBS. Before mounting, slices 
were washed two times with 0.1M Phospate Buffer, pH7.4. 
To mount them, slices were disposed on Superfrost™ (Thermo Fisher Scientific) microscope slides and 
allowed to dry. For retroviral-injected brains, slices were further dehydrated with toluene and covered 
with cover-glasses mounted with DPX mounting medium. For electroporated samples, slices were 
covered with cover-glasses mounted with Mowiol® 40-88 (Sigma).  
4.4.6    Electrophysiology 
To perform patch-clamp recordings on ex vivo brain slices, C57Bl/6J mice were injected with retroviruses 
at P5 as described in section 4.4.2 and analysed at 4 weeks post injection. 
Mice were terminally anaesthetised with CO2 and decapitated. The brain was dissected out in ice-cold 
modified artificial cerebro-spinal fluid (ACSF) solution (see Table 4.3) saturated with 5% CO2 and 95% 
O2, pH7.4. Dissected brains were cut in 300μm thick coronal slices at the vibratome (Leica VT12005) 
and transferred to standard ACSF prepared as described above but containing 2mM CaCl2 and 1mM 
MgCl2 (see Table 4.3). After equilibration at RT for at least 1h, the slices were placed in a recording 
chamber, superfused with 1ml/min of standard ACSF and mounted on a Zeiss Axio Imager 2 
epifluorescent microscope. Cells were visualized with a 40x objective (0.75 NA). Patch-clamp whole-cell 
recordings were performed at RT with electrodes filled with a fluorescent dye-containing solution to 
allow morphological analysis of the cells: 125mM K-Gluconate; 5mM NaCl; 2mM Na2-ATP; 2mM MgCl2; 
10mM EGTA; 10mM HEPES; 10mM Biocytin; 0.2mM Alexa 488/594 hydrazide (Invitrogen), pH7.4. 
Current-clamp recordings were obtained using an Axopatch 200B amplifier (Molecular Devices). Current 
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steps were triggered with the pClamp10 software (Molecular Devices), which was also used for further 
analysis. Seal resistances were between 4 and 18 GΩ. Series resistance and whole-cell capacitance were 
not compensated.  
4.5       Image acquisition and analysis 
4.5.1    Epifluorescent and confocal microscopy 
Pictures of in vitro experiments were taken with an upright Axio Imager.M2 epifluorescent microscope 
equipped with an ApoTome.2 system (Zeiss GmbH). Images were acquired with the 20x dry objective 
(NA 0.5) or the 40x dry objective (NA 0.75) in epifluorescent mode. 
For the quantification of in vivo experiments, pictures were taken at the Axio Imager.M2 in ApoTome 
mode. For illustrations of result from in vivo experiments of section 2.1 and for Fig.2.19, the image 
acquisition was performed at the TCS SP5 Confocal Laser Scanning inverted microscope (Leica) of the 
Institute of Molecular Biology (IMB, Mainz, Germany). This confocal microscope is equipped with four 
PMTs, four lasers (405 Diode, Argon, HeNe 543, HeNe 633) and a fast-resonant scanner. Pictures were 
taken with the 20x dry objective (NA 0.7) or with the 40x oil objective (NA 1.3). Serial Z-stacks of 0.4µm 
(Fig.2.17) and 0.8µm were acquired to image the whole thickness of the slices. For Fig.2.6C-C’’’/D-D’’’ 
and Fig.2.13, pictures were acquired at the Axio Imager.M2 in ApoTome mode with 63x oil objective 
(NA 1.25). Serial Z-stacks of 0.3µm were taken. For Fig.2.4, images were acquired at the Axio Imager.M2 
in ApoTome mode with the 20x dry objective. Serial Z-Stacks of 1.2µm were taken. 
For the other in utero electroporation illustrations, acquisition was performed at the TCS SP5 Confocal 
Laser Scanning inverted microscope (Leica) of the Microscopy and Scientific Imaging Unit (Instituto 
Cajal, Madrid, Spain). Tile scans were taken at the 20x oil objective (NA 0.7), with serial Z-stacks of 3µm. 
4.5.2    Image analyses and cell counting 
For quantifications of in vitro experiments, biological triplicates obtained by independent cultures from 
three different brains were performed. For each biological replicate, technical duplicates of every 
experimental condition were analysed and the mean of their results was considered. From Fig.2.2, six 
random pictures of each coverslip were acquired at the 20x objective. For Fig.2.3, a 4x4 tile scan of each 
coverslip was acquired at the 20x objective. Cell counting was performed by quantifying the number of 
marker-positive cells among the transduced population (eGFP- or DsRed-positive cells).  
For quantifications of in vivo experiments, tile scans of the areas containing transduced cells were taken 
at the Axio Imager.M2 in ApoTome mode, with a serial Z-stack of 1.25µm. Cells were quantified, after 
collapsing the Z-stacks via maximum intensity projection, by counting the marker-positive cells among 
transduced or double-transduced cells. 
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For illustrations, images were exported in TIFF format at the Zen Blue Light software (Zeiss GmbH) or 
with FIJI (National Institutes of Health), and the colour balance of each channel was uniformly adjusted 
with Photoshop (Adobe). If necessary, Lookup Tables were changed to maintain uniformity of colour 
coding among the same figure and noise was filtered via removal of outlier pixels in FIJI. To obtain some 
of the insets showing magnifications, as indicated by dashed squares, pictures were cropped in 
Photoshop. The final organisation of figures was performed in Illustrator (Adobe). 
4.5.3    Workflow for clonal analysis of StarTrack-electroporated cells 
The clonal analysis of cells electroporated with the StarTrack labelling system will be performed by mean 
of macros in Fiji that were developed at the Instituto Cajal (Madrid, Spain). The macros recognise only 
the original file of the confocal microscope’s software (LASX, Leica). After collecting all maximum 
intensity projections of confocal images obtained from one brain’s series, it is necessary to manually set 
thresholds for the minimum size of a cells and the minimum intensity level of each fluorescent signal. 
The main functions of the macros are (Fig.4.8): 
 identification of all electroporated cells in each image, according to the threshold for cells’ size 
manually set; 
 creation of the galleries’ folder, containing micrographs of each cell in each channel; 
 assignment of the barcodes, namely binary codes identifying the labelling pattern of a specific 
cell according to the thresholds for fluorescent intensity manually set; 
 merging and organisation of data derived from the thresholds’ analyses. 
One limitation of the macros is that they allow only the setting of a mean threshold of fluorescent 
intensity among all the channels, rather than the setting of one threshold value for each fluorophore. 
Thus, it is important to perform manual check and editing of the readout of the macros, so that each 
cell identified receives its real barcode. 
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4.6       Statistical analysis 
All results of quantifications are represented as means ± standard deviations (SD) and the statistical 
significance was analysed with One-Way ANOVA after checking normality in SPSS Statistics 23 V5 (IBM). 
Multiple comparisons were tested for significance with the Bonferroni post-hoc test in SPSS. Graphical 
representations of results were obtained in GraphPad Prism 5 (GraphPad). 
 
 
 
 
 
 
 
 
 
 
Fig.4.8 Workflow of clonal analysis of brains electroporated with the StarTrack clonal labelling system.  
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4.7       Materials 
4.7.1    Primary antibodies 
Table 4.1 List of primary antibodies. If necessary to specify, it is indicated if the antibody has been used 
for immunocytochemistry (ICC) or immunohistochemistry (IHC). 
 
Antigen Host species Dilution Company Cell types stained 
Adenomatous Polyposic 
Coli (APC) 
Mouse IgG2b 1:100 Calbiochem 
(OP80-100UG) 
Mature 
oligodendrocytes 
Achete Scute-like 1 (Ascl1) Mouse IgG1 1:400 ICC    
1:100 IHC 
BD Pahrmingen 
(550644) 
Cells expressing 
ASCL1 
Beta III tubuline (bIIItub) Mouse IgG2b 1:1000 Sigma (T8660) Neurons 
Doublecortin (DCX) Guinea pig 1:400 ICC Millipore 
(AB2253) 
Immature 
neurons 
Doublecortin (DCX) Goat 1:250 IHC Santa Cruz 
Biotechnology 
(sc-8066) 
Immature 
neurons 
γ-aminobutyric acid (GABA) Rabbit 1:300 Sigma (A2052) Interneurons 
Green Fluorescent Protein 
(GFP) 
Chicken 1:300 ICC  
1:1000 IHC 
AvesLab   (GFP-
1020) 
GFP- and eGFP-
labelled cells 
Glial Fibrillar Acidic Protein 
(GFAP) 
Rabbit 1:1000 ICC  
1:300 IHC 
Dako (Z0334 – 
29-2) 
Astrocytes 
Ionized calcium-binding 
adapter molecule 1 (IBA1) 
Rabbit 1:800 Wako (019-
19741) 
Microglia 
Cherry DsRed (mCherry) Chicken 1:300 IHC EnCor 
Biotechnology 
(CPCA-mCherry) 
DsRed-labelled 
cells 
Neuronal Nuclei (NeuN) Mouse IgG1 1:500 Millipore 
(MAB377) 
Mature neurons 
Red Fluorescent Protein 
(RFP) 
Rabbit 1:500 IHC Biomol 
(6004013795) 
DsRed-labelled 
cells 
Red Fluorescent Protein 
(RFP) 
Rat 1:400 Chromotek 
(5F8) 
DsRed-labelled 
cells 
SRY-Box 10 (Sox10) Goat 1:100 Santa Cruz 
Biotechnology 
(sc-17342) 
OPCs, pre-OPCs 
and 
oligodendrocytes 
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4.7.2    Secondary antibodies 
Table 4.2 List of secondary antibodies. It is specified if the antibody has been used for 
immunocytochemistry (ICC) or immunohistochemistry (IHC). 
 
Species specificity Fluorescent label Dilution Company 
Donkey -Chicken Alexa 488 1:1000 ICC      
1:200 IHC 
Jackson Immunoresearch 
(703-545-155) 
Donkey -Chicken Cy3 1:500 IHC Dianova (703-165-155) 
Donkey -Goat Cy3 1:500 IHC Dianova (705-165-147) 
Donkey -Goat Cy5 1:1000 ICC      
1:500 IHC 
Dianova (705-155-147) 
Donkey -Guinea pig Cy3 1:1000 ICC Dianova (706-166-148) 
Donkey -Mouse Alexa 405 1:200 IHC Jackson Immunoresearch 
(715-475-151) 
Donkey -Mouse Alexa 488 1:1000 ICC Invitrogen (A21202) 
Goat -Mouse Cy3 1:1000 ICC Dianova (115-165-166) 
Donkey -Mouse Alexa 647 1:500 IHC Invitrogen (A31571) 
Donkey -Rabbit Cy3 1:1000 ICC Dianova (711-165-152) 
Donkey -Rabbit A647 1:500 IHC Invitrogen (A31573) 
Goat -Rabbit Cy5 1:1000 ICC Dianova (115-155-144) 
Goat -Rat Cy3 1:1000 ICC Dianova (112-165-167) 
 
4.7.3    List of solutions 
Table 4.3 List of media and solutions.  
Solution Composition Storage 
1xPBS 137mM NaCl; 100mM Na2HPO4; 18mM KH2PO4: 2.7mM KCl; pH7.4 RT 
Astromedium DMEM/F12; 10%FBS; 5% Horse Serum; 1x PenStrep; 1xGlutaMax; 
1x B27 Supplement 
4°C up to 
one month 
PDL 1:100 1mg/ml PDL in sterile dH2O 4°C 
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Transfection 
Medium 
OptmiMEM; 1x GlutaMAX; 1xPenStrep; 10ng/µl EGF; 10ng/µl FGF-2 4°C up to 
one month 
B27 
Differentiation 
Medium 
DMEM/F12; 1xPenStrep; 1xGlutaMAX; 1x B27 Supplement 4°C up to 
one month 
0.4M 
Phosphate 
Buffer 
117mM Na2HPO4·12H2O; 128mM NaH2PO4·2H2O; pH7.4 RT 
4% PFA 4%w/v PFA; 0,4M Phosphate Buffer; up to volume in millQ H2O -20°C 
Blocking 
Solution ICC 
3% Bovine Serum Albumin; 0.5% Triton X-100; up to volume in 1x 
PBS 
-20°C 
Luria Bertani 10% Trypton; 5% Yeast Extract; 10% NaCl; up to volume in dH2O ; 
pH7.4 with NAOH 
RT 
Growth 
Medium 
DMEM/F12; 1xGlutamine; 10% FCS; 2µg/ml Puromycin; 0.3 mg/ml 
G418 Sulfate; 2µg/ml Tetracyclin 
4°C up to 
one month 
Plating 
Medium 
DMEM; 10% FCS; 1xGlutaMAX; 1xNEAA; 1xNa-Pyruvate; 0.5 µg/ml 
Tetracycline 
4°C up to 
one month 
Transfection 
Medium (1F8) 
DMEM; 1x Glutamine 4°C up to 
one month 
Packaging 
Medium 
DMEM; 10% FCS; 1xGlutaMAX; 1xNEAA; 1xNa-Pyruvate 4°C up to 
one month 
TBS-5 1M Tris/HCl, pH7.8; 5M NaCl; 1M KCl; 1M Mg2Cl 4°C 
Cryoprotective 
Solution 
20% Glucose + 40% Ethylene Glycol + 0.025% Sodium Azide + 
0.05M Phosphate Buffer pH7.4 
RT 
Blocking 
Solution IHC 
5% Donkey Serum; 0.1-0.3% Triton X-100 in 1xTBS 4°C up to 
two days 
Standard ACSF 125mM NaCl; 2.5mM KCl; 25mM NaHCO3; 2mM CaCl2; 1mM MgCl2; 
1.25mM NaH2PO4; 25mM Glucose 
RT 
Modified ACSF 125mM NaCl; 2.5mM KCl; 25mM NaHCO3; 0.5mM CaCl2; 4mM 
MgCl2; 1.25mM NaH2PO4; 25mM Glucose 
RT 
Fluorescent 
solution 
125mM K-Gluconate; 5mM NaCl; 2mM Na2-ATP; 2mM MgCl2; 
10mM EGTA; 10mM HEPES; 10mM Biocytin; 0.2mM Alexa 488/594 
hydrazide, pH7.4 
RT 
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4.7.4    List of reagents 
Table 4.4 List of reagents. Includes reagents and commercially available kits used. 
Reagent Company Catalog number/Identifier 
1 Kb ladder NEB N3232S 
100 bp ladder NEB N3231S 
100x GlutaMax Invitrogen 35050-0380 
10x Antractic Phos run Buffer NEB B0389 S 
1M Hydrochloric acid Applichem A1434.1000 
2-Propanol Sigma I9516-500ML 
4-hydroxy-tamoxifen Sigma H7904 
Acetic Acid Glacial Sigma ARK2183 
Agar Merck 1119251000 
Agarose Lonza 98200-100 
Alexa 488 hydrazide Life Technologies A10436 
Alexa 633 hydrazide Life Technologies A30634 
Alzane® 5mg/ml (Atipamezol) Pfizer PZN 11283538 
Ampicillin Sodium Salt AppliChem 4G017739 
Antarctic Phosphase NEB M0289S 
Aqua-polymount Polysciences Inc. 18606-20 
ATP disodium salt hydrate Sigma A26209 
B27 supplement Life Technologies 17504-044 
Bepanthen® Augen und Nasesalbe 5g Bepanthen PZN 01578675 
Biocytin Sigma B4261E 
BSA Sigma A9418-50 g 
DAPI Sigma D9542 
DMEM Gibco 21969-035 
DMEM-F12 Gibco 21331-020 
Donkey serum Merck Milipore S30-100ml 
Dorbene vet® (Medetomidin) Pfizer PZN 07725752 
DPX mountant for histology Sigma 06522 
Calcium Chloride dihydrate VWR 437053L 
Corn Oil Sigma C8267 
DH5α Competent Cells Invitrogen 18265017 
dNTP mix NEB N0447S 
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EGF PeproTech AF-100-15-1 mg 
Ethanol absolute Sigma 34923 
Ethidium bromide Sigma 46065 
Ethylene glycol Sigma 324558 
Ethylenediamine tetraacetic acid 
Disodiumsalt (EDTA) 
Calbiochem 15576-028/324503 
ethylene glycol tetraacetic acid 
(EGTA) 
Sigma E0396 
Fast Green FCF Sigma F7252 
FBS Invitrogen 10270-106 
Fentadon® 50µg/ml (Fentanyl) Albrecht PZN 00094716 
FGF-2 PeproTech 100-18B-100 ug 
Flumazenil 0.1mg/ml Hameln PZN 9611975 
G418 sulphate InVivoGen ant-gn-5 
GenJet Plus Tebu-bio SL100499 
Glucose Sigma G8270-1KG 
Glycerol 99% Sigma G5516-500ML 
Hepes 1M Sigma H0877-100ML 
Horse serum Invitrogen 16050-130 
Invivo jetPEI transfection reagent VWR 201-10 
Forene 100v/v (Isoflurane) Baxter PZN: 06497131 
Kanamycin sulfate Sigma 60615-5 g 
Ketaset® 100mg/ml (Ketamin) Zoetis PZN 12467849 
L-Glutamax Invitrogen 35050-0380 
L-glutamine Gibco 25030081 
Lipofectamine™2000 Invitrogen 11668-019 
LR Clonase™ II Enzyme Mix Invitrogen 11791-020 
Magnesium chloride anhydrous Sigma M8266 
Midazolam 5mg/ml Hameln PZN 3760906 
Mowiol® 40-88 Sigma 324590 
Non-essential amino acids Gibco 1140-035 
NucleoBond® Xtra Maxi EF kit Macherey-Nagel 740424.50 
NucleoSpin® Plasmid EasyPure Macherey-Nagel 740727.250 
NucleoSpin® Gel and PCR Clean-up Macherey-Nagel 740609.50 
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One Shot™ TOP10 Chemically 
Competent E. coli 
Invitrogen C404010 
OptiMEM™ Gibco 31985-047 
OptiPrep™ 60% (Iodixanol) Sigma D1556 
Paraformaldehyde Merck 8.18715.1000 
PBS pH 7.2 (10x) 500 ml 70013-016 
Pen/Strep, 10000u/ml Invitrogen 15140122 
pENTR™ 1A Dual Selection Vector Invitrogen A10462 
Platinum™ Pfx DNA Polymerase Invitrogen 11708-013 
Poly-D-Lysine Sigma P6407 
Potassium chloride Fluka 60129 
Potassium gluconate Sigma P1847 
Potassium hydroxide, granular Merck 1050330500 
Potassium Phosphate monobasic 
(KH2PO4) 
Calbiochem 529568 
PureLink™ HiPure Plasmid Filter 
Maxiprep Kit 
Invitrogen K210017 
Puromycin Sigma P9620 
Purple loading dye NEB B7024 S 
Quick Ligation™ kit NEB M2200S 
Rimadyl® 50mg/ml (Carprofen) Zoetis 2209276 
Rompun® 2% (Xylazine) Bayer PZN 1320422 
0.5 % Trypsin-EDTA Gibco 15400-054 
Sodium azide Sigma S2202 
Sodium bicarbonate Applichem A0384 
Sodium chloride Amresco 0241-1KG 
Sodium chloride 0.9% with 
benzylalcohol 0.9% 
Prepared in house by the Pharmacy of the University 
Medical Center Mainz 
Sodium phosphate dibasic (Na2HPO4) 
dodecahydrate 
Merck 106579 
Sodium dihydrogen phosphate 
(NaH2PO4) dihydrate 
Gen-Apex 33616.262 
Sodium hydroxide VWR 28244295 
Sodium Pyruvate Sigma P2256 
T4 DNA Ligase NEB M0202S 
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T4 DNA Ligase Buffer NEB B0202S 
T4 DNA polymerase NEB M0203S 
Tamoxifen Sigma T5648 
Temgesic® (Buprenorphin) RB Pharmaceuticals PZN 0912306 
Tetracyclin Sigma T660 
Tris Ultrapure Invitrogen 15504-020 
Tris-Hydrochloride CalBiochem 648317 
Triton x 100 Sigma X100-1L 
Trypan blue Gibco 15250-061 
Trypsin-EDTA, 0.5 % Life Technologies 15400054 
Tryptone Sigma (Fluka) T9410-250 g 
Tween 20 Sigma P1379-500ML 
Yeast extract Sigma Y1625 
 
 
4.7.5    List of recombinant DNA and organisms modified 
Table 4.5 List of recombinant DNA and organisms modified. Includes all constructs and organisms used 
in this study. 
Plasmid Original study/Origin 
pCAG-Ascl1-IRES-eGFP This study 
pCAG-Ascl1SA6-IRES-eGFP This study 
pCAG-Ascl1SD6-IRES-eGFP This study 
pCAG-Ascl1-IRES-DsRed This study 
pCAG-Ascl1SA6-IRES-DsRed This study 
pCAG-Ascl1SD6-IRES-DsRed This study 
pCAG-IRES-DsRed Heinrich et al. 2010 
pMIG-Bcl2-IRES-GFP Cheng et al. 2001 (Addgene 8793) 
pGFAP-Ascl1ERT2-IRES-eYFP This study 
pGFAP-Ngn2ERT2-IRES-eYFP This study 
pGFAP-eYFP García-Marqués e López-Mascaraque 2013 
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pGFAP-LSL-Bcl2 This study 
pGFAP-Sox2 This study 
pCMV-hyPBase García-Marqués e López-Mascaraque 2013 
pCAG-ERT2-Cre-ERT2 Figueres-Onãte et al. 2016 
pUbc-loxP-eGFP-loxP Figueres-Onãte et al. 2016 
pUbc-loxP-mCherry-loxP Figueres-Onãte et al. 2016 
pUbc-loxP-mKO-loxP Figueres-Onãte et al. 2016 
pUbc-loxP-mCerulean-loxP Figueres-Onãte et al. 2016 
pUbc-loxP-mTSapphire-loxP Figueres-Onãte et al. 2016 
pUbc-loxP-H2BeGFP-loxP Figueres-Onãte et al. 2016 
pUbc-loxP-H2BmCherry-loxP Figueres-Onãte et al. 2016 
pUbc-loxP-H2BmKO-loxP Figueres-Onãte et al. 2016 
pUbc-loxP-H2BmCerulean-loxP Figueres-Onãte et al. 2016 
pUbc-loxP-H2BmTSapphire-loxP Figueres-Onãte et al. 2016 
HEK293 RRID:CVCL_0045 
C57Bl6/J (Mus musculus) RRID:IMSR_JAX:000664 
 
4.7.6    List of primers 
Table 4.6 List of primers. fw=forward primer (sequencing); rev=reverse primer (sequencing); F=forward 
primer (cloning); R=reverse primer (cloning). Underlined nucleotides on cloning primers indicate 
annealing to target DNA. 
Primer Sequence Length 
(base pairs) 
Target 
E1fw CGTTTCTACAAACTCTTCCTGTT 23 pENTR 1ADS 
E1rev AACATCAGAGATTTTGAGACAC 22 pENTR 1ADS 
pUbc_fw GGTTTTGAACTATGCGCTC 19 
Human ubiquitin 
promoter, 3‘ end 
hGFAP1970_fw TGCCCAGGAAGCTCTGC 17 
Human GFAP promoter, 
3’ end 
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BGHpolyA_rev AACTAGAAGGCACAGTCG 18 BGH polyA, 3’end 
ERT2rev TTGATCATGAGCGGGCTTGG 20 ERT2, 5’ end 
polyA_rev CCAGCCACCACCTTCTGAT 19 PolyA, 5’ end 
Cre_fw CAAAATTTGCCTGCATTACC 22 Cre recombinase, 5’ end 
Sox2117_rev CGTTCATGGGCCTCTTGAC 19 Sox2, 5’ end 
hBcl2_rev CTGCGACAGCTTATAATG 18 hBcl2, 5’ end 
IRES555fw CGATGATAATATGGCCACAACC 19 IRES, 3’ end 
CAG477fw CGTGTGACCGGCGGCTCTA 19 CAG promoter, 3’ end 
IREScompl CACCGGCCTTATTCCAAGC 19 IRES, 5’ end 
40Fb_BamHI-
kozak-HA 
ATTCGGATCCAGCCACCATGTACCCAT
ACGATGTTCCAG 
39 Neurog2ERT2, N-terminus 
40R_IRES-BamHI 
AGATCGGATCCTTCATCGTGTTTTTCAA
AGG 
31 IRES, C-terminus 
41F_BamHI-ClaI-
IRES 
ATTAGGATCCCTATCGATATCGACGGT
ACAAACGATCC 
38 
IRES, N-terminus 
42F_ClaI-
Ascl1ERT2 
ATTAATCGATACCCGCACCATGGACTA
CAAG 
30 Ascl1ERT2, N-terminus 
42R_ERT2-ClaI 
AGATCATCGATGAGACTCGAGTCAAGC
TGTGG 
32 ERT2, C-terminus 
52F_BglII-ClaI-
kozak-hBcl2 
ATTAAGATCTAATCGATTCCACCATGG
CGCACG 
33 hBcl2, N-terminus 
52R_IRES-BglII 
TGATAGATCTTAGTGGCATATTATCATC
GTG 
31 IRES, C-terminus 
53F_BamHI-
Sox2 
ATTAGGATCCGGACCATGGACTACAAG
GACG 
31 Sox2, N-terminus 
53R_Sox2-
BamHI 
TGATGGATCCCGACTTACATGTGCGAC
AGG 
30 Sox2, C-terminus 
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4.7.7    List of software and algorithms 
Table 4.7 List of software and algorithms. 
Software or algorithm Company/Origin Identifier 
Image J (FIJI) NIH RRID:SCR_003070 
ZEN Carl Zeiss Microscopy RRID:SCR_013672 
SPSS IBM RRID:SCR_002865 
Graphpad Prism 5 Graphpad RRID:SCR_005375 
Ape (A Plasmid Editor) By M. Wayne Davis RRID:SCR_014266 
LASX Leica RRID:SCR_013673 
pClamp10 Molecular Devices RRID:SCR_011323 
Clustal Omega EBL-EBI RRID:SCR_001591 
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5  Appendix 
Appendix I - List of abbreviations (including genes and proteins mentioned in this manuscript) 
°C Celsius degrees 
3’-OH Hydroxy group left exposed at the 3’ of a nicked DNA filament 
3D 3 dimensional 
A Alanine 
AKT Protein Kinase B 
AM Astromedium 
ANOVA Analysis of variance 
APC Adenomatous polyposis coli 
AQP4 Aquaporin 4 
ASCL1 Achaete Scute-Like 1 
Atf3 Activating transcription factor 3 
ATOH1 Atonal bHLH Transcription Factor 1 
ATOH7 Atonal bHLH Transcription Factor 7 
BAM Brn2+Ascl1+Myt1l 
BCL2 B-cell lymphoma 2 
bHLH basic Helix-Loop-Helix 
bIIItub Beta III tubulin 
BMP Bone Morphogenetic Protein 
BrdU Bromodeoxyuridine 
BRN2 POU class 3-Homeobox 2 
BSA Bovine serum albumin 
c-Myc Myc proto-oncogene c 
Ca2+ Calcium ion 
CAG Chicken b-actin 
CANNTG Cytosine-Alanine-any base-any base-Thymidine-Guanine 
CBP CREB-binding protein 
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CDK Cyclin-dependent kinase 
CENPJ Centromere protein J 
ChIP Chromatin immunoprecipitation 
cm Centimetre 
CMV Cytomegalovirus 
CRISPR Clustered regularly interspaced short palindromic repeats 
Ctrl Control 
D Aspartic acid 
DAPI 4′,6-diamidino-2-phenylindole 
dCas9 Endonuclease deficient CRISPR associated protein 9 
DCX Doublecortin 
DDE/D Domain containing Aspartate-Aspartate-Glutamate/Aspartate 
dH2O Distilled water 
div Days in vitro 
DLX Distal-less homeobox 
DLX1/2 DLX1 and DLX2 
DNA Deoxyribonucleic acid 
dpi Days post injection 
DREADDs Designer Receptors Exclusively Activated by Designer Drugs 
Drosophila Drosophila melanogaster 
DsRed Discosoma red fluorescent protein 
E Embryonic day 
E. coli Escherichia coli 
E47 E protein 47 
EDTA Ethylenediaminetetraacetic acid 
EdU 5-Ethynyl-2´-deoxyuridine 
EF Endotoxin free 
EGF Epidermal growth factor 
eGFP Enhanced green fluorescent protein 
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Ephb2 Ephrin-type B receptor 2 
ERK Extracellular signal-regulated kinase 
ERT2 Modified ligand-binding domain of the oestrogen receptor 
eXFP Enhanced fluorescent protein 
FAIRE Formaldehyde-assisted isolation of regulatory elements 
FEZF2 Forebrain Embryonic Zinc Finger-like Protein 2 
FGF Fibroblast Growth factor 
g Gravity acceleration 
GΩ Giga Ohm 
GABA Gamma-Aminobutyric acid 
GABAergic That releases the neurotransmitter GABA 
gag Group-specific antigen  
Gata4 GATA binding protein 4 
GC-rich Rich in Guanosine and Cytosine 
GFAP Glial fibrillar acidic protein 
GFP Green fluorescent protein 
GLAST Glutamate aspartate transporter 
GLT-1 Glutamate transporter 1 
GSK3 Glycogen synthase kinase 3 
GTP Guanosine-5’-Triphosphate 
h hours 
H2B Histone 2B 
H3K4me1 Monomethylation of Lysine 4 on Histone 3 
H3K4me3 Trimethylation of Lysine 4 on Histone 3 
H4K20me3 Trimethylation of Lysine 20 on Histone 4 
H3K27ac Acethylation of Lysine 27 on Histone 4 
HEK Human embryonic kidney 
HES Hairy and enhancer of split 
hGFAP Human GFAP promoter 
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hiPSCs Human induced pluripotent stem cells 
HUWE1 HECT, UBA and WWE domain-containing protein 1 
hyPBase Hyperactive form of the PiggyBAC transposase 
Hz Hertz 
Iba1 Ionized calcium-binding adapter molecule 1 
ID Inhibitor of DNA binding 
IRES Internal ribosome entry 
JAK Janus Kinase 
Kb Kilobases (=1000 base pairs) 
Kir4.1 ATP-sensitive inward rectifier potassium channel 10 
Klf4 Kruppel-like factor 4 
miR/miRNA micro-RNA 
mKO Monomeric Kusabira orange 
LGE Lateral ganglionic eminence 
Lox (LoxP) Locus of X over P1 
m mouse 
Mef2c Myocyte enhancer factor 2C 
MEK Mitogen-activated protein-kinase 
MGE Medial ganglionic eminence 
min Minutes 
miRNA microRNA 
ml Millilitre 
mM millimolar 
MoMLV Moloney-Murine Laeukemia Virus 
mXFP Monomeric fluorescent protein 
MYOD Myogenic differentiation 1 
Myt1l Myelin transcription factor 1-like 
n Number of biological replicates 
Appendix 
 
 123 
ND4 Neuro D4 
NeuN Neuronal nuclei antigen 
NFIA Nuclear factor 1A-type 
NG2 Chondroitin sulfate proteloglycan 4 
NEUROG1 Neurogenin 1 
NEUROG1/2 Neurogenin 1 and Neurogenin 2 
NEUROG2 Neurogenin 2 
NFIA Nuclear factor 1 A-type 
NSC Neural stem cell 
Oct4 Octamer-binding transcription factor 4 
OLIG2 Oligodendrocyte lineage transcription factor 2 
OPC Oligodendrocyte progenitor cell 
P Postnatal day 
p300 Protein p300 
pASCL1 Collectively, wild type ASCL1, phospho-deficient ASCL1 and phospho-mutant ASCL1 
PAX6 Paired box6 
PBS Phosphate buffer saline 
PDGFR  Platelet-derived growth factor-alpha 
PDL Poly-D-Lysine hydrobromide 
PI3K Phosphoinositide 3 kinase 
pol DNA polymerase 
polyA Polyadenylation 
PTEN Phosphatase and tensin homolog 
PVDF Polyvinylidene fluorid 
PZN Pharmazentralnummer 
RAF Raf-1 proto-oncogene 
RAS RAS GTPase 
RBPJ Recombination signal binding protein for immunoglobulin kappa J region 
REST RE1-silencing transcription factor 
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RFP Red fluorescent protein 
RG Radial glia 
RGC Radial glial cell 
RNA Ribonucleic acid 
Rnd2 Rho family GTPase 2 
ROS Reactive oxygen species 
RT Room temperature 
RTK Receptor tyrosine kinase 
Runx2 Runt-related transcription factor 2 
RV Retrovirus 
SA Serine>Alanine mutation 
SA6 Serine>Alanine mutation at all six SP sites present in the protein 
SD Serine>aspartate mutation 
SD Standard deviation 
SD6 Serine>aspartate mutation at all six SP sites present in the protein 
SEZ Subependymal zone 
S/G2 Synthesis/Gap2  
sgRNA Small guide RNA 
Shh Sonic hedgehog 
Sox Sex-detemining region Y-box 
SP (S/P) Serine/Proline 
STAT Signal Transducer and Activator of Transcription proteins 
SVZ Subventricular zone 
TA-rich Rich in Thymidine and Alanine 
TBS Tris-buffered saline 
Tbx T-box 
tetO/tetR Tetracycline-repressed/Tetracycline responsive 
TF Transcription factor 
TIR (TR) Terminal inverted repeat (Terminal repeat) 
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Tlx Nuclear receptor TLX 
TM Transfection medium 
TP (T/P) Threonine/Proline 
U unit 
Ubq Ubiquitin promoter 
VP16  Transactivating tegument protein VP16 
VSV-G Vesicular stomatitis virus G-protein 
VZ Ventricular zone 
Wnt Wingless type MMTV integration site 
wpi Weeks post injection 
wt Wild type 
Xaenopus Xaenopus laevis 
xg Relative centrifugal force 
Y Thyrosine 
YFP Yellow fluorescent protein 
ZBTB20 Zinc finger and BTB domain-containing protein 20 
ZFP24 Zinc finger protein 24 
µg Microgram 
µl Microliter 
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Appendix III - Number of cells quantified for each experiment of section 2.2. Total number of cells 
analysed. The n of each experiment indicates the number of independent experiments (biological 
replicates). 
Experiment 
Figure - Experimental condition; staining 
quantified 
Number of 
animals (n) 
Total number of 
cells 
Transfection - 
in vitro 
Fig. 2.2 - Ascl1 wt; DCX 3 625 
Fig. 2.2  - Ascl1SA6; DCX 3 904 
Fig. 2.2  - Ascl1SD6; DCX 3 515 
Transduction - 
in vitro 
Fig. 2.3 – Ctrl; bIIItub 3 1398 
Fig. 2.3 - Ascl1 wt; bIIItub 3 3061 
Fig. 2.3 - Ascl1SA6; bIIItub 3 3462 
Fig. 2.3 - Ascl1SD6; bIIItub 3 4376 
Injection - 
3dpi 
Fig. 2.4 - Ctrl; Iba1/DCX 3 578 
Fig. 2.4 - Ctrl; GFAP/Sox10 3 753 
Injection - 
12dpi 
Fig. 2.6 - Ctrl; DCX 3 2157 
Fig. 2.6 - Ascl1 wt; DCX 4 720 
Fig. 2.6 - Ascl1SA6; DCX 3 409 
Fig. 2.6 - Ascl1SD6; DCX 3 286 
Fig. 2.7, 2.8 - Ctrl; GFAP/Sox10 3 1885 
Fig. 2.7, 2.8 - Ascl1 wt; GFAP/Sox10 4 848 
Fig. 2.7, 2.8 - Ascl1SA6; GFAP/Sox10 3 573 
Fig. 2.7, 2.8 - Ascl1SD6; GFAP/Sox10 3 286 
Fig. 2.9 - Ctrl; Sox10/APC 3 1830 
Fig. 2.9 - Ascl1 wt; Sox10/APC 4 1654 
Fig. 2.9 - Ascl1SA6; Sox10/APC 3 690 
Fig. 2.9 - Ascl1SD6; Sox10/APC 3 237 
Injection + 
Bcl2 - 12dpi 
Fig. 2.11, 2.12, 2.13 - Ascl1 wt, DCX/NeuN 3 2380 
Fig. 2.11, 2.12, 2.13 - Ascl1SA6, DCX/NeuN 3 836 
Fig. 2.11, 2.12, 2.13 - Ascl1SD6, DCX/NeuN 3 734 
Fig. 2.14 - Ascl1 wt, GABA 3 2258 
Fig. 2.14 - Ascl1SA6, GABA 3 556 
Fig. 2.14 - Ascl1SD6, GABA 3 643 
Fig. 2.15 - Ascl1SA6, electrophysiology 3 6 
 
Appendix IV - List of p-values for all comparisons represented in section 2.2. (see next page) Statistical 
analyses were run as One-Way ANOVA. Multiple comparisons were performed with Bonferroni post-
hoc. 
Figure number One-Way 
ANOVA p-value 
Comparison Bonferroni         
p-value 
Symbol 
Fig. 2.2 0.005 Ascl1SA6 vs Ascl1SD6 0,005 ** 
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Fig. 2.3 <0.001 
Ascl1 wt vs Ctrl <0.001 *** 
Ascl1SA6 vs Ctrl <0.001 *** 
Ascl1SD6 vs Ctrl <0.001 *** 
Ascl1 wt vs Ascl1SA6 0,001 ** 
Ascl1SD6 vs Ascl1SA6 0,028 * 
Fig. 2.6 <0.001 
Ascl1 wt vs Ctrl 0,001 ** 
Ascl1SA6 vs Ctrl <0.001 *** 
Ascl1SD6 vs Ctrl 0,004 ** 
Ascl1SD6 vs Ascl1SA6 0,031 * 
Fig. 2.7C <0.001 
Ascl1 wt vs Ctrl <0.001 *** 
Ascl1SA6 vs Ctrl <0.001 *** 
Ascl1SD6 vs Ctrl <0.001 *** 
Fig. 2.7C’ 0.001 
Ascl1 wt vs Ctrl 0,001 ** 
Ascl1 wt vs Ascl1SA6 0,033 * 
Ascl1 wt vs Ascl1SD6 0,021 * 
Fig. 2.8 0.001 
Ascl1SA6 vs Ctrl 0,002 ** 
Ascl1SD6 vs Ctrl 0,011 * 
Ascl1 wt vs Ascl1SA6 0,008 ** 
Fig. 2.9C <0.001 
Ascl1 wt vs Ctrl 0,001 ** 
Ascl1 wt vs Ascl1SA6 <0.001 *** 
Ascl1 wt vs Ascl1SD6 0,007 ** 
Fig. 2.9C’ 0.003 
Ascl1 wt vs Ascl1SA6 0,010 * 
Ascl1 wt vs Ascl1SD6 0,005 ** 
Fig. 2.11 <0.001 
Ascl1 wt GFP/RFP vs Ascl1 t RFP-only <0.001 ### 
Ascl1SA6 GFP/RFP vs Ascl1SA6 RFP-only 0,008 ## 
Ascl1SD6 GFP/RFP vs Ascl1SD6 RFP-only <0.001 ### 
Ascl1SA6 GFP/RFP vs Ascl1SD6 GFP/ RFP 0,005 ** 
Fig. 2.12 <0.001 
Ascl1SA6 GFP/RFP vs Ascl1SA6 RFP-only <0.001 ### 
Ascl1SD6 GFP/RFP vs Ascl1SD6 RFP-only 0,023 # 
Ascl1 wt GFP/RFP vs Ascl1SA6 GFP/ RFP <0.001 *** 
Ascl1SA6 GFP/RFP vs Ascl1SD6 GFP/ RFP <0.001 *** 
Fig. 2.13 <0.001 
Ascl1 wt GFP/RFP vs Ascl1 wt RFP-only 0,001 ## 
Ascl1SA6 GFP/RFP vs Ascl1SA6 RFP-only 0,001 ## 
Ascl1SD6 GFP/RFP vs Ascl1SD6 RFP-only 0,002 ## 
Ascl1 wt GFP/RFP vs Ascl1SA6 GFP/ RFP 0,008 ** 
Fig. 2.14 <0.001 
Ascl1SA6 GFP/RFP vs Ascl1SA6 RFP-only <0.001 ### 
Ascl1SD6 GFP/RFP vs Ascl1SD6 RFP-only 0,022 # 
Ascl1 wt GFP/RFP vs Ascl1SA6 GFP/ RFP <0.001 *** 
Ascl1SA6 GFP/RFP vs Ascl1SD6 GFP/ RFP <0.001 *** 
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